Section 40

EurekaMag Full Text Articles Chapter 39,022


Dull, B.J.; Salata, K.; Van Langenhove, A.; Goldman, P. 1987: 5-Aminosalicylate: oxidation by activated leukocytes and protection of cultured cells from oxidative damage. Biochemical Pharmacology 36(15): 2467-2472
Sutherland, L.R. 1991: 5-Aminosalicylates for prevention of recurrence in patients with Crohn's disease: time for a reappraisal?. Journal of Clinical Gastroenterology 13(1): 5-7
Roth, W. 1986: 5-Aminosalicylic acid -- a new therapeutic possibility in chronic inflammatory intestinal disease?. Leber Magen Darm 16(3): 176-178
Campieri, M.; Gionchetti, P.; Belluzzi, A.; Brignola, C.; Tabanelli, G.M.; Miglioli, M.; Barbara, L. 1988: 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis?. Journal of Clinical Gastroenterology 10(4): 406-409
Grisham, M.B.; Granger, D.N. 1989: 5-Aminosalicylic acid concentration in mucosal interstitium of cat small and large intestine. Digestive Diseases and Sciences 34(4): 573-578
Christensen, L.A.; Jacobsen, B.A. 1989: 5-Aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation. Netherlands Journal of Medicine 35(Suppl 1): S3-10
Sutherland, L.R.; Martin, F.; Greer, S.; Robinson, M.; Greenberger, N.; Saibil, F.; Martin, T.; Sparr, J.; Prokipchuk, E.; Borgen, L. 1987: 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92(6): 1894-1898
Rao, S.S. 1988: 5-Aminosalicylic acid enemas in distal colitis. Gastroenterology 95(6): 1698-1699
Friedman, L.S.; Richter, J.M.; Kirkham, S.E.; DeMonaco, H.J.; May, R.J. 1986: 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial. American Journal of Gastroenterology 81(6): 412-418
Guarino, J.; Chatzinoff, M.; Berk, T.; Friedman, L.S. 1987: 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: long-term results. American Journal of Gastroenterology 82(8): 732-737
Sutherland, L.R.; Martin, F. 1987: 5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada. Digestive Diseases and Sciences 32(12 Suppl): 64s-66s
Biddle, W.L.; Greenberger, N.J.; Swan, J.T.; McPhee, M.S.; Miner, P.B. 1988: 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 94(4): 1075-1079
Bondesen, S.; Tage-Jensen, U.; Jacobsen, O.; Hansen, S.H.; Rasmussen, S.N.; Hvidberg, E.F. 1986: 5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. a comparison of the fate of sulfasalazine and Pentasa. European Journal of Clinical Pharmacology 31(1): 23-26
Gionchetti, P.; Belluzzi, A.; Campieri, M.; Torresan, F.; Tabanelli, G.M.; Brignola, C.; Miglioli, M.; Barbara, L. 1988: 5-Aminosalicylic acid in patients with ulcerative colitis in remission: plasma levels after administration of a new rectal enema. Methods and Findings in Experimental and Clinical Pharmacology 10(10): 667-669
Bondesen, S.; Rasmussen, S.N.; Rask-Madsen, J.; Nielsen, O.H.; Lauritsen, K.; Binder, V.; Hansen, S.H.; Hvidberg, E.F. 1987: 5-Aminosalicylic acid in the treatment of inflammatory bowel disease. Acta Medica Scandinavica 221(3): 227-242
Mahida, Y.R.; Lamming, C.E.; Gallagher, A.; Hawthorne, A.B.; Hawkey, C.J. 1991: 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut 32(1): 50-54
Taggart, A.J.; Neumann, V.C.; Hill, J.; Astbury, C.; Le Gallez, P.; Dixon, J.S. 1986: 5-Aminosalicylic acid or sulphapyridine. which is the active moiety of sulphasalazine in rheumatoid arthritis?. Drugs 32(Suppl 1): 27-34
Kvietys, P.R.; Smith, S.M.; Grisham, M.B.; Manci, E.A. 1988: 5-Aminosalicylic acid protects against ischemia/reperfusion-induced gastric bleeding in the rat. Gastroenterology 94(3): 733-738
D'Arienzo, A.; Panarese, A.; D'Armiento, F.P.; Lancia, C.; Quattrone, P.; Giannattasio, F.; Boscaino, A.; Mazzacca, G. 1990: 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. American Journal of Gastroenterology 85(9): 1079-1082
Campieri, M.; Gionchetti, P.; Belluzzi, A.; Brignola, C.; Torresan, F.; Tampieri, M.; Iannone, P.; Miglioli, M.; Barbara, L. 1989: 5-Aminosalicylic acid suppositories in the management of ulcerative colitis. Diseases of the Colon and Rectum 32(5): 398-399
Hartmann, F. 1986: 5-Aminosalicylic acid--a new therapeutic possibility in chronic inflammatory bowel disease. Leber Magen Darm 16(1): 20-27
Luzzi, S.; Maggi, C.A.; Spagnesi, S.; Santicioli, P.; Zilletti, L. 1985: 5-Aminovaleric acid interactions with GABAA and GABAB receptors in guinea-pig ileum. Journal of Autonomic Pharmacology 5(1): 65-69
Albone, E.S.; Robins, S.P.; Patel, D. 1976: 5-Aminovaleric acid, a major free amino acid component of the anal sac secretion of the red fox, Vulpes vulpes. Comparative Biochemistry and Physiology. B Comparative Biochemistry 55(4): 483-486
Massa, S.; Corelli, F.; Artico, M.; Mai, A.; Silvestri, R.; Pantaleoni, G.C.; Palumbo, G.; Fanini, D.; Giorgi, R. 1989: 5-Aroyl-5,6-dihydro-4H-pyrrolo[1,2-a][1,4]benzodiazepin-4-carboxylic acids: synthesis and analgesic and neurobehavioral activity. Farmaco 44(2): 109-123
Dal Piaz, V.; Ciciani, G.; Bañez, M.; Vadillo, S.; Valle, J.; Torroba, T. 1986: 5-Aryl-3-(2-arylvinyl)-2-methylisoxazolium tetrafluoborates as selective antibacterial compounds. Bollettino Chimico Farmaceutico 125(11): 384-386
Paul, K.; Blanton, C.D. 1976: 5-Aryloxy-6-methoxy-8-aminoquinolines as potential prophylactic antimalarials. Journal of Pharmaceutical Sciences 65(10): 1527-1530
Walter, R.; Skala, G.; Smith, C.W. 1978: 5-Aspartic acid]-oxytocin: first 5-position neurohypophyseal hormone analogue possessing significant biological activity. Journal of the American Chemical Society 100(3): 792-793
Clavel, M.; Monfardini, S.; Fosså, S.; Smyth, J.; Renard, J.; Kaye, S.B. 1992: 5-Aza-2'-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase Ii from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group. Annals of Oncology: Official Journal of the European Society for Medical Oncology 3(5): 399-400
Pinto, A.; Zagonel, V.; Attadia, V.; Bullian, P.L.; Gattei, V.; Carbone, A.; Monfardini, S.; Colombatti, A. 1989: 5-Aza-2'-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplantation 4(Suppl): 28-32
Bartolucci, S.; Estenoz, M.; Longo, A.; Santoro, B.; Momparler, R.L.; Rossi, M.; Augusti-Tocco, G. 1989: 5-Aza-2'-deoxycytidine as inducer of differentiation and growth inhibition in mouse neuroblastoma cells. Cell Differentiation and Development: the Official Journal of the International Society of Developmental Biologists 27(1): 47-55
Bouchard, J.; Leclerc, J.M.; Thibodeau, L.; Walker, M.C. 1988: 5-Aza-cytosine derivative chemotherapy in AIDS. Annales de l'Institut Pasteur. Virology 139(3): 309-317
Pancaldi, S.; Del Senno, L.; Fasulo, M.P.; Poli, F.; Vannini, G.L. 1988: 5-Azacytidine accelerates yeast-mycelium conversion in Candida albicans. Cell Biology International Reports 12(1): 35-40
Humphries, R.K.; Dover, G.; Young, N.S.; Moore, J.G.; Charache, S.; Ley, T.; Nienhuis, A.W. 1985: 5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin. Journal of Clinical Investigation 75(2): 547-557
Kwok, F.W.; Ng, S.F. 1989: 5-Azacytidine affects the programming of expression of the somatic nucleus of Paramecium. Development 105(3): 559-568
Pathak, V.K.; Temin, H.M. 1992: 5-Azacytidine and RNA secondary structure increase the retrovirus mutation rate. Journal of Virology 66(5): 3093-3100
Leshin, M. 1985: 5-Azacytidine and sodium butyrate induce expression of aromatase in fibroblasts from chickens carrying the henny feathering trait but not from wild-type chickens. Proceedings of the National Academy of Sciences of the United States of America 82(9): 3005-3009
Cavaliere, A.; Bufalari, A.; Vitali, R. 1987: 5-Azacytidine carcinogenesis in BALB/c mice. Cancer Letters 37(1): 51-58
Dover, G.J.; Charache, S.; Boyer, S.H.; Vogelsang, G.; Moyer, M. 1985: 5-Azacytidine increases HbF production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens. Blood 66(3): 527-532
Foster, R.; Jahroudi, N.; Gedamu, L. 1991: 5-Azacytidine increases the total cellular copper content and basal level metallothionein mRNA accumulation of human Hep G2 cells. Biochimica et Biophysica Acta 1088(3): 373-379
Deguchi, Y.; Negoro, S.; Hara, H.; Kishimoto, S. 1988: 5-Azacytidine induced inhibition of mitogenic response by agents that activate or augment activation of human peripheral blood T lymphocytes. Biochemical and Biophysical Research Communications 151(3): 1395-1401
Osgood, C.J.; Seward, S.M. 1989: 5-Azacytidine induces sex chromosome loss and interchange in immature germ cells of Drosophila mei-9 males. Environmental and Molecular Mutagenesis 14(3): 135-145
Zerbini, M.; Musiani, M.; Gibellini, D.; Gentilomi, G.; La Placa, M. 1991: 5-Azacytidine induction of a cellular heat shock protein and expression of the major immediate early protein of human cytomegalovirus in Vero cells. Microbiologica 14(4): 287-294
Sato, M.; Azuma, M.; Hayashi, Y.; Yoshida, H.; Yanagawa, T.; Yura, Y. 1987: 5-Azacytidine induction of stable myoepithelial and acinar cells from a human salivary intercalated duct cell clone. Cancer Research 47(16): 4453-4459
Kopelovich, L. 1987: 5-Azacytidine inhibits adipocytic conversion of human skin fibroblasts by Kirsten murine sarcoma virus and dexamethasone. Experimental Cell Biology 55(5): 276-280
Call, K.M.; Thilly, W.G. 1991: 5-Azacytidine inhibits the induction of transient TK-deficient cells by 5-bromodeoxyuridine. a novel hypothesis for the facilitation of hypermethylation by 5-bromodeoxyuridine. Mutation Research 248(1): 101-114
Yoshida, H.; Yoshida, M.; Merino, R.; Shibata, T.; Izui, S. 1990: 5-Azacytidine inhibits the lpr gene-induced lymphadenopathy and acceleration of lupus-like syndrome in MRL/MpJ-lpr/lpr mice. European Journal of Immunology 20(9): 1989-1993
Chiu, C.P.; Blau, H.M. 1985: 5-Azacytidine permits gene activation in a previously noninducible cell type. Cell 40(2): 417-424
Honda, S.; Matsuo, M. 1987: 5-Azacytidine shortens the in vitro lifespan of human diploid cells. Cell Biology International Reports 11(2): 141
Dunbar, C.; Travis, W.; Kan, Y.W.; Nienhuis, A. 1989: 5-Azacytidine treatment in a beta (0)-thalassaemic patient unable to be transfused due to multiple alloantibodies. British Journal of Haematology 72(3): 467-468
Shin, T.H.; Paterson, A.J.; Grant, J.H.; Meluch, A.A.; Kudlow, J.E. 1992: 5-Azacytidine treatment of HA-A melanoma cells induces Sp1 activity and concomitant transforming growth factor alpha expression. Molecular and Cellular Biology 12(9): 3998-4006
Farrar, W.L.; Ruscetti, F.W.; Young, H.A. 1985: 5-Azacytidine treatment of a murine cytotoxic T cell line alters interferon-gamma gene induction by interleukin 2. Journal of Immunology 135(3): 1551-1554
Schindler, D.; Haaf, T.; Schmid, M. 1985: 5-Azacytidine treatments in the characterization of a t(1;21)(q12;q22) carrier karyotype. Clinical Genetics 27(1): 72-77
Masucci, M.G.; Contreras-Salazar, B.; Ragnar, E.; Falk, K.; Minarovits, J.; Ernberg, I.; Klein, G. 1989: 5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line rael. Journal of Virology 63(7): 3135-3141
Stallings, R.L.; Crawford, B.D.; Tobey, R.A.; Tesmer, J.; Hildebrand, C.E. 1986: 5-Azacytidine-induced conversion to cadmium resistance correlates with early S phase replication of inactive metallothionein genes in synchronized CHO cells. Somatic Cell and Molecular Genetics 12(5): 423-432
Gray, M.D.; Jesch, S.A.; Stein, G.H. 1991: 5-Azacytidine-induced demethylation of DNA to senescent level does not block proliferation of human fibroblasts. Journal of Cellular Physiology 149(3): 477-484
Takeuchi, I.K.; Takeuchi, Y.K. 1985: 5-Azacytidine-induced exencephaly in mice. Journal of Anatomy 140: 403-412
Hansen, R.S.; Gartler, S.M. 1990: 5-Azacytidine-induced reactivation of the human X chromosome-linked PGK1 gene is associated with a large region of cytosine demethylation in the 5' CpG island. Proceedings of the National Academy of Sciences of the United States of America 87(11): 4174-4178
Mitani, H.; Yagi, T.; Leiler, C.Y.; Takebe, H. 1989: 5-Azacytidine-induced recovery of O6-alkylguanine--DNA alkyltransferase activity in mouse Ha821 cells. Carcinogenesis 10(10): 1879-1882
Burbank, D.E.; Shields, S.L.; Schuster, A.M.; Van Etten, J.L. 1990: 5-Azacytidine-resistant mutants of Chlorella virus IL-3A. Virology 176(1): 311-315
Weisman, S.J.; Berkow, R.L.; Weetman, R.M.; Baehner, R.L. 1985: 5-Azacytidine: acute central nervous system toxicity. American Journal of Pediatric Hematology/Oncology 7(1): 86-88
Barbé, J.; Gibert, I.; Guerrero, R. 1986: 5-Azacytidine: survival and induction of the SOS response in Escherichia coli K-12. Mutation Research 166(1): 9-16
Haaf, T.; Schmid, M. 1989: 5-Azadeoxycytidine induced undercondensation in the giant X chromosomes of Microtus agrestis. Chromosoma 98(2): 93-98
Evans, R.K.; Johnson, J.D.; Haley, B.E. 1986: 5-Azido-2'-deoxyuridine 5'-triphosphate: a photoaffinity-labeling reagent and tool for the enzymatic synthesis of photoactive DNA. Proceedings of the National Academy of Sciences of the United States of America 83(15): 5382-5386
Seela, F.; Rosemeyer, H. 1977: 5-Azido-omega-bromo-2-nitroacetophenone. a crosslinking reagent with groups of selective reactivity. Hoppe-Seyler's Zeitschrift für Physiologische Chemie 358(1): 129-131
Gossrau, R.; Eschenfelder, V.; Brossmer, R. 1977: 5-Brom-3-indolyl-alpha-ketoside of 5-N-acetyl-D-neuraminic acid a new substrate for the light and electron microscopic demonstration of mammalian neuraminidase. Histochemistry 53(2): 189-192
Knol, J.A.; Stetson, P.L.; Wagner, J.G.; Johnson, N.J.; Yang, Z.M.; Prieskorn, D.; Terrio, P.; Knutsen, C.A.; Ensminger, W.D. 1989: 5-Bromo-2'-deoxyuridine incorporation into DNA in hepatic VX2 tumor-bearing rabbits. Journal of Surgical Research 47(2): 112-116
Tsunamoto, K.; Imashuku, S.; Hibi, S.; Esumi, N.; Kato, K. 1988: 5-Bromo-2'-deoxyuridine induces S 100 protein in human neuroblastoma cells in culture. Progress in Clinical and Biological Research 271: 327-336
Inoue, Y.K.; Nishibe, Y.; Kimura, T. 1990: 5-Bromodeoxyuridine enhancement of Inoue-Melnick virus synthesis in human colon carcinoma cell lines. Journal of Medical Virology 31(4): 249-252
Sakamoto, H.; Traincard, F.; Vo-Quang, T.; Ternynck, T.; Guesdon, J.L.; Avrameas, S. 1987: 5-Bromodeoxyuridine in vivo labelling of M13 DNA, and its use as a non-radioactive probe for hybridization experiments. Molecular and Cellular Probes 1(1): 109-120
Goldé, A.; Rouillard, D. 1979: 5-Bromodeoxyuridine inhibition of the transformation of Rous sarcoma virus-infected chicken cells. Comptes Rendus des Seances de l'Academie des Sciences. Serie D Sciences Naturelles 289(16): 1267-1270
Dickinson, D.G.; Baker, R.F. 1979: 5-Bromodeoxyuridine inhibits sequence changes within inverted repeat DNA during embryogenesis. Science 205(4408): 816-818
Heartlein, M.W.; Tsuji, H.; Latt, S.A. 1987: 5-Bromodeoxyuridine-dependent increase in sister chromatid exchange formation in Bloom's syndrome is associated with reduction in topoisomerase Ii activity. Experimental Cell Research 169(1): 245-254
Napalkov, N.P.; Anisimov, V.N.; Likhachev, A.J.; Tomatis, L. 1989: 5-Bromodeoxyuridine-induced carcinogenesis and its modification by persistent estrus syndrome, unilateral nephrectomy, and X-irradiation in rats. Cancer Research 49(2): 318-323
Saxena, P.R.; Verdouw, P.D. 1985: 5-Carboxamide tryptamine, a compound with high affinity for 5-hydroxytryptamine1 binding sites, dilates arterioles and constricts arteriovenous anastomoses. British Journal of Pharmacology 84(2): 533-544
Connor, H.E.; Feniuk, W.; Humphrey, P.P.; Perren, M.J. 1986: 5-Carboxamidotryptamine is a selective agonist at 5-hydroxytryptamine receptors mediating vasodilatation and tachycardia in anaesthetized cats. British Journal of Pharmacology 87(2): 417-426
Trevethick, M.A.; Feniuk, W.; Humphrey, P.P. 1986: 5-Carboxamidotryptamine: a potent agonist mediating relaxation and elevation of cyclic AMP in the isolated neonatal porcine vena cava. Life Sciences 38(16): 1521-1528
Beck, S.G. 1989: 5-Carboxyamidotryptamine mimics only the 5-HT elicited hyperpolarization of hippocampal pyramidal cells via 5-HT1A receptor. Neuroscience Letters 99(1-2): 101-106
Nawojski, A.; Nawrocka, W.; Liszkiewicz, H. 1985: 5-Carboxylic derivatives of some 1,5-benzodiazepines. Polish Journal of Pharmacology and Pharmacy 37(1): 69-72
Fawcett, T.; Garrido-Pertierra, A.; Cooper, R.A. 1989: 5-Carboxymethyl-2-hydroxymuconic semialdehyde dehydrogenases of Escherichia coli C and Klebsiella pneumoniae M5a1 show very high N-terminal sequence homology. Fems Microbiology Letters 57(3): 307-311
Balzarini, J.; van Aerschot, A.; Herdewijn, P.; de Clercq, E. 1989: 5-Chloro-substituted derivatives of 2', 3'-didehydro-2',3'-dideoxyuridine, 3'-fluoro-2',3'-dideoxyuridine and 3'-azido-2',3'-dideoxyuridine as anti-HIV agents. Biochemical Pharmacology 38(6): 869-874
Stobetskiĭ, V.I.; Mironova, L.L. 1988: 5-Chlorodeoxyuridine, more effectively than 5-bromodeoxyuridine, induces the formation of specific dicentric chromosomes in cells with micronuclei. Tsitologiia 30(12): 1498-1500
Jaffe, E.K.; Abrams, W.R.; Kaempfen, H.X.; Harris, K.A. 1992: 5-Chlorolevulinate modification of porphobilinogen synthase identifies a potential role for the catalytic zinc. Biochemistry 31(7): 2113-2123
Bernier, J.L.; Hénichart, J.P.; Warin, V.; Trentesaux, C.; Jardillier, J.C. 1985: 5-Cinnamoyl-6-aminouracil derivatives as novel anticancer agents. Synthesis, biological evaluation, and structure-activity relationships. Journal of Medicinal Chemistry 28(4): 497-502
Janda, M.; Hemmerich, P. 1976: 5-Deaza- and 5-thiariboflavins: a simple pathway to antimetabolites of vitamin B2. Angewandte Chemie 15(7): 443-444
Lindstedt, S.; Steen, G. 1975: 5-Decynedioic acid, an acetylenic compound in human urine. Clinical Chemistry 21(13): 1964-1969
Maitra, U.S.; Sprinson, D.B. 1978: 5-Dehydro-3-deoxy-D-arabino-heptulosonic acid 7-phosphate. An intermediate in the 3-dehydroquinate synthase reaction. Journal of Biological Chemistry 253(15): 5426-5430
Kulhánek, M.; Tadra, M.; Pacák, J.; Trejbalová, H.; Cerný, M. 1977: 5-Deoxy-5-fluoro-L-sorbose originating from 2-deoxy-2-fluoro-D-glucitol by fermentation with Acetomonas oxydans. Folia Microbiologica 22(4): 295-297
Huynh, Q.K. 1991: 5-Enolpyruvylshikimate-3-phosphate synthase from Escherichia coli--the substrate analogue bromopyruvate inactivates the enzyme by modifying Cys-408 and Lys-411. Archives of Biochemistry and Biophysics 284(2): 407-412
Davis, W.B.; Oakes, J.E.; Vacik, J.P.; Rebert, R.R.; Taylor, J.A. 1979: 5-Ethyl-2'-deoxyuridine as a systemic agent for treatment of herpes simplex virus encephalitis. Comparison of effects in a normal and immunosuppressed murine model. Advances in Ophthalmology 38: 140-150
Walter, R.D.; Gauri, K.K. 1975: 5-Ethyl-2'-deoxyuridine-5'-monophosphate inhibition of the thymidylate synthetase from Escherichia coli. Biochemical Pharmacology 24(9): 1025-1027
Tuominen, H.; Bergstrom, D.; Vilpo, J.A. 1985: 5-Ethyl-2'-deoxyuridine. Cytotoxicity and DNA incorporation demonstrated with human leukemic cells and PHA-stimulated lymphocytes in vitro. Acta Chemica Scandinavica. Series B: Organic Chemistry and Biochemistry 39(9): 735-743
Jeney, A.; Barrie, S.E.; Taylor, G.A.; Newell, D.R.; Harrap, K.R.; Szabolcs, A.; Lapis, K.; Otvös, L. 1986: 5-Ethyl-2'-deoxyuridine: an explanation for its lack of cytotoxic action in vivo. European Journal of Cancer and Clinical Oncology 22(5): 557-562
Suenaga, M. 1988: 5-FU and HCFU concentrations in serum and tissues in hepatocellular carcinoma after HCFU oral administration. Gan no Rinsho. Japan Journal of Cancer Clinics 34(6): 744-748
Hazlewood, B. 1990: 5-FU and leucovorin: unexpected side effects. Oncology Nursing Forum 17(5): 762
Bugnon, P.Y.; Elhage, A.; Bounoua, F.; Gautier-Benoît, C. 1992: 5-FU cardiotoxicity in adjuvant chemotherapy for colonic cancer letter). Bulletin du Cancer 79(4): 365-367
Oiwa, T.; Saito, H. 1986: 5-FU concentration in blood and tissue of patients with primary lung cancer after oral administration of UFT. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 13(3 Part 1): 525-530
Masuda, F.; Suzuki, M.; Ohnishi, T.; Nakada, J.; Mori, Y.; Iizuka, N.; Machida, T. 1985: 5-FU concentration in blood and tissue of patients with renal cell carcinoma after administration of UFT. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 12(2): 320-324
Seo, Y.; Hara, Y.; Furusawa, M.; Nakane, H.; Saeki, K.; Tsujitani, S.; Sonoda, T.; Nohtsuka, T.; Kameda, K.; Tomoda, H. 1988: 5-FU concentration in portal blood after oral administration of 1-hexylcarbamoyl-5-fluorouracil (HCFU). Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(5): 1803-1805
Arima, S.; Futami, K.; Shigeta, M.; Kinashi, M.; Shimura, H. 1986: 5-FU concentration in the blood and tissue of patients with gastric and colorectal cancer after administration of UFT or tegafur. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 13(8): 2618-2624
Takahashi, N. 1991: 5-FU concentration in the tissue of gastric cancer, and evaluation of cancer chemotherapy with angiotensin-Ii. Nihon Geka Gakkai Zasshi 92(7): 775-784
Koida, T.; Kimura, M. 1985: 5-FU concentration in the tissues (tumor and lymph node) of breast cancer patients given preoperative administration of UFT and FT. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 12(5): 1147-1151
Takeshita, M.; Ishikawa, H.; Seki, M.; Ikeya, T.; Miyamoto, Y.; Izuo, M.; Tozuka, S.; Usui, R.; Kaneko, H. 1985: 5-FU concentration in tissues of gastric cancer patients with preoperative administration of UFT--especially in comparison with FT-207. Gan no Rinsho. Japan Journal of Cancer Clinics 31(13): 1697-1703
Fukunaga, H.; Katsumi, M.; Aoki, Y.; Oka, S.; Konishi, R.; Yukawa, H.; Kawaguchi, T.; Tamaki, Y.; Takifuji, K. 1987: 5-FU concentration in tumor tissue and the antitumor effect in patients with gastric cancer after oral administration of UFT. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(9): 2735-2739
Izbicki, R.M.; Baker, L.H.; Samson, M.K.; McDonald, B.; Vaitkevicius, V.K. 1977: 5-FU infusion and cyclophosphamide in the treatment of advanced ovarian cancer. Cancer Treatment Reports 61(8): 1573-1575
Shah, A.; MacDonald, W.; Goldie, J.; Gudauskas, G.; Brisebois, B. 1985: 5-FU infusion in advanced colorectal cancer: a comparison of three dose schedules. Cancer Treatment Reports 69(7-8): 739-742
Bohno, K.; Ushijima, T. 1989: 5-FU intra-arterial infusion and simultaneous irradiation in the treatment of esophageal cancer and metastatic lung cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(8 Part 2): 2701-2706
Katz, I.M. 1992: 5-FU trabeculectomy. Ophthalmology 99(1): 3
Awrich, A.; Fletcher, W.S.; Klotz, J.H.; Minton, J.P.; Hill, G.J.; Aust, J.B.; Grage, T.B.; Multhauf, P.M. 1979: 5-FU versus combination therapy with tubercidin, streptozotocin, and 5-FU in the treatment of pancreatic carcinomas: COG protocol 7230. Journal of Surgical Oncology 12(3): 267-273
Tanimura, T.; Kaneshige, E.; Fujiwara, K.; Kobashi, Y.; Inoue, K.; Kono, I.; Sekiba, K. 1986: 5-FU, FT-207 and uracil concentrations in the serum and tissues of patients with cervical cancer after UFT oral administration. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 13(2): 349-355
Nakano, S.; Mitsugi, K.; Ichinose, I.; Kuroki, M.; Anzai, K.; Nakamura, M.; Niho, Y. 1991: 5-FU-leucovorin and cisplatin sequential chemotherapy with dipyridamole for non-small cell lung cancer (NSCLC). a pilot study for 5 cases. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 18(8): 1375-1378
Arai, Y.; Kido, C.; Endo, T.; Miyake, Y.; Sato, Y.; Ozawa, H. 1988: 5-FU/ADR/MMC combined hepatic infusion in liver metastases from gastric cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(8 Part 2): 2433-2436
Arbuck, S.G. 1987: 5-FU/leucovorin: biochemical modulation that works?. Oncology 1(2): 61-74
Link, J.S.; Bateman, J.R.; Paroly, W.S.; Durkin, W.J.; Peters, R.L. 1977: 5-Flourouracil in hepatocellular carcinoma: report of twenty-one cases. Cancer 39(5): 1936-1939
De Melo, S.J.; Luu-Duc, C.; Thomasson, F.; Narcisse, G.; Gaultier, C. 1992: 5-Fluoro (3H) pyrimidine-4-ones: synthesis, reactivity and pharmacological properties. Annales Pharmaceutiques Francaises 50(1): 39-51
Csaky, K.G.; LaCreta, F.P.; Warren, B.S.; Williams, W.M. 1988: 5-Fluoro-2'-deoxyuridine elimination by the isolated perfused rat liver. Cancer Research 48(13): 3561-3565
Roobol, C.; De Dobbeleer, G.B.; Bernheim, J.L. 1986: 5-Fluoro-5'-deoxyuridine is an inhibitor of uridylate nucleotidase in L1210 leukaemia. Advances in Experimental Medicine and Biology 195 Pt B: 177-183
Fabbri, A.; Tacchella, A.; Belli, M.L.; Toriello, E. 1987: 5-Fluorocytosine and Candida yeasts. Chemioterapia: International Journal of the Mediterranean Society of ChemoTherapy 6(1): 8-11
Polak, A. 1987: 5-Fluorocytosine and combinations. Annales de Biologie Clinique 45(6): 669-672
Osterman, D.G.; DePillis, G.D.; Wu, J.C.; Matsuda, A.; Santi, D.V. 1988: 5-Fluorocytosine in DNA is a mechanism-based inhibitor of Hhai methylase. Biochemistry 27(14): 5204-5210
Ittel, T.H.; Legler, U.F.; Polak, A.; Glöckner, W.M.; Sieberth, H.G. 1987: 5-Fluorocytosine kinetics in patients with acute renal failure undergoing continuous hemofiltration. ChemoTherapy 33(2): 77-84
Chin, C.S.; Cheong, Y.M.; Wong, Y.H. 1989: 5-Fluorocytosine resistance in clinical isolates of Cryptococcus neoformans. Medical Journal of Malaysia 44(3): 194-198
Cohen, B.A.; Looij, B.J.; Wittner, M. 1977: 5-Fluorocytosine, a valuable fungicidal agent in specific culture media. Annales de la Societe Belge de Medecine Tropicale 57(1): 55
Otcenásek, M.; Kejda, J. 1989: 5-Fluorocytosine. a neglected systemic antimycotic in Czechoslovakia. Casopis Lekaru Ceskych 128(43-44): 1385-1389
Habener, J.F.; Vo, C.D.; Le, D.B.; Gryan, G.P.; Ercolani, L.; Wang, A.H. 1988: 5-Fluorodeoxyuridine as an alternative to the synthesis of mixed hybridization probes for the detection of specific gene sequences. Proceedings of the National Academy of Sciences of the United States of America 85(6): 1735-1739
Daune, G.; Gerhart, F.; Seiler, N. 1988: 5-Fluoromethylornithine, an irreversible and specific inhibitor of L-ornithine:2-oxo-acid aminotransferase. Biochemical Journal 253(2): 481-488
Zak, V.L.; Kelln, R.A. 1978: 5-Fluoroorotate-resistant mutants of Salmonella typhimurium. Canadian Journal of Microbiology 24(11): 1339-1345
Heath, T.D.; Lopez, N.G.; Stern, W.H.; Papahadjopoulos, D. 1985: 5-Fluoroorotate: a new liposome-dependent cytotoxic agent. Febs Letters 187(1): 73-75
Boeke, J.D.; Trueheart, J.; Natsoulis, G.; Fink, G.R. 1987: 5-Fluoroorotic acid as a selective agent in yeast molecular genetics. Methods in Enzymology 154: 164-175
Lönn, U.; Lönn, S.; Nylen, U.; Winblad, G. 1989: 5-Fluoropyrimidine-induced DNA damage in human colon adenocarcinoma and its augmentation by the nucleoside transport inhibitor dipyridamole. Cancer Research 49(5): 1085-1089
Pellegrini, F.; Di Noto, G.; Ansuini, G.; Pisani, E.; Russo, P.; Luzi Fedeli, S.; Torresi, U.; Guidi, F.; Cellerino, R. 1986: 5-Fluorouracil (5-FU) cardiotoxicity. Evaluation by dynamic ECG. Recenti Progressi in Medicina 77(1): 46-49
Goya, N.; Yanagisawa, H.; Nakamura, R.; Toma, H. 1990: 5-Fluorouracil (5-FU) concentration in prostatic tissue of rats and in prostatic cancer patients after oral administration of 5-FU. Hinyokika Kiyo. Acta Urologica Japonica 36(5): 549-555
Macdonald, J.S.; Kisner, D.F.; Smythe, T.; Woolley, P.V.; Smith, L.; Schein, P.S. 1976: 5-Fluorouracil (5-FU), methyl-CCNU, and vincristine in the treatment of advanced colorectal cancer: phase Ii study utilizing weekly 5-FU. Cancer Treatment Reports 60(11): 1597-1600
Wei, X.Y.; Zhou, X.M. 1987: 5-Fluorouracil (5-Fu) in the treatment of prostatic hyperplasia. Urological Research 15(1): 35-37
Brohée, D. 1991: 5-Fluorouracil (5FU) with or without folinic acid (LV) in human colorectal cancer? Multivariate meta-analysis of the literature. Medical Oncology and Tumor PharmacoTherapy 8(4): 271-280
Franchi, F.; Barone, C.; Seminara, P.; Codacci-Pisanelli, G.; Codacci-Pisanelli, M.; Ferri, G.M.; Garufi, C.; Grieco, A.; Pagani, V. 1991: 5-Fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. in vitro activity of the two drugs in short-term tumor cultures. Medical Oncology and Tumor PharmacoTherapy 8(2): 75-78
Franchi, F.; Barone, C.; Ricevuto, E.; Cassano, A.; Astone, A.; Pozzo, C.; Sofo, L.; Netri, G.; Ratto, C.; Coco, C. 1991: 5-Fluorouracil (FU) with folinic acid (FA) and mitomycin C (MMC) in the adjuvant treatment of colorectal carcinoma. Part I. Evaluation of toxicity. Medical Oncology and Tumor PharmacoTherapy 8(2): 69-73
Erlichman, C. 1988: 5-Fluorouracil (FUra) and folinic acid (FA) therapy in patients with colorectal cancer. Advances in Experimental Medicine and Biology 244: 185-192
Brugarolas, A.; Rivas, A.; Lacave, A.J.; Gonzalez-Palacois, F.; Froufe, A. 1975: 5-Fluorouracil (NSC-19893) compared to cyclophosphamide (NSC-26271) in bronchogenic carcinoma: results of a clinical study. Cancer ChemoTherapy Reports 59(5): 1025-1026
Stolinsky, D.C.; Pugh, R.P.; Bateman, J.R. 1975: 5-Fluorouracil (NSC-19893) therapy for pancreatic carcinoma: comparison of oral and intravenous routes. Cancer ChemoTherapy Reports 59(5): 1031-1033
Von Eyben, F.E.; Larsen, V.; Pedersen, H. 1976: 5-Fluorouracil (NSC-19893), DTIC (NSC-45388), BCNU (NSC-409962), and vincristine (NSC-67574) in advanced colorectal carcinoma. Cancer Treatment Reports 60(1): 29-32
Constantinescu, C.; Puiu, R.; Straja, D. 1989: 5-Fluorouracil (ftorafur) in the treatment of acute pancreatitis. Indications for and efficacy of its use. Revista de Medicina Interna Neurologe Psihiatrie Neurochirurgie Dermato-Venerologie. Medicina Interna 41(5): 443-448
Baba, T.; Kidera, Y.; Kimura, N.T.; Aoki, K.; Kamura, T.; Taniguchi, S.; Nishikawa, K. 1978: 5-Fluorouracil O-beta-D-glucuronide as a newly synthesized chemically modified, nontoxic anticancer drug. Gan 69(2): 283-284
Wright, M.M.; Grajewski, A.L.; Cristol, S.M.; Parrish, R.K. 1991: 5-Fluorouracil after trabeculectomy and the iridocorneal endothelial syndrome. Ophthalmology 98(3): 314-316
Becher, R.; Kurschel, E.; Wandl, U.; Kloke, O.; Scheulen, M.; Weinhardt, O.; Höffken, K.; Niederle, N.; Khan, H.; Bergner, S. 1988: 5-Fluorouracil and 5-formyltetrahydrofolate in advanced malignancies. Advances in Experimental Medicine and Biology 244: 225-232
Maehara, Y.; Kusumoto, T.; Kusumoto, H.; Anai, H.; Sakaguchi, Y.; Kido, Y.; Okamura, T.; Korenaga, D.; Sugimachi, K. 1989: 5-Fluorouracil and UFT-sensitive gastric carcinoma has a high level of thymidylate synthase. Cancer 63(9): 1693-1696
Eisenstaedt, R.S.; Neilan, B.A.; Bartolucci, A. 1987: 5-Fluorouracil and cytarabine--ineffective treatment in advanced colorectal carcinoma: a Southeastern Cancer Study Group Trial. Cancer Treatment Reports 71(7-8): 779-780
Zaniboni, A.; Simoncini, E.; Marpicati, P.; Montini, E.; Palazzi, M.; Pipino, G.; Marini, G. 1989: 5-Fluorouracil and dipyridamole in metastatic breast cancer: a pilot study. Journal of ChemoTherapy 1(4): 266-268
Goldberg, I. 1991: 5-Fluorouracil and filtering surgery. Australian and New Zealand Journal of Ophthalmology 19(3): 173
Erlichman, C.; Fine, S. 1987: 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 5(9): 1492-1493
Budd, G.T.; Fleming, T.R.; Bukowski, R.M.; McCracken, J.D.; Rivkin, S.E.; O'Bryan, R.M.; Balcerzak, S.P.; Macdonald, J.S. 1987: 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. a Southwest Oncology Group Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 5(2): 272-277
Creaven, P.J. 1988: 5-Fluorouracil and folinic acid: summary of clinical experience. Advances in Experimental Medicine and Biology 244: 303-311
Heuer, D.K.; Parrish, R.K.; Gressel, M.G.; Hodapp, E.; Desjardins, D.C.; Skuta, G.L.; Palmberg, P.F.; Nevárez, J.A.; Rockwood, E.J. 1986: 5-Fluorouracil and glaucoma filtering surgery. III. Intermediate follow-up of a pilot study. Ophthalmology 93(12): 1537-1546
Asbury, R.F.; Boros, L.; Brower, M.; Woll, J.; Chang, A.; Bennett, J. 1987: 5-Fluorouracil and high-dose folic acid treatment for metastatic colon cancer. American Journal of Clinical Oncology 10(1): 47-49
Marini, G.; Simoncini, E.; Zaniboni, A.; Gorni, F.; Marpicati, P.; Zambruni, A. 1987: 5-Fluorouracil and high-dose folinic acid as salvage treatment of advanced breast cancer: an update. Oncology 44(6): 336-340
Merlano, M.; Bacigalupo, A.; Benasso, M.; Grimaldi, A.; Toma, S.; Benedetti, G.; Comella, G.; Cacace, F.; Rosso, R. 1990: 5-Fluorouracil and high-dose folinic acid as second-line chemotherapy in head and neck cancer. American Journal of Clinical Oncology 13(1): 1-3
Colozza, M.; Tonato, M.; Belsanti, V.; Mosconi, A.M.; Fiorucci, S.; Gernini, I.; Rambotti, P.; Davis, S. 1988: 5-Fluorouracil and isoprinosine in the treatment of advanced colorectal cancer. a limited phase I, Ii evaluation. Cancer 62(6): 1049-1052
Van Eeden, H.; Falkson, G.; Burger, W.; Ansell, S.M. 1992: 5-Fluorouracil and leucovorin in hepatocellular carcinoma. Annals of Oncology: Official Journal of the European Society for Medical Oncology 3(5): 404-405
Grem, J.L. 1990: 5-Fluorouracil and levamisole in colorectal carcinoma. Cancer Investigation 8(2): 283-284
Abbass, M.G.; Amir, S.G.; Abdel Hafiz, A.M. 1988: 5-Fluorouracil and mesodermal structures of the teeth in albino rats. Egyptian Dental Journal 34(1): 43-52
Lokich, J.J.; Phillips, D.; Green, R.; Paul, S.; Sonneborn, H.; Zipoli, T.E.; Curt, G. 1985: 5-Fluorouracil and methotrexate administered simultaneously as a continuous infusion. a phase i study. Cancer 56(10): 2395-2398
Aspegren, K.; Landberg, T. 1986: 5-Fluorouracil and mitomycin C in advanced breast cancer. RadioTherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 6(2): 121-126
Palmeri, S.; Gebbia, V.; Rausa, L. 1990: 5-Fluorouracil and recombinant alpha interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study. Journal of ChemoTherapy 2(5): 327-330
Pazdur, R.; Jackson, D.; Shepherd, B.; Saddler, D.; Font, L.; McCardell, M.; Myers, P.; Schmidt, S. 1991: 5-Fluorouracil and recombinant interferon alfa-2a: review of activity and toxicity in advanced colorectal carcinomas. Oncology Nursing Forum 18(1 Suppl): 11-17
Adenis, J.P.; Duprat, F. 1990: 5-Fluorouracil and trabeculectomy. a trial of low doses. Journal Francais d'Ophtalmologie 13(4): 169-175
Carter, S.K. 1979: 5-Fluorouracil as adjuvant chemotherapy for large bowel cancer. Is it appropriate for routine community use?. Cancer ChemoTherapy and Pharmacology 2(2): 81-84
Will, C.L.; Dolnick, B.J. 1987: 5-Fluorouracil augmentation of dihydrofolate reductase RNA containing contiguous exon and intron sequences in KB7B cells. Journal of Biological Chemistry 262(12): 5433-5436
Will, C.L.; Dolnick, B.J. 1986: 5-Fluorouracil augmentation of dihydrofolate reductase gene transcripts containing intervening sequences in methotrexate-resistant KB cells. Molecular Pharmacology 29(6): 643-648
Hansen, R.M.; Quebbeman, E.; Anderson, T. 1989: 5-Fluorouracil by protracted venous infusion. a review of current progress. Oncology 46(4): 245-250
Hansen, R.M. 1991: 5-Fluorouracil by protracted venous infusion: a review of recent clinical studies. Cancer Investigation 9(6): 637-642
Cavaliere, A.; Alberti, P.F.; Vitali, R. 1990: 5-Fluorouracil carcinogenesis in BALB/c mice. Tumori 76(2): 179-181
Gradishar, W.J.; Vokes, E.E. 1990: 5-Fluorouracil cardiotoxicity: a critical review. Annals of Oncology: Official Journal of the European Society for Medical Oncology 1(6): 409-414
Patel, B.; Kloner, R.A.; Ensley, J.; Al-Sarraf, M.; Kish, J.; Wynne, J. 1987: 5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators. American Journal of the Medical Sciences 294(4): 238-243
Sugarbaker, P.H.; Gianola, F.J.; Barofsky, I.; Hancock, S.L.; Wesley, R. 1986: 5-Fluorouracil chemotherapy and pelvic radiation in the treatment of large bowel cancer. Decreased toxicity in combined treatment with 5-fluorouracil administration through the intraperitoneal route. Cancer 58(4): 826-831
Au, J.L.; Sadée, W. 1979: 5-Fluorouracil concentrations in human plasma following R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) administration. Cancer Research 39(10): 4289-4290
Corbett, T.H.; Bissery, M.C.; Mucci-LoRusso, P.; Polin, L. 1989: 5-Fluorouracil containing combinations in murine tumor systems. Investigational new Drugs 7(1): 37-49
Yamashita, S.; Suda, Y.; Masada, M.; Nadai, T.; Sumi, M. 1989: 5-Fluorouracil derivatives with serum protein binding potencies. Chemical and Pharmaceutical Bulletin 37(10): 2861-2863
Ozaki, S.; Watanabe, Y.; Hoshiko, T.; Nagase, T.; Ogasawara, T.; Furukawa, H.; Uemura, A.; Ishikawa, K.; Mori, H.; Hoshi, A. 1986: 5-Fluorouracil derivatives. X. Synthesis and antitumor activities of alpha-alkoxyalkyl-5-fluorouracils. Chemical and Pharmaceutical Bulletin 34(1): 150-157
Ozaki, S.; Nagase, T.; Tamai, H.; Mori, H.; Hoshi, A.; Iigo, M. 1987: 5-Fluorouracil derivatives. XII. Synthesis and antitumor activity of alpha-alkylthiomethyl-, alpha-alkylsulfinylmethyl-, alpha-alkylsulfonylmethyl-, and alpha-acylthiomethyl-5-fluorouracils. Chemical and Pharmaceutical Bulletin 35(9): 3894-3897
Ozaki, S.; Akiyama, T.; Morita, T.; Kumegawa, M.; Nagase, T.; Uehara, N.; Hoshi, A. 1990: 5-Fluorouracil derivatives. XX. Synthesis and antitumor activity of 5'-O-unsaturated acyl-5-fluorouridines. Chemical and Pharmaceutical Bulletin 38(11): 3164-3166
Donowitz, G.R.; Quesenberry, P. 1986: 5-Fluorouracil effect on cultured murine stem cell progeny and peripheral leukocytes. Experimental Hematology 14(3): 207-214
Brunetti, I.; Falcone, A.; Calabresi, P.; Goulette, F.A.; Darnowski, J.W. 1990: 5-Fluorouracil enhances azidothymidine cytotoxicity: in vitro, in vivo, and biochemical studies. Cancer Research 50(13): 4026-4031
Ansfield, F.J.; Greenspan, E.M. 1979: 5-Fluorouracil for gastrointestinal cancer. New England Journal of Medicine 301(6): 328-329
Kitazawa, Y.; Taniguchi, T.; Nakano, Y.; Shirato, S.; Yamamoto, T. 1987: 5-Fluorouracil for trabeculectomy in glaucoma. Graefe's Archive for Clinical and Experimental Ophthalmology 225(6): 403-405
Haggard, M.E.; Cangir, A.; Ragab, A.H.; Komp, D.; Falletta, J.; Humphrey, G.B. 1977: 5-Fluorouracil in childhood solid tumors. Cancer Treatment Reports 61(1): 69-71
Malaviya, A.N.; Singh, R.R.; Dhar, A.; Gupta, Y.K.; Kumar, A.; Agarwal, P.; Mathur, R.; Bhide, N.K. 1988: 5-Fluorouracil in progressive systemic sclerosis: is it safe?. Annals of the Rheumatic Diseases 47(11): 964-965
Tonetti, F.; Calvi, A. 1989: 5-Fluorouracil in the treatment of acute pancreatitis. our experience. Minerva Dietologica e Gastroenterologica 35(3): 201-204
Goncalves, J.C. 1975: 5-Fluorouracil in the treatment of common warts of the hands. a double-blind study. British Journal of Dermatology 92(1): 89-91
Wallin, J. 1977: 5-Fluorouracil in the treatment of penile and urethral condylomata acuminata. British Journal of Venereal Diseases 53(4): 240-243
Jeng, S.; Ku, W.C.; Fan, D. 1989: 5-Fluorouracil in trabeculectomy: preliminary report. Journal of the Formosan Medical Association 88(11-12): 1171-1173
Teder, H.; Erichsen, C.; Christensson, P.I.; Jönsson, P.E.; Stenram, U. 1987: 5-Fluorouracil incorporation into RNA of a rat liver adenocarcinoma after hepatic artery injection together with degradable starch microspheres. Cancer Drug Delivery 4(3): 169-176
Jeske, J.; Hansen, R.M.; Libnoch, J.A.; Anderson, T. 1990: 5-Fluorouracil infusion and low-dose weekly cisplatin: an analysis of increased toxicity. American Journal of Clinical Oncology 13(6): 485-488
Weir, A.B.; Niell, H.B.; Griffin, J.P. 1989: 5-Fluorouracil infusion and mitomycin combination chemotherapy in the management of patients with advanced non-small-cell lung cancer. American Journal of Clinical Oncology 12(6): 521-523
Weinberg, M.J.; Rauth, A.M. 1987: 5-Fluorouracil infusions and fractionated doses of radiation: studies with a murine squamous cell carcinoma. International Journal of Radiation Oncology Biology Physics 13(11): 1691-1699
Maehara, Y.; Kusumoto, T.; Emi, Y.; Anai, H.; Sakaguchi, Y.; Kohnoe, S.; Sugimachi, K. 1990: 5-Fluorouracil is converted to F-nucleotides more extensively and is more cytotoxic in poorly differentiated than in well differentiated human gastric carcinoma. Anticancer Research 10(4): 1091-1094
Maeda, H.; Miyamoto, T.; Mochinaga, N.; Tsunoda, T. 1991: 5-Fluorouracil level and pyrimidine nucleoside phosphorylase activity in cancer patients after oral administration of doxifluridine (5'-DFUR). Gan to Kagaku Ryoho. Cancer and ChemoTherapy 18(6): 965-969
Smalley, S.R.; Kimler, B.F.; Evans, R.G. 1991: 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. International Journal of Radiation Oncology Biology Physics 20(2): 207-211
Moore, D.H.; Fowler, W.C.; Crumpler, L.S. 1990: 5-Fluorouracil neurotoxicity. Gynecologic Oncology 36(1): 152-154
Carlsson, G.; Gustavsson, B.G.; Spears, C.P.; Hafström, L.O. 1990: 5-Fluorouracil plus leucovorin as adjuvant treatment of an experimental liver tumor in rats. Anticancer Research 10(3): 813-816
Loprinzi, C.L.; Ingle, J.N.; Schaid, D.J.; Buckner, J.C.; Edmonson, J.H.; Allegra, C.J. 1991: 5-Fluorouracil plus leucovorin in women with metastatic breast cancer. a phase Ii study. American Journal of Clinical Oncology 14(1): 30-32
Hamilton, J.M.; Sznol, M.; Friedman, M.A. 1990: 5-Fluorouracil plus levamisole: effective adjuvant treatment for colon cancer. Important Advances in Oncology 1990: 115-130
Taal, B.G.; ten Bokkel Huinink, W.W.; Franklin, H.R.; McVie, J.G. 1990: 5-Fluorouracil plus tauromustine in advanced colorectal cancer: unexpected negative results. European Journal of Cancer 26(7): 856
Byfield, J.E. 1989: 5-Fluorouracil radiation sensitization--a brief review. Investigational new Drugs 7(1): 111-116
Jabboury, K.; Holmes, F.A.; Hortobagyi, G. 1989: 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer 64(4): 793-797
Lerner, C.; Harrison, D.E. 1990: 5-Fluorouracil spares hemopoietic stem cells responsible for long-term repopulation. Experimental Hematology 18(2): 114-118
Shapiro, M.S.; Thoft, R.A.; Friend, J.; Parrish, R.K.; Gressel, M.G. 1985: 5-Fluorouracil toxicity to the ocular surface epithelium. Investigative Ophthalmology and Visual Science 26(4): 580-583
von Wangenheim, K.H.; Peterson, H.P.; Cronkite, E.P.; Feinendegen, L.E. 1987: 5-Fluorouracil treatment after irradiation impairs recovery of bone marrow functions. Radiation and Environmental Biophysics 26(2): 163-170
Zimmerman, R.J.; VanWinkle, T.J.; Mantel, N.; Frei, E.; Goldin, A. 1986: 5-Fluorouracil treatment of a human colon adenocarcinoma implanted in the subrenal capsule site of athymic mice. Cancer Research 46(2): 694-700
Djawari, D. 1986: 5-Fluorouracil treatment of condylomata acuminata. Zeitschrift für Hautkrankheiten 61(7): 463-469
Ermens, A.A.; Kroes, A.C.; Lindemans, J.; Abels, J. 1986: 5-Fluorouracil treatment of rat leukemia and a reappraisal of its application in human leukemia. Anticancer Research 6(4): 797-800
De Lisi, V.; Cocconi, G.; Tonato, M.; Di Costanzo, F.; Leonardi, F.; Soldani, M. 1988: 5-Fluorouracil versus a combination of BCNU, adriamycin, 5-FU and mitomycin C in advanced gastric cancer: a prospective randomized study of the Italian Clinical Research Oncology Group. Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres Dans les Recherches sur le Cancer 110: 212-218
Evans, W.K.; Wierzbicki, R.; Shepherd, F.A.; Rusthoven, J.; Stewart, D.J.; Aitken, S.E.; Maroun, J.A.; Ezzat, A. 1990: 5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. Cancer Investigation 8(3-4): 345-349
Loprinzi, C.L. 1989: 5-Fluorouracil with leucovorin in breast cancer. Cancer 63(6 Suppl): 1045-1047
Vokes, E.E.; Vijayakumar, S.; Hoffman, P.C.; Ferguson, M.K.; Bitran, J.D.; Krishnasamy, S.; Jacobs, R.; Golomb, H.M. 1990: 5-Fluorouracil with oral leucovorin and hydroxyurea and concomitant radiotherapy for stage IIi non-small cell lung cancer. Cancer 66(3): 437-442
Maehara, Y.; Sakaguchi, Y.; Takahashi, I.; Yoshida, M.; Kusumoto, H.; Masuda, H.; Sugimachi, K. 1992: 5-Fluorouracil's cytotoxicity is enhanced both in vitro and in vivo by concomitant treatment with hyperthermia and dipyridamole. Cancer ChemoTherapy and Pharmacology 29(4): 257-260
Flechtner, H.; Queisser, W.; Heim, M.E.; Henss, H.; Arnold, H.; Fritze, D.; Herrmann, R.; Fritsch, H.; Fritz, M.; Trux, F.A. 1987: 5-Fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) combination chemotherapy for advanced gastric carcinoma. a phase-Ii trial by the "chemotherapiegruppe gastrointestinaler tumoren (CGT)". Onkologie 10(2): 67-71
Inoue, K.; Horikoshi, N.; Mukaiyama, T.; Ogawa, M.; Kuraishi, Y. 1989: 5-Fluorouracil, adriamycin, and mitomycin C (FAM) combination chemotherapy in adenocarcinoma of the parotid gland. Gan no Rinsho. Japan Journal of Cancer Clinics 35(4): 481-485
Butler, T.P.; MacDonald, J.S.; Smith, F.P.; Smith, L.F.; Woolley, P.V.; Schein, P.S. 1979: 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for adenocarcinoma of the lung. Cancer 43(4): 1183-1188
Shepherd, F.A.; Evans, W.K.; Burkes, R.; Paul, K.; DeBoer, G. 1986: 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) in the treatment of inoperable adenocarcinoma of the lung. American Journal of Clinical Oncology 9(5): 392-396
Lopez, M.; Papaldo, P.; Di Lauro, L.; Vici, P.; Carpano, S.; Conti, E.M. 1989: 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer. Oncology 46(1): 1-5
Triozzi, P.L.; Brantley, A.; Fisher, S.; Cole, T.B.; Crocker, I.; Huang, A.T. 1987: 5-Fluorouracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck. Cancer 59(5): 887-890
Biran, H.; Sulkes, A.; Biran, S. 1989: 5-Fluorouracil, doxorubicin (adriamycin) and mitomycin-C (FAM) in advanced gastric cancer: observations on response, patient characteristics, myelosuppression and delivered dosage. Oncology 46(2): 83-87
Van der Gaast, A.; Verweij, J.; Planting, A.S.; Stoter, G. 1988: 5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary. European Journal of Cancer and Clinical Oncology 24(4): 765-768
Schlumberger, M.; Brugieres, L.; Gicquel, C.; Travagli, J.P.; Droz, J.P.; Parmentier, C. 1991: 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer 67(12): 2997-3000
Schlumberger, M.; Ostronoff, M.; Bellaiche, M.; Rougier, P.; Droz, J.P.; Parmentier, C. 1988: 5-Fluorouracil, doxorubicin, and cisplatin regimen in adrenal cortical carcinoma. Cancer 61(8): 1492-1494
Shaw, M.T.; Shaw, M.K. 1987: 5-Fluorouracil, doxorubicin, and mitomycin-C in the treatment of adenocarcinoma and large cell carcinoma of the lung. Cancer 60(6): 1190-1193
Zamagni, C.; Martoni, A.; Ercolino, L.; Baroni, M.; Tanneberger, S.; Pannuti, F. 1991: 5-Fluorouracil, epirubicin and cyclophosphamide (FEC combination) in advanced breast cancer. Journal of ChemoTherapy 3(2): 126-129
Lopez, M.; Natali, M.; Di Lauro, L.; Tonini, G.; Carpano, S.; Vici, P.; Conti, E.M. 1990: 5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer. American Journal of Clinical Oncology 13(3): 204-207
Flaherty, L.; Wozniak, A.; Redman, B.; Kraut, M.; Martino, S.; Heilbrun, L.; Valdivieso, M. 1991: 5-Fluorouracil, etoposide, and cisplatin in the management of metastatic non-small cell lung cancer. Cancer 68(5): 944-947
Becouarn, Y.; Brunet, R.; Bussières, E.; Marée, D. 1988: 5-Fluorouracil, high-dose folinic acid, and mitomycin C combination chemotherapy in advanced gastrointestinal adenocarcinomas. a pilot study. Oncology 45(4): 269-272
Vokes, E.E.; Moormeier, J.A.; Ratain, M.J.; Egorin, M.J.; Haraf, D.J.; Mick, R.; Weichselbaum, R.R. 1992: 5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study. Cancer ChemoTherapy and Pharmacology 29(3): 178-184
Suenaga, M. 1987: 5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(12): 3313-3318
Furue, H. 1987: 5-Fluorouracil--recent advances in clinical studies. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(8): 2612-2615
Freeman, N.J.; Costanza, M.E. 1988: 5-Fluorouracil-associated cardiotoxicity. Cancer 61(1): 36-45
Spain, M.; McPherson, D. 1989: 5-Fluorouracil-induced angina. Journal of the Oklahoma State Medical Association 82(8): 407-409
Bardakji, Z.; Jolivet, J.; Langelier, Y.; Besner, J.G.; Ayoub, J. 1986: 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Clinical, pharmacokinetic and in vitro cytotoxicity studies. Cancer ChemoTherapy and Pharmacology 18(2): 140-144
Nagle, D.P.; Teal, R.; Eisenbraun, A. 1987: 5-Fluorouracil-resistant strain of Methanobacterium thermoautotrophicum. Journal of Bacteriology 169(9): 4119-4123
Hartenstein, R.; Wendt, T.G.; Kastenbauer, E.R. 1988: 5-Fluorouracil/folinic acid/cisplatin-combination and simultaneous accelerated split-course radiotherapy in advanced head and neck cancer. Advances in Experimental Medicine and Biology 244: 275-284
Benita, S.; Zouai, O.; Benoit, J.P. 1986: 5-Fluorouracil:carnauba wax microspheres for chemoembolization: an in vitro evaluation. Journal of Pharmaceutical Sciences 75(9): 847-851
Langen, P.; Waschke, S.R.; Waschke, K.; Bärwolff, D.; Reefschläger, J.; Schulz, P.; Preussel, B.; Lehmann, C. 1976: 5-Formyl-2'-deoxyuridine: cytostatic and antiviral properties and possible modes of action. Acta Biologica et Medica Germanica 35(12): 1625-1633
Keltjens, J.T.; Brugman, A.J.; Kesseleer, J.M.; te Brömmelstroet, B.W.; van der Drift, C.; Vogels, G.D. 1992: 5-Formyl-5,6,7,8-tetrahydromethanopterin is the intermediate in the process of methanogenesis in Methanosarcina barkeri. Biofactors 3(4): 249-255
Armstrong, V.; Sternbach, H.; Eckstein, F. 1977: 5-Formyl-UTP for DNA-dependent RNA polymerase. Methods in Enzymology 46: 346-352
Kasai, H.; Iida, A.; Yamaizumi, Z.; Nishimura, S.; Tanooka, H. 1990: 5-Formyldeoxyuridine: a new type of DNA damage induced by ionizing radiation and its mutagenicity to salmonella strain TA102. Mutation Research 243(4): 249-253
Stover, P.; Schirch, V. 1991: 5-Formyltetrahydrofolate polyglutamates are slow tight binding inhibitors of serine hydroxymethyltransferase. Journal of Biological Chemistry 266(3): 1543-1550
Zhang, H.C. 1991: 5-Fu as remedy for unsuccessful glaucoma filtration surgery. Chinese Journal of Ophthalmology 27(6): 335-337
Villani, F.; Guindani, A.; Pagnoni, A. 1979: 5-Fuorouracil cardiotoxicity. Tumori 65(4): 487-495
Gordon, J.A.; Figard, P.H.; Quinby, G.E.; Spector, A.A. 1989: 5-HETE: uptake, distribution, and metabolism in MDCK cells. American Journal of Physiology 256(1 Part 1): C1-10
Almay, B.G.; Häggendal, J.; von Knorring, L.; Oreland, L. 1987: 5-HIAA and HVA in CSF in patients with idiopathic pain disorders. Biological Psychiatry 22(4): 403-412
Massarotti, M.; Migliore, A.; Roccella, P.; Toffano, G. 1976: 5-HIAA and HVA levels in the cerebrospinal fluid of hydrocephalic patients. Acta Neurologica 31(5): 601-613
Csernansky, J.G.; King, R.J.; Faustman, W.O.; Moses, J.A.; Poscher, M.E.; Faull, K.F. 1990: 5-HIAA in cerebrospinal fluid and deficit schizophrenic characteristics. British Journal of Psychiatry: the Journal of Mental Science 156: 501-507
Asberg, M.; Träskman, L.; Thorén, P. 1976: 5-HIAA in the cerebrospinal fluid. a biochemical suicide predictor?. Archives of General Psychiatry 33(10): 1193-1197
Elghozi, J.L.; Laude, D. 1989: 5-HIAA: perspectives in nephrology. Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales 183(1): 8-25
Abbott, A. 1991: 5-HT advances on four fronts. Trends in Pharmacological Sciences 12(10): 359-360
Minor, B.G.; Archer, T.; Post, C.; Jonsson, G.; Mohammed, A.K. 1986: 5-HT agonist induced analgesia modulated by central but not peripheral noradrenaline depletion in rats. Journal of Neural Transmission 66(3-4): 243-259
Gjerris, A.; Sørensen, A.S.; Rafaelsen, O.J.; Werdelin, L.; Alling, C.; Linnoila, M. 1987: 5-HT and 5-HIAA in cerebrospinal fluid in depression. Journal of Affective Disorders 12(1): 13-22
Fillion, G.; Fillion, M.P.; Jacob, J.; Rousselle, J.C. 1976: 5-HT and LSD high affinity binding sites to brain synaptosomal membranes. British Journal of Pharmacology 58(3): 425P-426P
Sellers, E.M.; Higgins, G.A.; Sobell, M.B. 1992: 5-HT and alcohol abuse. Trends in Pharmacological Sciences 13(2): 69-75
Johnston, A.L.; File, S.E. 1986: 5-HT and anxiety: promises and pitfalls. Pharmacology Biochemistry and Behavior 24(5): 1467-1470
Anzini, M.; Cappelli, A.; Vomero, S.; Botta, M.; Cagnotto, A. 1990: 5-HT and benzodiazepine receptor ligands. III. Synthesis and receptor affinities of 1,2,4-triazolo[4',3':1,6]pyridazino[4,5-b]quinoline and 2,3-dihydro-9-phenyl-1H-pyrrolo[3,4-b]quinoline-1-one derivatives. Farmaco 45(11): 1169-1179
Dafny, N.; Burks, T.F. 1977: 5-HT and morphine interaction, effects on sensory input in caudate nucleus and substantia nigra. Neuropharmacology 16(9): 577-585
Oka, T. 1978: 5-HT and narcotic-induced hypothermia. General Pharmacology 9(3): 151-154
Van Praag, H.M. 1987: 5-HT and the functional approach. Biological Psychiatry 22(12): 1503-1504
Petersen, E.N.; Edvinsson, L.; Hardebo, J.E. 1979: 5-HT antagonism on cerebral and common carotid arteries by the 5-HT uptake inhibitors femoxetine and paroxetine. Acta Pharmacologica et Toxicologica 45(4): 296-301
Costall, B.; Fortune, D.H.; Naylor, R.J. 1977: 5-HT antagonists inhibit neuroleptic and morphine antagonism of the hyperactivity induced by DA from the nucleus accumbens. British Journal of Pharmacology 60(2): 266P-267P
Brodie, M.J. 1990: Established anticonvulsants and treatment of refractory epilepsy. Lancet 336(8711): 350-354
Gaudin-Chazal, G.; Daszuta, A.; Faudon, M.; Ternaux, J.P. 1979: 5-HT concentration in cat's brain. Brain Research 160(2): 281-293
Wang, S.G. 1989: 5-HT contents change in peripheral blood of workers exposed to microwave and high frequency radiation. Zhonghua Yu Fang Yi Xue Za Zhi 23(4): 207-210
Eide, P.K.; Hole, K.; Berge, O.G.; Broch, O.J. 1988: 5-HT depletion with 5,7-DHT, PCA and PCPA in mice: differential effects on the sensitivity to 5-MeODMT, 8-OH-DPAT and 5-HTP as measured by two nociceptive tests. Brain Research 440(1): 42-52
Saxena, P.R. 1991: 5-HT in migraine--an introduction. Journal of Neurology 238(Suppl 1): S36-S37
Fozard, J.R.; Kalkman, H.O. 1992: 5-HT in nervous system disease and migraine. Current Opinion in Neurology and Neurosurgery 5(4): 496-502
Achazi, R.K. 1979: 5-HT induced accumulation of 3',5'-AMP and the phosphorylation of paramyosin in the ABRM of Mytilus edulis. Malacologia 18(1-2): 465-468
Barzilai, A.; Kennedy, T.E.; Sweatt, J.D.; Kandel, E.R. 1989: 5-HT modulates protein synthesis and the expression of specific proteins during long-term facilitation in Aplysia sensory neurons. Neuron 2(6): 1577-1586
Kiehn, O.; Harris-Warrick, R.M. 1992: 5-HT modulation of hyperpolarization-activated inward current and calcium-dependent outward current in a crustacean motor neuron. Journal of Neurophysiology 68(2): 496-508
Lorez, H.P.; Richards, J.G. 1975: 5-HT nerve terminals in the fourth ventricle of the rat brain: their identification and distribution studied by fluorescence histochemistry and electron microscopy. Cell and Tissue Research 165(1): 37-48
Cowen, P.J.; Cohen, P.R.; McCance, S.L.; Friston, K.J. 1990: 5-HT neuroendocrine responses during psychotropic drug treatment: an investigation of the effects of lithium. Journal of Neuroscience Methods 34(1-3): 201-205
Beubler, E.; Badhri, P.; Schirgi-Degen, A. 1992: 5-HT receptor antagonists and heat-stable Escherichia coli enterotoxin-induced effects in the rat. European Journal of Pharmacology 219(3): 445-450
McKeith, I.G.; Marshall, E.F.; Ferrier, I.N.; Armstrong, M.M.; Kennedy, W.N.; Perry, R.H.; Perry, E.K.; Eccleston, D. 1987: 5-HT receptor binding in post-mortem brain from patients with affective disorder. Journal of Affective Disorders 13(1): 67-74
Van Heuven-Nolsen, D. 1988: 5-HT receptor subtype-specific drugs and the cardiovascular system. Trends in Pharmacological Sciences 9(12): 423-425
Gershon, M.D.; Wade, P.R.; Kirchgessner, A.L.; Tamir, H. 1990: 5-HT receptor subtypes outside the central nervous system. Roles in the physiology of the gut. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 3(5-6): 385-395
Ono, H.; Ono, S.S.; Fukuda, H. 1991: 5-HT receptor-mediated regulation of thyrotropin-releasing hormone release in rat spinal cord. European Journal of Pharmacology 203(2): 283-285
Rose, F.C. 1989: 5-HT receptors and arteriovenous shunts. Lancet 2(8669): 975
Parsons, A.A. 1991: 5-HT receptors in human and animal cerebrovasculature. Trends in Pharmacological Sciences 12(8): 310-315
Angus, J.A. 1989: 5-HT receptors in the coronary circulation. Trends in Pharmacological Sciences 10(3): 89-90
Yocca, F.D.; Maayani, S. 1990: 5-HT receptors linked to adenylyl cyclase activity in mammalian brain. Annals of the new York Academy of Sciences 600: 212-223
Hoyer, D.; Schoeffter, P. 1991: 5-HT receptors: subtypes and second messengers. Journal of Receptor Research 11(1-4): 197-214
Ternaux, J.P.; Hery, F.; Hamon, M.; Bourgoin, S.; Glowinski, J. 1977: 5-HT release from ependymal surface of the caudate nucleus in 'encéphale isolé' cats. Brain Research 132(3): 575-579
Uneyama, H.; Munakata, M.; Akaike, N. 1992: 5-HT response of rat hippocampal pyramidal cell bodies. Neuroreport 3(7): 633-636
Netter, P. 1986: 5-HT reuptake inhibitors in healthy human subjects. Clinical Neuropharmacology 9(Suppl 4): 162-164
Baldwin, D.; Bullock, T.; Montgomery, D.; Montgomery, S. 1991: 5-HT reuptake inhibitors, tricyclic antidepressants and suicidal behaviour. International Clinical Psychopharmacology 6(Suppl 3): 49-55; Discussion: 55-56
Rendu, F.; Caen, J. 1976: 5-HT uptake in platelet populations. Scandinavian Journal of Haematology 17(4): 317-318
Møller, S.E. 1990: 5-HT uptake inhibitors and tricyclic antidepressants: relation between tryptophan availability and clinical response in depressed patients. European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology 1(1): 41-44
Park, W.K.; Azmitia, E.C. 1991: 5-HT, MDMA (ecstasy), and nimodipine effects on 45Ca-uptake into rat brain synaptosomes. Annals of the new York Academy of Sciences 635: 438-440
Van Kammen, D.P. 1987: 5-HT, a neurotransmitter for all seasons?. Biological Psychiatry 22(1): 1-3
Rocke, D.A.; Murray, W.B.; Osborn, I.J. 1990: Towards safer anaesthesia--implementing practice standards. South African Medical Journal 78(9): 501-502
Asarch, K.B.; Ransom, R.W.; Shih, J.C. 1985: 5-HT-1a and 5-HT-1b selectivity of two phenylpiperazine derivatives: evidence for 5-HT-1b heterogeneity. Life Sciences 36(13): 1265-1273
Myers, R.D.; Waller, M.B. 1975: 5-HT-and norepinephrine-induced release of ACh from the thalamus and mesencephalon of the monkey during thermoregulation. Brain Research 84(1): 47-61
Cowen, T.; Alafaci, C.; Crockard, H.A.; Burnstock, G. 1986: 5-HT-containing nerves to major cerebral arteries of the gerbil originate in the superior cervical ganglia. Brain Research 384(1): 51-59
Tsutsumi, M.; Sanders-Bush, E. 1990: 5-HT-induced transferrin production by choroid plexus epithelial cells in culture: role of 5-HT1c receptor. Journal of Pharmacology and Experimental Therapeutics 254(1): 253-257
Salvi, E.; Renda, T. 1989: 5-HT-like immunoreactive cells in chicken intestine: ontogenesis, morphology and topography. Cellular and Molecular Biology 35(3): 297-304
Luscombe, G.; Jenner, P.; Marsden, C.D. 1986: 5-HT-mediated myoclonus in the guinea pig as a model of brainstem 5-HT and tryptamine receptor action. Advances in Neurology 43: 529-543
Pan, Z.Z.; Colmers, W.F.; Williams, J.T. 1989: 5-HT-mediated synaptic potentials in the dorsal raphe nucleus: interactions with excitatory amino acid and GABA neurotransmission. Journal of Neurophysiology 62(2): 481-486
Zuardi, A.W. 1990: 5-HT-related drugs and human experimental anxiety. Neuroscience and Biobehavioral Reviews 14(4): 507-510
Larsen, J.J.; Hyttel, J. 1985: 5-HT-uptake inhibition potentiates antinociception induced by morphine, pethidine, methadone and ketobemidone in rats. Acta Pharmacologica et Toxicologica 57(3): 214-218
Sharp, T.; Bramwell, S.R.; Grahame-Smith, D.G. 1989: 5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. British Journal of Pharmacology 96(2): 283-290
Glennon, R.A.; McKenney, J.D.; Lyon, R.A.; Titeler, M. 1986: 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. Journal of Medicinal Chemistry 29(2): 194-199
Glennon, R.A.; Slusher, R.M.; Lyon, R.A.; Titeler, M.; McKenney, J.D. 1986: 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. Journal of Medicinal Chemistry 29(11): 2375-2380
Ismaiel, A.M.; Titeler, M.; Miller, K.J.; Smith, T.S.; Glennon, R.A. 1990: 5-HT1 and 5-HT2 binding profiles of the serotonergic agents alpha-methylserotonin and 2-methylserotonin. Journal of Medicinal Chemistry 33(2): 755-758
Scroggs, R.S.; Anderson, E.G. 1990: 5-HT1 receptor agonists reduce the Ca+ component of sensory neuron action potentials. European Journal of Pharmacology 178(2): 229-232
Waeber, C.; Palacios, J.M. 1990: 5-HT1 receptor binding sites in the guinea pig superior colliculus are predominantly of the 5-HT1D class and are presynaptically located on primary retinal afferents. Brain Research 528(2): 207-211
Lucki, I. 1992: 5-HT1 receptors and behavior. Neuroscience and Biobehavioral Reviews 16(1): 83-93
Molodsova, G.F.; Il'iuchenok, R.I. 1989: 5-HT1 receptors in rats with amnesia. Biulleten' Eksperimental'noi Biologii i Meditsiny 108(7): 51-52
Skangiel-Kramska, J.; Kossut, M. 1992: 5-HT1 receptors in the structures of visual pathway of normal and monocularly deprived kittens. Acta Neurobiologiae Experimentalis 52(2): 71-81
Coiro, V.; Volpi, R.; Capretti, L.; Speroni, G.; Bianconi, L.; Cavazzini, U.; Marcato, A.; Buonanno, G.; Caiazza, A.; Chiodera, P. 1990: 5-HT1-, but not 5-HT2-serotonergic, M1-, M2-muscarinic cholinergic or dopaminergic receptors mediate the ACTH/cortisol response to metoclopramide in man. Hormone Research 33(6): 233-238
Dzoljic, M.R.; Ukponmwan, O.E.; Saxena, P.R. 1992: 5-HT1-like receptor agonists enhance wakefulness. Neuropharmacology 31(7): 623-633
Den Boer, M.O.; Villalón, C.M.; Saxena, P.R. 1992: 5-HT1-like receptor mediated changes in porcine carotid haemodynamics: are 5-HT1D receptors involved?. Naunyn-Schmiedeberg's Archives of Pharmacology 345(5): 509-515
Sahin-Erdemli, I.; Hoyer, D.; Stoll, A.; Seiler, M.P.; Schoeffter, P. 1991: 5-HT1-like receptors mediate 5-hydroxytryptamine-induced contraction of guinea-pig isolated iliac artery. British Journal of Pharmacology 102(2): 386-390
Parsons, A.A.; Whalley, E.T.; Feniuk, W.; Connor, H.E.; Humphrey, P.P. 1989: 5-HT1-like receptors mediate 5-hydroxytryptamine-induced contraction of human isolated basilar artery. British Journal of Pharmacology 96(2): 434-440
Van Heuven-Nolsen, D.; Tysse Klasen, T.H.; Luo, Q.F.; Saxena, P.R. 1990: 5-HT1-like receptors mediate contractions of the rabbit saphenous vein. European Journal of Pharmacology 191(3): 375-382
Van Oosterhout, A.J.; Hofman, G.; Woutersen-Van Nijnanten, F.M.; Nijkamp, F.P. 1991: 5-HT1-like receptors mediate potentiation of cholinergic nerve-mediated contraction of isolated mouse trachea. European Journal of Pharmacology 209(3): 237-244
Montgomery, A.M.; Rose, I.C.; Herberg, L.J. 1991: 5-HT1A agonists and dopamine: the effects of 8-OH-DPAT and buspirone on brain-stimulation reward. Journal of Neural Transmission. General Section 83(1-2): 139-148
Bianchi, C.; Siniscalchi, A.; Beani, L. 1990: 5-HT1A agonists increase and 5-HT3 agonists decrease acetylcholine efflux from the cerebral cortex of freely-moving guinea-pigs. British Journal of Pharmacology 101(2): 448-452
Edwards, E.; Whitaker-Azmitia, P.M.; Harkins, K. 1990: 5-HT1A and 5-HT1B agonists play a differential role on the respiratory frequency in rats. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 3(2): 129-136
Eison, A.S.; Wright, R.N. 1992: 5-HT1A and 5-HT2 receptors mediate discrete behaviors in the Mongolian gerbil. Pharmacology Biochemistry and Behavior 43(1): 131-137
Chaouloff, F.; Jeanrenaud, B. 1987: 5-HT1A and alpha-2 adrenergic receptors mediate the hyperglycemic and hypoinsulinemic effects of 8-hydroxy-2-(di-n-propylamino)tetralin in the conscious rat. Journal of Pharmacology and Experimental Therapeutics 243(3): 1159-1166
Raymond, J.R.; Albers, F.J.; Middleton, J.P.; Lefkowitz, R.J.; Caron, M.G.; Obeid, L.M.; Dennis, V.W. 1991: 5-HT1A and histamine H1 receptors in Hela cells stimulate phosphoinositide hydrolysis and phosphate uptake via distinct G protein pools. Journal of Biological Chemistry 266(1): 372-379
Glitz, D.A.; Pohl, R. 1991: 5-HT1A partial agonists. what is their future?. Drugs 41(1): 11-18
Claustre, Y.; Bénavidès, J.; Scatton, B. 1988: 5-HT1A receptor agonists inhibit carbachol-induced stimulation of phosphoinositide turnover in the rat hippocampus. European Journal of Pharmacology 149(1-2): 149-153
Simon, P.; Guardiola, B.; Bizot-Espiard, J.; Schiavi, P.; Costentin, J. 1992: 5-HT1A receptor agonists prevent in rats the yawning and penile erections induced by direct dopamine agonists. Psychopharmacology 108(1-2): 47-50
Lesch, K.P.; Disselkamp-Tietze, J.; Schmidtke, A. 1990: 5-HT1A receptor function in depression: effect of chronic amitriptyline treatment. Journal of Neural Transmission. General Section 80(2): 157-161
Lesch, K.P. 1991: 5-HT1A receptor responsivity in anxiety disorders and depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 15(6): 723-733
Lesch, K.P.; Mayer, S.; Disselkamp-Tietze, J.; Hoh, A.; Wiesmann, M.; Osterheider, M.; Schulte, H.M. 1990: 5-HT1A receptor responsivity in unipolar depression. Evaluation of ipsapirone-induced ACTH and cortisol secretion in patients and controls. Biological Psychiatry 28(7): 620-628
Lesch, K.P.; Aulakh, C.S.; Murphy, D.L. 1992: 5-HT1A receptor sensitivity in depression and anxiety disorders: molecular mechanisms of neuroadaption. Clinical Neuropharmacology 15 Suppl 1 Pt A: 208a-209a
Lesch, K.P.; Wiesmann, M.; Hoh, A.; Müller, T.; Disselkamp-Tietze, J.; Osterheider, M.; Schulte, H.M. 1992: 5-HT1A receptor-effector system responsivity in panic disorder. Psychopharmacology 106(1): 111-117
Newberry, N.R. 1992: 5-HT1A receptors activate a potassium conductance in rat ventromedial hypothalamic neurones. European Journal of Pharmacology 210(2): 209-212
Frazer, A.; Hensler, J.G. 1990: 5-HT1A receptors and 5-HT1A-mediated responses: effect of treatments that modify serotonergic neurotransmission. Annals of the new York Academy of Sciences 600: 460-474; Discussion: 474-475
Sikich, L.; Hickok, J.M.; Todd, R.D. 1990: 5-HT1A receptors control neurite branching during development. Brain Research. Developmental Brain Research 56(2): 269-274
Saxena, P.R.; Villalón, C.M. 1990: Cardiovascular effects of serotonin agonists and antagonists. Journal of Cardiovascular Pharmacology 15(Suppl 7): S17-S34
Newberry, N.R. 1989: 5-HT1A receptors mediate a hyperpolarisation of rat ventromedial hypothalamic neurones in vitro. British Journal of Pharmacology 98(Suppl): 809p
Frambes, N.A.; Kirstein, C.L.; Moody, C.A.; Spear, L.P. 1990: 5-HT1A, 5-HT1B and 5-HT2 receptor agonists induce differential behavioral responses in preweanling rat pups. European Journal of Pharmacology 182(1): 9-17
Borbe, H.O.; Metzenauer, P.; Szelenyi, I. 1991: 5-HT1A-agonistic properties of naftopidil, a novel antihypertensive drug. European Journal of Pharmacology 205(1): 105-107
Cannon, J.G.; Jackson, H.; Long, J.P.; Leonard, P.; Bhatnagar, R.K. 1989: 5-HT1A-receptor antagonism: N-alkyl derivatives of (R)-(-)-8,11-dimethoxynoraporphine. Journal of Medicinal Chemistry 32(8): 1959-1962
Markstein, R.; Hoyer, D.; Engel, G. 1986: 5-HT1A-receptors mediate stimulation of adenylate cyclase in rat hippocampus. Naunyn-Schmiedeberg's Archives of Pharmacology 333(4): 335-341
Varrault, A.; Leviel, V.; Bockaert, J. 1991: 5-HT1A-sensitive adenylyl cyclase of rodent hippocampal neurons: effects of antidepressant treatments and chronic stimulation with agonists. Journal of Pharmacology and Experimental Therapeutics 257(1): 433-438
Kennett, G.A.; Dourish, C.T.; Curzon, G. 1987: 5-HT1B agonists induce anorexia at a postsynaptic site. European Journal of Pharmacology 141(3): 429-435
Jazayeri, A.; Meyer, W.J.; Kent, T.A. 1989: 5-HT1B and 5-HT2 serotonin binding sites in cultured Wistar-Kyoto rat aortic smooth muscle cells. European Journal of Pharmacology 169(1): 183-187
Bouhelal, R.; Smounya, L.; Bockaert, J. 1988: 5-HT1B receptors are negatively coupled with adenylate cyclase in rat substantia nigra. European Journal of Pharmacology 151(2): 189-196
Fozard, J.R.; Gray, J.A. 1989: 5-HT1C receptor activation: a key step in the initiation of migraine?. Trends in Pharmacological Sciences 10(8): 307-309
Hoyer, D.; Waeber, C.; Schoeffter, P.; Palacios, J.M.; Dravid, A. 1989: 5-HT1C receptor-mediated stimulation of inositol phosphate production in pig choroid plexus. A pharmacological characterization. Naunyn-Schmiedeberg's Archives of Pharmacology 339(3): 252-258
Jenck, F.; Broekkamp, C.L.; Van Delft, A.M. 1990: 5-HT1C receptors in the serotonergic control of periaqueductal gray induced aversion in rats. Psychopharmacology 100(3): 372-376
Claustre, Y.; Eudeline, B.; Benavides, J.; Scatton, B. 1992: 5-HT1C receptors mediate phosphoinositide turnover activation in the immature rat hippocampus. European Journal of Pharmacology 225(1): 37-41
Sumner, M.J.; Humphrey, P.P. 1989: 5-HT1D binding sites in porcine brain can be sub-divided by GR43175. British Journal of Pharmacology 98(1): 29-31
Bruinvels, A.T.; Lery, H.; Nozulak, J.; Palacios, J.M.; Hoyer, D. 1992: 5-HT1D binding sites in various species: similar pharmacological profile in dog, monkey, calf, guinea-pig and human brain membranes. Naunyn-Schmiedeberg's Archives of Pharmacology 346(3): 243-248
Hoyer, D.; Schoeffter, P. 1988: 5-HT1D receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in calf substantia nigra. European Journal of Pharmacology 147(1): 145-147
Waeber, C.; Zhang, L.A.; Palacios, J.M. 1990: 5-HT1D receptors in the guinea pig brain: pre- and postsynaptic localizations in the striatonigral pathway. Brain Research 528(2): 197-206
Edwards, E.; Harkins, K.; Wright, G.; Henn, F.A. 1991: 5-HT1b receptors in an animal model of depression. Neuropharmacology 30(1): 101-105
Molineaux, S.M.; Jessell, T.M.; Axel, R.; Julius, D. 1989: 5-HT1c receptor is a prominent serotonin receptor subtype in the central nervous system. Proceedings of the National Academy of Sciences of the United States of America 86(17): 6793-6797
Beubler, E.; Horina, G. 1990: 5-HT2 and 5-HT3 receptor subtypes mediate cholera toxin-induced intestinal fluid secretion in the rat. Gastroenterology 99(1): 83-89
Todorović, S.; Anderson, E.G. 1990: 5-HT2 and 5-HT3 receptors mediate two distinct depolarizing responses in rat dorsal root ganglion neurons. Brain Research 511(1): 71-79
Bersani, G.; Grispini, A.; Marini, S.; Pasini, A.; Valducci, M.; Ciani, N. 1990: 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clinical Neuropharmacology 13(6): 500-506
Muramatsu, M.; Tamaki-Ohashi, J.; Usuki, C.; Araki, H.; Chaki, S.; Aihara, H. 1988: 5-HT2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from rat brain striatal slices. European Journal of Pharmacology 153(1): 89-95
Brunken, W.J.; Daw, N.W. 1986: 5-HT2 antagonists reduce ON responses in the rabbit retina. Brain Research 384(1): 161-165
Schmidt, C.J.; Taylor, V.L.; Abbate, G.M.; Nieduzak, T.R. 1991: 5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa. Journal of Pharmacology and Experimental Therapeutics 256(1): 230-235
Maura, G.; Carbone, R.; Guido, M.; Pestarino, M.; Raiteri, M. 1991: 5-HT2 presynaptic receptors mediate inhibition of glutamate release from cerebellar mossy fibre terminals. European Journal of Pharmacology 202(2): 185-190
McCall, R.B.; Harris, L.T. 1988: 5-HT2 receptor agonists increase spontaneous sympathetic nerve discharge. European Journal of Pharmacology 151(1): 113-116
Staner, L.; Kempenaers, C.; Simonnet, M.P.; Fransolet, L.; Mendlewicz, J. 1992: 5-HT2 receptor antagonism and slow-wave sleep in major depression. Acta Psychiatrica Scandinavica 86(2): 133-137
Bersani, G.; Pozzi, F.; Marini, S.; Grispini, A.; Pasini, A.; Ciani, N. 1991: 5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. Acta Psychiatrica Scandinavica 83(4): 244-248
Mylecharane, E.J. 1991: 5-HT2 receptor antagonists and migraine therapy. Journal of Neurology 238(Suppl 1): S45-S52
Sorensen, S.M.; Humphreys, T.M.; Taylor, V.L.; Schmidt, C.J. 1992: 5-HT2 receptor antagonists reverse amphetamine-induced slowing of dopaminergic neurons by interfering with stimulated dopamine synthesis. Journal of Pharmacology and Experimental Therapeutics 260(2): 872-878
Jazrawi, S.P.; Horton, R.W. 1989: 5-HT2 receptor binding and 5-HT uptake in mouse brain: developmental changes and the relationship to audiogenic seizure susceptibility in DBA/2J mice. Brain Research. Developmental Brain Research 45(2): 257-263
Saller, C.F.; Czupryna, M.J.; Salama, A.I. 1990: 5-HT2 receptor blockade by ICi 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade. Journal of Pharmacology and Experimental Therapeutics 253(3): 1162-1170
Corson, M.A.; Alexander, R.W.; Berk, B.C. 1992: 5-HT2 receptor mRNA is overexpressed in cultured rat aortic smooth muscle cells relative to normal aorta. American Journal of Physiology 262(2 Part 1): C309-C315
Zhang, L.; Dyer, D.C. 1991: 5-HT2 receptor-stimulated calcium influx in ovine uterine artery in late pregnancy. Archives Internationales de Pharmacodynamie et de Therapie 310: 46-55
Cory, R.N.; Berta, P.; Haiech, J.; Bockaert, J. 1986: 5-HT2 receptor-stimulated inositol phosphate formation in rat aortic myocytes. European Journal of Pharmacology 131(1): 153-157
Dugovic, C.; Wauquier, A. 1987: 5-HT2 receptors could be primarily involved in the regulation of slow-wave sleep in the rat. European Journal of Pharmacology 137(1): 145-146
Merahi, N.; Orer, H.S.; Laguzzi, R. 1992: 5-HT2 receptors in the nucleus tractus solitarius: characterisation and role in cardiovascular regulation in the rat. Brain Research 575(1): 74-78
Dursun, S.M. 1992: 5-HT2 receptors, hallucinations, and dementia. British Journal of Psychiatry: the Journal of Mental Science 161: 719
Leysen, J.E.; Pauwels, P.J. 1990: 5-HT2 receptors, roles and regulation. Annals of the new York Academy of Sciences 600: 183-191; Discussion: 192-193
Cohen, M.L.; Schenck, K.W.; Kurz, K.D. 1988: 5-HT2-receptor antagonists: alpha 1- vs. 5-HT2-receptor blocking properties in blood vessels. Journal of Cardiovascular Pharmacology 11(Suppl 1): S25-S29
Glennon, R.A.; Young, R.; Dukat, M. 1992: 5-HT3 agonist 2-methylserotonin as a training drug in discrimination studies. Pharmacology Biochemistry and Behavior 41(2): 361-364
Pinkerton, C.R.; Williams, D.; Wootton, C.; Meller, S.T.; McElwain, T.J. 1990: 5-HT3 antagonist ondansetron--an effective outpatient antiemetic in cancer treatment. Archives of Disease in Childhood 65(8): 822-825
Abbott, A. 1990: 5-HT3 antagonists and ligands for dopamine D1- and autoreceptors offer new leads for antipsychotic drugs. Trends in Pharmacological Sciences 11(2): 49-51
Marschner, N.; Beyer, J.H.; Räth, U.; Souchon, R. 1992: 5-HT3 antagonists in therapy of cystostatic drug-induced vomiting. Der Internist 33(11): 768-771
Middlefell, V.C.; Price, T.L. 1991: 5-HT3 receptor agonism may be responsible for the emetic effects of zacopride in the ferret. British Journal of Pharmacology 103(1): 1011-1012
Yoshida, N.; Omoya, H.; Kato, S.; Ito, T. 1992: 5-HT3 receptor antagonist effects of DAT-582, (R) enantiomer of AS-5370. European Journal of Pharmacology 216(3): 435-440
Koulu, M.; Lappalainen, J.; Hietala, J.; Sjöholm, B.; Virtanen, R. 1990: 5-HT3 receptor antagonist ondansetron does not alter effects of amphetamine on DA metabolism. Neuroreport 1(2): 126-128
Tyers, M.B. 1991: 5-HT3 receptor antagonists. Drug Design and Delivery 7(3): 175-181
Ferrari, M.D. 1991: 5-HT3 receptor antagonists and migraine therapy. Journal of Neurology 238(Suppl 1): S53-S56
Reith, M.E. 1990: 5-HT3 receptor antagonists attenuate cocaine-induced locomotion in mice. European Journal of Pharmacology 186(2-3): 327-330
Costall, B.; Domeney, A.M.; Naylor, R.J. 1990: 5-HT3 receptor antagonists attenuate dopamine-induced hyperactivity in the rat. Neuroreport 1(1): 77-80
Suzuki, T.; Shiozaki, Y.; Masukawa, Y.; Misawa, M. 1992: 5-HT3 receptor antagonists block cocaine- and methamphetamine-induced place preference. Yakubutsu Seishin Kodo 12(1): 33-38
Carboni, E.; Acquas, E.; Leone, P.; Perezzani, L.; Di Chiara, G. 1988: 5-HT3 receptor antagonists block morphine- and nicotine-induced place-preference conditioning. European Journal of Pharmacology 151(1): 159-160
Saria, A.; Javorsky, F.; Humpel, C.; Gamse, R. 1990: 5-HT3 receptor antagonists inhibit sensory neuropeptide release from the rat spinal cord. Neuroreport 1(2): 104-106
Hasegawa, Y.; Kurachi, M.; Okuyama, S.; Araki, H.; Otomo, S. 1990: 5-HT3 receptor antagonists inhibit the response of kappa opioid receptors in the morphine-induced Straub tail [corrected. European Journal of Pharmacology 190(3): 399-401
Higgins, G.A.; Kilpatrick, G.J.; Bunce, K.T.; Jones, B.J.; Tyers, M.B. 1989: 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. British Journal of Pharmacology 97(1): 247-255
Martin, P.; Gozlan, H.; Puech, A.J. 1992: 5-HT3 receptor antagonists reverse helpless behaviour in rats. European Journal of Pharmacology 212(1): 73-78
Seynaeve, C.; Verweij, J.; de Mulder, P.H. 1991: 5-HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron. Anti-Cancer Drugs 2(4): 343-355
Aapro, M.S. 1991: 5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 42(4): 551-568
Anonymous 1987: 5-HT3 receptor antagonists: a new class of antiemetics. Lancet 1(8548): 1470-1471
Smith, R.A. 1991: 5-HT3 receptor blockers. Surgery 110(3): 575
Yang, J.; Mathie, A.; Hille, B. 1992: 5-HT3 receptor channels in dissociated rat superior cervical ganglion neurons. Journal of Physiology 448: 237-256
Bell, J.; Zhang, X.N.; Whitaker-Azmitia, P.M. 1992: 5-HT3 receptor-active drugs alter development of spinal serotonergic innervation: lack of effect of other serotonergic agents. Brain Research 571(2): 293-297
Kilpatrick, G.J.; Bunce, K.T.; Tyers, M.B. 1990: 5-HT3 receptors. Medicinal Research Reviews 10(4): 441-475
Tyers, M.B. 1991: 5-HT3 receptors and the therapeutic potential of 5-HT3 receptor antagonists. Therapie 46(6): 431-435
Acquas, E.; Carboni, E.; Leone, P.; Di Chiara, G. 1988: 5-HT3 receptors antagonists block morphine- and nicotine- but not amphetamine-induced place-preference conditioning. Pharmacological Research Communications 20(12): 1113-1114
Williams, G.M.; Smith, D.L.; Smith, D.J. 1992: 5-HT3 receptors are not involved in the modulation of the K(+)-evoked release of [3H]5-HT from spinal cord synaptosomes of rat. Neuropharmacology 31(8): 725-733
Imperato, A.; Angelucci, L. 1989: 5-HT3 receptors control dopamine release in the nucleus accumbens of freely moving rats. Neuroscience Letters 101(2): 214-217
Boess, F.G.; Sepúlveda, M.I.; Lummis, S.C.; Martin, I.L. 1992: 5-HT3 receptors in NG108-15 neuroblastoma x glioma cells: effect of the novel agonist 1-(m-chlorophenyl)-biguanide. Neuropharmacology 31(6): 561-564
Yakel, J.L.; Jackson, M.B. 1988: 5-HT3 receptors mediate rapid responses in cultured hippocampus and a clonal cell line. Neuron 1(7): 615-621
Glaum, S.R.; Proudfit, H.K.; Anderson, E.G. 1990: 5-HT3 receptors modulate spinal nociceptive reflexes. Brain Research 510(1): 12-16
Ashby, C.R.; Minabe, Y.; Edwards, E.; Wang, R.Y. 1991: 5-HT3-like receptors in the rat medial prefrontal cortex: an electrophysiological study. Brain Research 550(2): 181-191
Moummi, C.; Yang, D.C.; Gullikson, G.W. 1992: 5-HT4 receptor activation induces relaxation and associated cAMP generation in rat esophagus. European Journal of Pharmacology 216(1): 47-52
Kaumann, A.J. 1991: 5-HT4-like receptors in mammalian atria. Journal of Neural Transmission. Supplementum 34: 195-201
Briley, M.; Grahame-Smith, D. 1992: 5-HT: on the psychiatrist's couch. Trends in Pharmacological Sciences 13(9): 337-338
Wicker, L.S.; Ashton, W.T.; Boltz, R.C.; Meurer, L.C.; Miller, B.J.; Nichols, E.A.; Sigal, N.H.; Tolman, R.L.; Peterson, L.B. 1988: 5-Halo-6-phenyl pyrimidinones and 8-substituted guanosines: biological response modifiers with similar effects on B cells. Cellular Immunology 112(1): 156-165
Greer, S.; Schildkraut, I.; Zimmerman, T.; Kaufman, H. 1975: 5-Halogenated analogs of deoxycytidine as selective inhibitors of the replication of herpes simplex viruses in cell culture and related studies of intracranial herpes simplex virus infections in mice. Annals of the new York Academy of Sciences 255: 359-365
Balzarini, J.; Van Aerschot, A.; Pauwels, R.; Baba, M.; Schols, D.; Herdewijn, P.; De Clercq, E. 1989: 5-Halogeno-3'-fluoro-2',3'-dideoxyuridines as inhibitors of human immunodeficiency virus (HIV): potent and selective anti-HIV activity of 3'-fluoro-2',3'-dideoxy-5-chlorouridine. Molecular Pharmacology 35(5): 571-577
Cory, J.G.; Halley, M.C.; Jeney, A.; Lapis, K. 1990: 5-Hexyl-2'-deoxyuridine blocks the cytotoxic effects of 5-fluorodeoxyuridine or deoxyadenosine in leukemia L1210 cells in culture. Cancer Research 50(15): 4552-4556
Nigam, S.; Müller, S. 1989: 5-Hydroperoxyeicosatetraenoic acid (5-HPETE) enhances the synthesis of 1-O-alkyl-2-sn-acetyl-glycero-3-phosphocholine (PAF) in fMet-Leu-Phe-stimulated HL-60 cells: key role of diacylglycerol (DAG) in activation of protein kinase C (PKC). Free Radical Research Communications 7(3-6): 171-178
Deliganis, A.V.; Peroutka, S.J. 1991: 5-Hydroxtryptamine1D receptor agonism predicts antimigraine efficacy. Headache 31(4): 228-231
Vecht, C.J.; van Woerkom, T.C.; Teelken, A.W.; Minderhoud, J.M. 1975: 5-Hydroxy indoleacetic acid (5-HIAA) levels in the cerebrospinal fluid in consciousness and unconsciousness after head injury. Life Sciences 16(7): 1179-1185
Hacksell, U.; Arvidsson, L.E.; Johansson, A.M.; Nilsson, J.L.; Sanchez, D.; Andersson, B.; Lindberg, P.; Wikström, H.; Hjorth, S.; Svensson, K. 1985: 5-Hydroxy-2-methyl-2-(di-n-propylamino)tetralin: synthesis and central pharmacological effects. Acta Pharmaceutica Suecica 22(2): 65-74
Pavel, S.; Matous, B.; Duchon, J.; Bubnová, E. 1978: 5-Hydroxy-6-methoxy-2-indolylcarboxylic and 6-hydroxy-5-methoxy-2-indolylcarboxylic acids in the urine of hamsters with melanotic melanoma. Neoplasma 25(3): 343-347
Roesel, R.A.; Blankenship, P.R.; Ganapathy, V.; Leibach, F.H. 1985: 5-Hydroxy-L-lysine excretion in cystinuria. Journal of Inherited Metabolic Disease 8(3): 123-126
Saavedra, J.M. 1976: 5-Hydroxy-L-tryptophan decarboxylase activity: microassay and distribution in discrete rat brain nuclei. Journal of Neurochemistry 26(3): 585-589
Notsu, T.; Ohhashi, K.; Tanaka, I.; Ishikawa, H.; Niho, T.; Fukutake, K.; Mizota, M. 1992: 5-Hydroxydecanoate inhibits ATP-sensitive K+ channel currents in guinea-pig single ventricular myocytes. European Journal of Pharmacology 220(1): 35-41
Nichols, R.C.; Vanderhoek, J.Y. 1990: 5-Hydroxyeicosanoids selectively stimulate the human neutrophil 15-lipoxygenase to use endogenous substrate. Journal of Experimental Medicine 171(2): 367-375
O'Flaherty, J.T.; Nishihira, J. 1987: 5-Hydroxyeicosatetraenoate promotes Ca2+ and protein kinase C mobilization in neutrophils. Biochemical and Biophysical Research Communications 148(2): 575-581
Ikegami, H.; Hirota, K.; Koike, K.; Jikihara, H.; Miyake, A.; Aono, T.; Tanizawa, O. 1990: 5-Hydroxyeicosatetraenoic acid and phorbol ester stimulate prolactin release from rat anterior pituitary cells by different mechanisms. Endocrinologia Japonica 37(6): 809-817
Koike, K.; Judd, A.M.; MacLeod, R.M. 1985: 5-Hydroxyeicosatetraenoic acid increases prolactin release from rat anterior pituitary cells. Endocrinology 116(5): 1813-1817
Walsh, S.W. 1989: 5-Hydroxyeicosatetraenoic acid, leukotriene C4, and prostaglandin F2 alpha in amniotic fluid before and during term and preterm labor. American Journal of Obstetrics and Gynecology 161(5): 1352-1360
Shirakawa, J.; Tanaka, C.; Saijoh, K. 1990: 5-Hydroxyindole acetic acid assay and the clinical significance. Nihon Rinsho. Japanese Journal of Clinical Medicine 48 Suppl: 175-177
Gordon, J.W.; Weil-Malherbe, H. 1975: 5-Hydroxyindole acetic acid methyl ester: a possible artifact arising in the method of lindqvist. Analytical Biochemistry 68(2): 669-671
Tóth, G.; Fekete, M. 1986: 5-Hydroxyindole acetic excretion in newborns, infants and children. Acta Paediatrica Hungarica 27(3): 221-226
Beck, O.; Eriksson, C.J.; Kiianmaa, K.; Lundman, A. 1986: 5-Hydroxyindoleacetic acid and 5-hydroxytryptophol levels in rat brain: effects of ethanol, pyrazole, cyanamide and disulfiram treatment. Drug and Alcohol Dependence 16(4): 303-308
Spioch, F.M. 1979: 5-Hydroxyindoleacetic acid and creatinine excretion in thermal stress. Medycyna Pracy 30(1): 63-72
Giroud, M.; Dumas, R.; Dauvergne, M.; D'Athis, P.; Rochette, L.; Beley, A.; Bralet, J. 1990: 5-Hydroxyindoleacetic acid and homovanillic acid in cerebrospinal fluid of children with febrile convulsions. Epilepsia 31(2): 178-181
Massarotti, M.; Roccella, P.; Toffano, G. 1978: 5-Hydroxyindoleacetic acid and homovanillic acid in human cerebrospinal fluid below partial and complete spinal subarachnoid block. European Neurology 17(3): 174-180
Dhandzhieva, M.; Nedelcheva, K.; Popov, B. 1976: 5-Hydroxyindoleacetic acid as a biological test of lead absorption. Gigiena Truda i Professional'nye Zabolevaniya (11): 52-54
Borg, S.; Kvande, H.; Liljeberg, P.; Mossberg, D.; Valverius, P. 1985: 5-Hydroxyindoleacetic acid in cerebrospinal fluid in alcoholic patients under different clinical conditions. Alcohol 2(3): 415-418
Ricaurte, G.A.; DeLanney, L.E.; Wiener, S.G.; Irwin, I.; Langston, J.W. 1988: 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Research 474(2): 359-363
Bertilsson, L. 1987: 5-Hydroxyindoleacetic acid in cerebrospinal fluid--methodological and clinical aspects. Life Sciences 41(7): 821-824
Buckingham, R.L.; Radulovacki, M. 1975: 5-Hydroxyindoleacetic acid in cerebrospinal fluid:an indicator of slow-wave sleep. Brain Research 99(2): 440-443
Kahilainen, L.I.; Bergstrom, D.E.; Vilpo, J.A. 1985: 5-Hydroxymethyl-2'-deoxyuridine. Cytotoxicity and DNA incorporation studied by using a novel [2-14C]-derivative with normal and leukemic human hematopoietic cells. Acta Chemica Scandinavica. Series B: Organic Chemistry and Biochemistry 39(6): 477-484
Larsen, S.H.; Berry, D.M.; Paschal, J.W.; Gilliam, J.M. 1989: 5-Hydroxymethylblasticidin S and blasticidin S from Streptomyces setonii culture A83094. Journal of Antibiotics 42(3): 470-471
Cannon, S.V.; Cummings, A.; Teebor, G.W. 1988: 5-Hydroxymethylcytosine DNA glycosylase activity in mammalian tissue. Biochemical and Biophysical Research Communications 151(3): 1173-1179
Boorstein, R.J.; Levy, D.D.; Teebor, G.W. 1987: 5-Hydroxymethyluracil-DNA glycosylase activity may be a differentiated mammalian function. Mutation Research 183(3): 257-263
Yamamoto, T.; Moriwaki, Y.; Takahashi, S.; Hada, T.; Higashino, K. 1987: 5-Hydroxypyrazinamide, a human metabolite of pyrazinamide. Biochemical Pharmacology 36(14): 2415-2416
Barnette, M.S.; Grous, M.; Manning, C.D.; Price, W.J.; Nelson, A.H.; Bondinell, W.E.; Barone, F.C.; Ormsbee, H.S. 1992: 5-Hydroxytryptamine (5-HT) and SK&F 103829 contract canine lower esophageal sphincter smooth muscle by stimulating 5-HT2 receptors. Receptor 2(3): 155-167
Coppen, A.; Turner, P.; Rowsell, A.R.; Padgham, C. 1976: 5-Hydroxytryptamine (5-HT) in the whole-blood of patients with depressive illness. Postgraduate Medical Journal 52(605): 156-158
Schoeffter, P.; Hoyer, D. 1990: 5-Hydroxytryptamine (5-HT)-induced endothelium-dependent relaxation of pig coronary arteries is mediated by 5-HT receptors similar to the 5-HT1D receptor subtype. Journal of Pharmacology and Experimental Therapeutics 252(1): 387-395
Brazell, C.; McClue, S.J.; Preston, G.C.; King, B.; Stahl, S.M. 1991: 5-Hydroxytryptamine (5-HT)-induced shape change in human platelets determined by computerized data acquisition: correlation with [125I]-iodoLSD binding at 5-HT2 receptors. Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 2(1): 17-24
Bermudez, J.; Fake, C.S.; Joiner, G.F.; Joiner, K.A.; King, F.D.; Miner, W.D.; Sanger, G.J. 1990: 5-Hydroxytryptamine (5-HT3) receptor antagonists. 1. Indazole and indolizine-3-carboxylic acid derivatives. Journal of Medicinal Chemistry 33(7): 1924-1929
Bermudez, J.; Dabbs, S.; Joiner, K.A.; King, F.D. 1990: 5-Hydroxytryptamine (5-HT3) receptor antagonists. 2. 1-Indolinecarboxamides. Journal of Medicinal Chemistry 33(7): 1929-1932
Bermudez, J.; Dabbs, S.; King, F.D. 1990: 5-Hydroxytryptamine (5-HT3) receptor antagonists. 3. Ortho-substituted phenylureas. Journal of Medicinal Chemistry 33(7): 1932-1935
Van Dongen, P.A.; Grillner, S.; Hökfelt, T. 1986: 5-Hydroxytryptamine (serotonin) causes a reduction in the afterhyperpolarization following the action potential in lamprey motoneurons and premotor interneurons. Brain Research 366(1-2): 320-325
El-Mahdy, S.A. 1990: 5-Hydroxytryptamine (serotonin) enhances ventricular arrhythmias induced by acute coronary artery ligation in rats. Research Communications in Chemical Pathology and Pharmacology 68(3): 383-386
Bremer, K. 1991: 5-Hydroxytryptamine (serotonin) subtype 3 antagonists, a major step in prophylaxis and control of cytostatic and radiation-induced emesis. Journal of Cancer Research and Clinical Oncology 117(1): 85-87
Bassiouni, B.A.; Rafei, A.A. 1979: 5-Hydroxytryptamine (serotonin), copper and ceruloplasmin plasma concentrations in spontaneous abortion. European Journal of Obstetrics Gynecology and Reproductive Biology 9(2): 81-88
Thomas, T.N.; Redburn, D.A. 1979: 5-Hydroxytryptamine -- a neurotransmitter of bovine retina. Experimental Eye Research 28(1): 55-61
Rigdon, G.C.; Weatherspoon, J.K. 1992: 5-Hydroxytryptamine 1a receptor agonists block prepulse inhibition of acoustic startle reflex. Journal of Pharmacology and Experimental Therapeutics 263(2): 486-493
Schoeffter, P.; Hoyer, D. 1989: 5-Hydroxytryptamine 5-HT1B and 5-HT1D receptors mediating inhibition of adenylate cyclase activity. Pharmacological comparison with special reference to the effects of yohimbine, rauwolscine and some beta-adrenoceptor antagonists. Naunyn-Schmiedeberg's Archives of Pharmacology 340(3): 285-292
Costall, B.; Kelly, M.E.; Naylor, R.J.; Tan, C.C.; Tattersall, F.D. 1986: 5-Hydroxytryptamine M-receptor antagonism in the hypothalamus facilitates gastric emptying in the guinea-pig. Neuropharmacology 25(11): 1293-1296
Costall, B.; Domeney, A.M.; Naylor, R.J.; Tattersall, F.D. 1986: 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology 25(8): 959-961
Sagrada, A.; Brancaccio, N.; Schiavone, A. 1990: 5-Hydroxytryptamine affects rat migrating myoelectric complexes through different receptor subtypes: evidence from 5-hydroxytryptophan administration. Life Sciences 46(17): 1207-1216
Ono, H.; Miyamoto, M.; Kobayashi, M.; Fukuda, H. 1987: 5-Hydroxytryptamine agonistic action of methysergide and the absence of supersensitivity to 5-HT agonists in spinal flexor reflexes in rats. Neuropharmacology 26(9): 1371-1375
Sugden, D. 1990: 5-Hydroxytryptamine amplifies beta-adrenergic stimulation of N-acetyltransferase activity in rat pinealocytes. Journal of Neurochemistry 55(5): 1655-1658
Teshima, S.; Funatsu, K.; Satoh, H.; Inanaga, K. 1986: 5-Hydroxytryptamine and (+)-lysergic acid diethylamide displace [3H]thyrotropin-releasing hormone at its binding sites in the rat limbic forebrain. Regulatory Peptides 14(4): 293-299
Farthing, M.J. 1991: 5-Hydroxytryptamine and 5-hydroxytryptamine-3 receptor antagonists. Scandinavian Journal of Gastroenterology. Suppl 188: 92-100
De Clerck, F.; Loots, W.; Somers, Y.; Beetens, J.; Wouters, L.; Wynants, J.; Janssen, P.A. 1990: 5-Hydroxytryptamine and arachidonic acid metabolites modulate extensive platelet activation induced by collagen in cats in vivo. British Journal of Pharmacology 99(4): 631-636
Soinila, S.; Ahonen, M.; Joh, T.H.; Steinbusch, H.W. 1988: 5-Hydroxytryptamine and catecholamines in developing sympathetic cells of the rat. Journal of the Autonomic Nervous System 22(3): 193-202
Curzon, G. 1989: 5-Hydroxytryptamine and corticosterone in an animal model of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 13(3-4): 305-310
Yates, C.M.; Simpson, J.; Gordon, A. 1990: 5-Hydroxytryptamine and dopamine in pre-senile and senile Alzheimer-type dementia. Biochemical Society Transactions 18(3): 422-423
Cookson, J.; Silverstone, T. 1976: 5-Hydroxytryptamine and dopamine pathways in mania: a pilot study of fenfluramine and pimozide. British Journal of Clinical Pharmacology 3(5): 942-943
Gordon, J.L.; Olverman, H.J. 1978: 5-Hydroxytryptamine and dopamine transport by rat and human blood platelets. British Journal of Pharmacology 62(2): 219-226
Lance, J.W.; Lambert, G.A.; Goadsby, P.J.; Zagami, A.S. 1989: 5-Hydroxytryptamine and its putative aetiological involvement in migraine. Cephalalgia: An International Journal of Headache 9(Suppl 9): 7-13
Lance, J.W. 1991: 5-Hydroxytryptamine and its role in migraine. European Neurology 31(5): 279-281
Ogren, S.; Ross, S.B.; Baumann, L. 1975: 5-Hydroxytryptamine and learning: long-term effects of P-chloroamphetamine on acquisition. Medical Biology 53(3): 165-168
Nicholson, A.N.; Pascoe, P.A. 1986: 5-Hydroxytryptamine and noradrenaline uptake inhibition: studies on sleep in man. Neuropharmacology 25(10): 1079-1083
Sicuteri, F.; Anselmi, B.; Del Bene, E.; Galli, P. 1975: 5-Hydroxytryptamine and pain modulation in man: a clinical pharmacological approach with tryptophan and parachlorophenylalanine. Acta Vitaminologica et Enzymologica 29(1-6): 66-68
Ross, J.W.; Smith, H.; Spicer, B.A. 1978: 5-Hydroxytryptamine and rat passive peritoneal anaphylaxis. International Archives of Allergy and Applied Immunology 57(5): 444-450
Dragan, Y.P.; Ellis, E.F. 1990: 5-Hydroxytryptamine and the metabolism of arachidonic acid by the lipoxygenase and cyclooxygenase of washed human platelets. Biochemical Pharmacology 40(2): 309-314
Humphrey, P.P. 1991: 5-Hydroxytryptamine and the pathophysiology of migraine. Journal of Neurology 238(Suppl 1): S38-S44
De Clerck, F.; Janssen, P.A. 1990: 5-Hydroxytryptamine and thromboxane A2 in ischaemic heart disease. Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 1(2): 201-209
Ganey, P.E.; Roth, R.A. 1987: 5-Hydroxytryptamine and thromboxane in platelets from rats treated with monocrotaline pyrrole. Toxicology and Applied Pharmacology 88(2): 157-164
Stachow, A.; Jablonska, S.; Skiendzielewska, A. 1977: 5-Hydroxytryptamine and tryptamine pathways in scleroderma. British Journal of Dermatology 97(2): 147-154
Okawuasaba, F.K.; Weir, B.K.; Cook, D.A.; Krueger, C.A. 1979: 5-Hydroxytryptamine and vasospasm induced by subarachnoid hemorrhage. Proceedings of the Western Pharmacology Society 22: 441-445
Scholtysik, G.; Imoto, Y.; Yatani, A.; Brown, A.M. 1988: 5-Hydroxytryptamine antagonist ICS 205-930 blocks cardiac potassium, sodium and calcium currents. Journal of Pharmacology and Experimental Therapeutics 245(3): 773-778
Archer, T. 1987: 5-Hydroxytryptamine antagonists and the 5-methoxy-N,N-dimethyltryptamine-induced changes of postdecapitation convulsions. Pharmacology and Toxicology 60(1): 37-42
Nakano, T.; Taira, N. 1976: 5-Hydroxytryptamine as a sensitizer of somatic nociceptors for pain-producing substances. European Journal of Pharmacology 38(1): 23-29
Ishitani, R.; Miyakawa, A.; Saito, R.; Iwamoto, T. 1977: 5-Hydroxytryptamine binding to butanol extracts from myelin fragments. Experientia 33(7): 932-933
Gunning, S.J.; Naylor, R.J. 1985: 5-Hydroxytryptamine can antagonize the ability of metoclopramide and SCH 23390 to enhance electrical field stimulation-evoked contractions of guinea-pig isolated stomach muscle. Journal of Pharmacy and Pharmacology 37(1): 78-80
Banki, C.M. 1978: 5-Hydroxytryptamine content of the whole blood in psychiatric illness and alcoholism. Acta Psychiatrica Scandinavica 57(3): 232-238
Connor, H.E.; Feniuk, W.; Humphrey, P.P. 1989: 5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation. European Journal of Pharmacology 161(1): 91-94
Akasu, T.; Koketsu, K. 1986: 5-Hydroxytryptamine decreases the sensitivity of nicotinic acetylcholine receptor in bull-frog sympathetic ganglion cells. Journal of Physiology 380: 93-109
Manzini, S.; Maggi, C.A.; Meli, A. 1986: 5-Hydroxytryptamine delays relaxation time of norepinephrine-induced vasoconstriction. American Journal of Physiology 250(1 Part 2): H121-H130
Bertilsson, L.; Koslow, S.H.; Costa, E. 1975: 5-Hydroxytryptamine depletion in mesencephalic nuclei of rat brain following a single injection of p-chloroamphetamine. Brain Research 91(2): 348-350
Pike, G.K.; Kerr, D.I. 1986: 5-Hydroxytryptamine depresses depolarizing responses to GABA in the rat isolated vagus nerve. European Journal of Pharmacology 131(2-3): 297-300
Nyborg, N.C.; Mikkelsen, E.O. 1990: 5-Hydroxytryptamine does not release endothelium-derived relaxing factor in rat isolated coronary arteries. European Journal of Pharmacology 186(2-3): 295-300
Morita, K.; Katayama, Y. 1987: 5-Hydroxytryptamine effects on the somata of bullfrog primary afferent neurons. Neuroscience 21(3): 1007-1018
Newberry, N.R.; Gilbert, M.J. 1989: 5-Hydroxytryptamine evokes three distinct responses on the rat superior cervical ganglion in vitro. European Journal of Pharmacology 162(2): 197-205
Cronau, L.H.; Kerstein, M.D.; Mandel, S.; Gillis, C.N. 1976: 5-Hydroxytryptamine extraction by the lung. Surgery Gynecology and Obstetrics 143(1): 51-55
Akasu, T. 1988: 5-Hydroxytryptamine facilitates GABA-induced depolarization in bullfrog primary afferent neurons. Neuroscience Letters 92(3): 270-274
Beck, S.G.; Choi, K.C. 1991: 5-Hydroxytryptamine hyperpolarizes CA3 hippocampal pyramidal cells through an increase in potassium conductance. Neuroscience Letters 133(1): 93-96
Korczyn, A.D.; Lazarovits, J.; Dvilanski, A.; Eshel, Y.; Nathan, I. 1985: 5-Hydroxytryptamine in platelets of torsion dystonia patients. Acta Neurologica Scandinavica 71(2): 171-173
Das, M.; Mohanakumar, K.P.; Chauhan, S.P.; Ganguly, D.K. 1989: 5-Hydroxytryptamine in the phrenic nerve diaphragm: evidence for its existence and release. Neuroscience Letters 97(3): 345-349
Beck, S.G. 1992: 5-Hydroxytryptamine increases excitability of CA1 hippocampal pyramidal cells. Synapse 10(4): 334-340
Monopoli, A.; Conti, A.; Forlani, A.; Ongini, E.; Antona, C.; Biglioli, P. 1990: 5-Hydroxytryptamine induces contraction in isolated human mammary artery: effect of ketanserin. Cardiovascular Drugs and Therapy 4(Suppl 1): 59-61
Beesley, A.; Levin, R.J. 1991: 5-Hydroxytryptamine induces electrogenic secretion and simultaneously activates a modulating inhibitory neural circuit in rat small intestine in vitro. Experimental Physiology 76(4): 607-610
Hamamori, Y.; Yokoyama, M.; Yamada, M.; Akita, H.; Goshima, K.; Fukuzaki, H. 1990: 5-Hydroxytryptamine induces phospholipase C-mediated hydrolysis of phosphoinositides through 5-hydroxytryptamine-2 receptors in cultured fetal mouse ventricular myocytes. Circulation Research 66(6): 1474-1483
Itakura, T.; Yokote, H.; Kimura, H.; Kamei, I.; Nakakita, K.; Naka, Y.; Nakai, K.; Imai, H.; Komai, N. 1985: 5-Hydroxytryptamine innervation of vessels in the rat cerebral cortex. Immunohistochemical findings and hydrogen clearance study of rCBF. Journal of Neurosurgery 62(1): 42-47
Bradbury, A.J.; Costall, B.; Naylor, R.J.; Onaivi, E.S. 1987: 5-Hydroxytryptamine involvement in the locomotor activity suppressant effects of amphetamine in the mouse. Psychopharmacology 93(4): 457-465
Kitazawa, T. 1989: 5-Hydroxytryptamine is a possible neurotransmitter of the non-cholinergic excitatory nerves in the longitudinal muscle of rainbow trout stomach (Salmo gairdneri). British Journal of Pharmacology 98(3): 781-790
Purdy, R.E.; Murray, D.L.; Stupecky, G.L. 1985: 5-Hydroxytryptamine is an alpha agonist in rabbit blood vessels. Proceedings of the Western Pharmacology Society 28: 123-125
Torii, Y.; Saito, H.; Matsuki, N. 1991: 5-Hydroxytryptamine is emetogenic in the house musk shrew, Suncus murinus. Naunyn-Schmiedeberg's Archives of Pharmacology 344(5): 564-567
Laekeman, G.M.; Herman, A.G. 1978: 5-Hydroxytryptamine is not involved in the response of the guinea-pig ileum during the Schultz-Dale reaction. Archives Internationales de Pharmacodynamie et de Therapie 232(2): 342
Shannon, N.J.; Moore, K.E. 1987: 5-Hydroxytryptamine is synthesized in neurons terminating in the neural and intermediate lobes of the rat pituitary gland. Brain Research 402(2): 287-292
Fetkovska, N.; Amstein, R.; Ferracin, F.; Regenass, M.; Bühler, F.R.; Pletscher, A. 1990: 5-Hydroxytryptamine kinetics and activation of blood platelets in patients with essential hypertension. Hypertension 15(3): 267-273
Mankad, P.S.; Chester, A.H.; Yacoub, M.H. 1991: 5-Hydroxytryptamine mediates endothelium dependent coronary vasodilatation in the isolated rat heart by the release of nitric oxide. Cardiovascular Research 25(3): 244-248
Yoshimura, M.; Higashi, H. 1985: 5-Hydroxytryptamine mediates inhibitory postsynaptic potentials in rat dorsal raphe neurons. Neuroscience Letters 53(1): 69-74
Morin, D.; Monteau, R.; Hilaire, G. 1991: 5-Hydroxytryptamine modulates central respiratory activity in the newborn rat: an in vitro study. European Journal of Pharmacology 192(1): 89-95
Di Prisco, G.V.; Dubuc, R.; Wallén, P.; Grillner, S. 1992: 5-Hydroxytryptamine modulates spike frequency regulation in reticulospinal neurons involved in the control of locomotion in lamprey. Neuroscience Letters 134(2): 279-283
Seong, Y.H.; Baba, A.; Matsuda, T.; Iwata, H. 1990: 5-Hydroxytryptamine modulation of electrically induced twitch responses of mouse vas deferens: involvement of multiple 5-hydroxytryptamine receptors. Journal of Pharmacology and Experimental Therapeutics 254(3): 1012-1016
Chernick, W.; Bobyock, E.; Bradford, P. 1989: 5-Hydroxytryptamine modulation of rat parotid salivary gland secretion. Journal of Dental Research 68(1): 59-63
Nishimura, T.; Akasu, T. 1989: 5-Hydroxytryptamine produces presynaptic facilitation of cholinergic transmission in rabbit parasympathetic ganglia. Journal of the Autonomic Nervous System 26(3): 251-260
Gretler, D.D.; Jones, K.C.; Murphy, M.B. 1992: 5-Hydroxytryptamine receptor activity of the dopamine receptor agonist fenoldopam in canine tracheal smooth muscle. Journal of Pharmacology and Experimental Therapeutics 260(2): 491-498
Buzzi, M.G.; Dimitriadou, V.; Theoharides, T.C.; Moskowitz, M.A. 1992: 5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigeminal stimulation. Brain Research 583(1-2): 137-149
Mørk, A.; Geisler, A. 1990: 5-Hydroxytryptamine receptor agonists influence calcium-stimulated adenylate cyclase activity in the cerebral cortex and hippocampus of the rat. European Journal of Pharmacology 175(3): 237-244
Buchheit, K.H.; Costall, B.; Engel, G.; Gunning, S.J.; Naylor, R.J.; Richardson, B.P. 1985: 5-Hydroxytryptamine receptor antagonism by metoclopramide and ICS 205-930 in the guinea-pig leads to enhancement of contractions of stomach muscle strips induced by electrical field stimulation and facilitation of gastric emptying in-vivo. Journal of Pharmacy and Pharmacology 37(9): 664-667
Clancy, B.M.; Maayani, S. 1985: 5-Hydroxytryptamine receptor in isolated rabbit aorta: characterization with tryptamine analogs. Journal of Pharmacology and Experimental Therapeutics 233(3): 761-769
Connor, H.E.; Feniuk, W.; Humphrey, P.P. 1991: 5-Hydroxytryptamine receptor profile. Cardiovascular Research 25(3): 263-264
Chester, A.H.; Martin, G.R.; Bodelsson, M.; Arneklo-Nobin, B.; Tadjkarimi, S.; Tornebrandt, K.; Yacoub, M.H. 1990: 5-Hydroxytryptamine receptor profile in healthy and diseased human epicardial coronary arteries. Cardiovascular Research 24(11): 932-937
Peroutka, S.J. 1990: 5-Hydroxytryptamine receptor subtypes. Pharmacology and Toxicology 67(5): 373-383
Sumita, T.; Ishikawa, N.; Hashiba, Y.; Takagi, K.; Satake, T. 1989: 5-Hydroxytryptamine receptor subtypes participating in pulmonary edema in dogs. European Journal of Pharmacology 164(1): 69-75
Peroutka, S.J. 1988: 5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization. Trends in Neurosciences 11(11): 496-500
Schmidt, A.W.; Peroutka, S.J. 1989: 5-Hydroxytryptamine receptor "families". Faseb Journal: Official Publication of the Federation of American Societies for Experimental Biology 3(11): 2242-2249
Won, S.J.; Lin, M.T. 1988: 5-Hydroxytryptamine receptors in the hypothalamus mediate thermoregulatory responses in rabbits. Naunyn-Schmiedeberg's Archives of Pharmacology 338(3): 256-261
Born, G.V.; Michal, F. 1975: 5-Hydroxytryptamine receptors of platelets. Ciba Foundation Symposium 35: 287-307
Göthert, M. 1992: 5-Hydroxytryptamine receptors. An example for the complexity of chemical transmission of information in the brain. Arzneimittel-Forschung 42(2a): 238-246
Kuhn, D.M.; Wolf, W.A.; Youdim, M.B. 1985: 5-Hydroxytryptamine release in vivo from a cytoplasmic pool: studies on the 5-HT behavioural syndrome in reserpinized rats. British Journal of Pharmacology 84(1): 121-129
Sweeney, M.I.; White, T.D.; Sawynok, J. 1990: 5-Hydroxytryptamine releases adenosine and cyclic AMP from primary afferent nerve terminals in the spinal cord in vivo. Brain Research 528(1): 55-61
Sweeney, M.; White, T.; Sawynok, J. 1988: 5-Hydroxytryptamine releases adenosine from primary afferent nerve terminals in the spinal cord. Brain Research 462(2): 346-349
Sułowska, Z.; Wyczółkowska, J. 1991: 5-Hydroxytryptamine releasing activity of the supernatants from cultured mouse spleen cells. Archivum Immunologiae et Therapiae Experimentalis 39(1-2): 139-145
Gill, J.K.; Stansby, G.; Shukla, N.; Hamilton, G.; Barradas, M.A.; Jeremy, J.Y. 1992: 5-Hydroxytryptamine stimulates 45Ca2+ uptake by human umbilical vein endothelial cells in culture: mediation by 5-HT2 receptor subtypes. European Journal of Pharmacology 214(2-3): 269-272
Hu, S.B.; Lightman, S.L.; Tannahill, L.A. 1992: 5-Hydroxytryptamine stimulates corticosteroid-sensitive CRF release from cultured foetal hypothalamic cells. Role of protein kinases. Brain Research 574(1-2): 266-270
Ford, A.P.; Baxter, G.S.; Eglen, R.M.; Clarke, D.E. 1992: 5-Hydroxytryptamine stimulates cyclic AMP formation in the tunica muscularis mucosae of the rat oesophagus via 5-HT4 receptors. European Journal of Pharmacology 211(1): 117-120
Hansson, E.; Simonsson, P.; Alling, C. 1987: 5-Hydroxytryptamine stimulates the formation of inositol phosphate in astrocytes from different regions of the brain. Neuropharmacology 26(9): 1377-1382
Hirafuji, M.; Ogura, Y. 1987: 5-Hydroxytryptamine stimulates the release of prostacyclin but not thromboxane A2 from isolated rat dental pulp. European Journal of Pharmacology 136(3): 433-436
Fayolle, C.; Fillion, M.P.; Barone, P.; Oudar, P.; Rousselle, J.C.; Fillion, G. 1988: 5-Hydroxytryptamine stimulates two distinct adenylate cyclase activities in rat brain: high-affinity activation is related to a 5-HT1 subtype different from 5-HT1A, 5-HT1B, and 5-HT1C. Fundamental and Clinical Pharmacology 2(3): 195-214
Graham, C.W.; Green, A.R.; Woods, H.F.; Youdim, M.B. 1975: 5-Hydroxytryptamine synthesis in the isolated perfused rat brain. British Journal of Pharmacology 53(3): 450P-451P
Bender, D.A. 1975: 5-Hydroxytryptamine synthesis in the rat brain after chlorpromazine administration. Biochemical Society Transactions 3(5): 704-706
Nakaki, T.; Roth, B.L.; Chuang, D.M.; Costa, E. 1985: 5-Hydroxytryptamine uptake and imipramine binding sites in neurotumor NCB-20 cells. Journal of Neurochemistry 45(3): 920-925
Vigneswaran, W.T.; Stanbrook, H.S.; Doctor, R.; McCormick, S.; Schwappach, J.; Johnston, M.R. 1989: 5-Hydroxytryptamine uptake in oxygen radical-mediated acute lung injury. American Review of Respiratory Disease 139(2): 382-386
Poulat, P.; Marlier, L.; Rajaofetra, N.; Privat, A. 1992: 5-Hydroxytryptamine, substance P and thyrotropin-releasing hormone synapses in the intermediolateral cell column of the rat thoracic spinal cord. Neuroscience Letters 136(1): 19-22
Arvidsson, U.; Cullheim, S.; Ulfhake, B.; Bennett, G.W.; Fone, K.C.; Cuello, A.C.; Verhofstad, A.A.; Visser, T.J.; Hökfelt, T. 1990: 5-Hydroxytryptamine, substance P, and thyrotropin-releasing hormone in the adult cat spinal cord segment L7: immunohistochemical and chemical studies. Synapse 6(3): 237-270
Angelis, L.; Predominato, M.; Vertua, R. 1975: 5-Hydroxytryptamine-14C and dexamphetamine-14C uptake by fundal sarcolemma preparations: effect of thermal and chemical alterations as indirect approach to the problem of the common receptor. Archives Internationales de Pharmacodynamie et de Therapie 216(1): 51-56
Idzikowski, C.; Mills, F.J.; Glennard, R. 1986: 5-Hydroxytryptamine-2 antagonist increases human slow wave sleep. Brain Research 378(1): 164-168
Glaum, S.R.; Brooks, P.A.; Spyer, K.M.; Miller, R.J. 1992: 5-Hydroxytryptamine-3 receptors modulate synaptic activity in the rat nucleus tractus solitarius in vitro. Brain Research 589(1): 62-68
Guharay, F.; Ramsey, R.L.; Usherwood, P.N. 1985: 5-Hydroxytryptamine-activated single-channel currents recorded from murine neuroblastoma cells. Brain Research 340(2): 325-332
Sundler, F.; Alumets, J.; Håkanson, R. 1977: 5-Hydroxytryptamine-containing enterochromaffin cells: storage site of substance P. Acta Physiologica Scandinavica. Supplementum 452: 121-123
Yu, J.G.; Lee, T.J. 1989: 5-Hydroxytryptamine-containing fibers in cerebral arteries of the cat, rat and guinea pig. Blood Vessels 26(1): 33-43
Häppölä, O. 1988: 5-Hydroxytryptamine-immunoreactive neurons and nerve fibers in the superior cervical ganglion of the rat. Neuroscience 27(1): 301-307
Macquin-Mavier, I.; Jarreau, P.H.; Istin, N.; Harf, A. 1991: 5-Hydroxytryptamine-induced bronchoconstriction in the guinea-pig: effect of 5-HT2 receptor activation on acetylcholine release. British Journal of Pharmacology 102(4): 1003-1007
Doğan, N.; Ciçek, E.; Cenik, A.G.; Singirik, E.; Kiliç, M.; Ozcan, A.S. 1991: 5-Hydroxytryptamine-induced contraction of human isolated umbilical artery and its dependence on cellular and extracellular Ca++. Archives Internationales de Pharmacodynamie et de Therapie 312: 79-85
Bax, W.A.; Van Heuven-Nolsen, D.; Bos, E.; Simoons, M.L.; Saxena, P.R. 1992: 5-Hydroxytryptamine-induced contractions of the human isolated saphenous vein: involvement of 5-HT2 and 5-HT1D-like receptors, and a comparison with grafted veins. Naunyn-Schmiedeberg's Archives of Pharmacology 345(5): 500-508
Bom, A.H.; Duncker, D.J.; Saxena, P.R.; Verdouw, P.D. 1988: 5-Hydroxytryptamine-induced tachycardia in the pig: possible involvement of a new type of 5-hydroxytryptamine receptor. British Journal of Pharmacology 93(3): 663-671
Higgins, W.J. 1977: 5-Hydroxytryptamine-induced tachyphylaxis of the molluscan heart and concomitant desensitization of adenylate cyclase. Journal of Cyclic Nucleotide Research 3(4): 293-302
Verbeuren, T.J.; Mennecier, P.; Laubie, M. 1991: 5-Hydroxytryptamine-induced vasodilatation in the isolated perfused rat kidney: are endothelial 5-HT1A receptors involved?. European Journal of Pharmacology 201(1): 17-27
Brodde, O.E. 1990: 5-Hydroxytryptamine-receptor subtypes. Clinical Physiology and Biochemistry 8(Suppl 3): 19-27
Bäckström, I.T.; Marcusson, J.O. 1987: 5-Hydroxytryptamine-sensitive [3H]imipramine binding of protein nature in the human brain. I. Characteristics. Brain Research 425(1): 128-136
Marcusson, J.O.; Alafuzoff, I.; Bäckström, I.T.; Ericson, E.; Gottfries, C.G.; Winblad, B. 1987: 5-Hydroxytryptamine-sensitive [3H]imipramine binding of protein nature in the human brain. II. Effect of normal aging and dementia disorders. Brain Research 425(1): 137-145
Kendall, D.A.; Nahorski, S.R. 1985: 5-Hydroxytryptamine-stimulated inositol phospholipid hydrolysis in rat cerebral cortex slices: pharmacological characterization and effects of antidepressants. Journal of Pharmacology and Experimental Therapeutics 233(2): 473-479
Godfrey, P.P.; McClue, S.J.; Young, M.M.; Heal, D.J. 1988: 5-Hydroxytryptamine-stimulated inositol phospholipid hydrolysis in the mouse cortex has pharmacological characteristics compatible with mediation via 5-HT2 receptors but this response does not reflect altered 5-HT2 function after 5,7-dihydroxytryptamine lesioning or repeated antidepressant treatments. Journal of Neurochemistry 50(3): 730-738
Francis, P.T.; Pangalos, M.N.; Pearson, R.C.; Middlemiss, D.N.; Stratmann, G.C.; Bowen, D.M. 1992: 5-Hydroxytryptamine1A but not 5-hydroxytryptamine2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin. Journal of Pharmacology and Experimental Therapeutics 261(3): 1273-1281
Kostowski, W.; Dyr, W.; Krzascik, P.; Järbe, T.; Archer, T. 1992: 5-Hydroxytryptamine1A receptor agonists in animal models of depression and anxiety. Pharmacology and Toxicology 71(1): 24-30
Koenig, J.I.; Meltzer, H.Y.; Gudelsky, G.A. 1988: 5-Hydroxytryptamine1A receptor-mediated effects of buspirone, gepirone and ipsapirone. Pharmacology Biochemistry and Behavior 29(4): 711-715
Lucki, I.; Wieland, S. 1990: 5-Hydroxytryptamine1A receptors and behavioral responses. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 3(5-6): 481-493
Harrington, M.A.; Oksenberg, D.; Peroutka, S.J. 1988: 5-Hydroxytryptamine1A receptors are linked to a Gi-adenylate cyclase complex in rat hippocampus. European Journal of Pharmacology 154(1): 95-98
Helke, C.J.; Thor, K.B.; Phillips, E.T. 1991: 5-Hydroxytryptamine1C/2 agonists in the thoracic spinal cord: cardiovascular effects and binding sites in the intermediolateral cell column. Journal of Pharmacology and Experimental Therapeutics 259(3): 1335-1343
VandenBerg, S.R.; Britt, S.G.; Redpath, G.T.; Gonias, S.L. 1989: 5-Hydroxytryptamine2 (5-HT2) structure-function relationships of the nitro and amino phenylpiperazines on intact human platelets. Biochemical Pharmacology 38(23): 4237-4244
Araneda, R.; Andrade, R. 1991: 5-Hydroxytryptamine2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40(2): 399-412
Cohen, M.L.; Parli, C.J.; Fuller, R.W. 1989: 5-Hydroxytryptamine2 receptor antagonist activity of the acid metabolite (1-isopropyl dihydrolysergic acid) of the ergoline ester, sergolexole (LY281067). Journal of Pharmacology and Experimental Therapeutics 251(3): 1006-1011
Roth, B.L.; Nakaki, T.; Chuang, D.M.; Costa, E. 1986: 5-Hydroxytryptamine2 receptors coupled to phospholipase C in rat aorta: modulation of phosphoinositide turnover by phorbol ester. Journal of Pharmacology and Experimental Therapeutics 238(2): 480-485
Wilson, H.; Coffman, W.J.; Cohen, M.L. 1990: 5-Hydroxytryptamine3 receptors mediate tachycardia in conscious instrumented dogs. Journal of Pharmacology and Experimental Therapeutics 252(2): 683-688
Maura, G.; Andrioli, G.C.; Cavazzani, P.; Raiteri, M. 1992: 5-Hydroxytryptamine3 receptors sited on cholinergic axon terminals of human cerebral cortex mediate inhibition of acetylcholine release. Journal of Neurochemistry 58(6): 2334-2337
Andrade, R.; Chaput, Y. 1991: 5-Hydroxytryptamine4-like receptors mediate the slow excitatory response to serotonin in the rat hippocampus. Journal of Pharmacology and Experimental Therapeutics 257(3): 930-937
Saxena, P.R.; Villalón, C.M. 1991: 5-Hydroxytryptamine: a chameleon in the heart. Trends in Pharmacological Sciences 12(6): 223-227
Korneliussen, H. 1976: 5-Hydroxytryptamine: autoradiographic evidence for uptake into fibroblast cell nuclei. Experientia 32(4): 443-445
Costall, B.; Naylor, R.J. 1990: 5-Hydroxytryptamine: new receptors and novel drugs for gastrointestinal motor disorders. Scandinavian Journal of Gastroenterology 25(8): 769-787
Aliño, J.J.; Gutierrez, J.L.; Iglesias, M.L. 1976: 5-Hydroxytryptophan (5-HTP) and a MAOi (nialamide) in the treatment of depressions. a double-blind controlled study. International Pharmacopsychiatry 11(1): 8-15
Mitchell, G.S.; Sloan, H.E.; Jiang, C.; Miletic, V.; Hayashi, F.; Lipski, J. 1992: 5-Hydroxytryptophan (5-HTP) augments spontaneous and evoked phrenic motoneuron discharge in spinalized rats. Neuroscience Letters 141(1): 75-78
Touret, M.; Kitahama, K.; Geffard, M.; Jouvet, M. 1987: 5-Hydroxytryptophan (5-HTP)-immunoreactive neurons in the rat brain tissue. Neuroscience Letters 80(3): 263-267
Itskovitz, H.D.; Werber, J.L.; Sheridan, A.M.; Brewer, T.F.; Stier, C.T. 1989: 5-Hydroxytryptophan and carbidopa in spontaneously hypertensive rats. Journal of Hypertension 7(4): 311-315
Schemann, M.; Ehrlein, H.J. 1986: 5-Hydroxytryptophan and cisapride stimulate propulsive jejunal motility and transit of chyme in dogs. Digestion 34(4): 229-235
Petre-Quadens, O.; De Lee, C. 1975: 5-Hydroxytryptophan and sleep in Down's syndrome. Journal of the Neurological Sciences 26(3): 443-453
Devoino, L.; Eliseeva, L.; Eremina, O.; Idova, G.; Cheido, M. 1976: 5-Hydroxytryptophan effect on the development of the immune response: IgM and IgG antibodies and rosette formation in primary and secondary responses. European Journal of Immunology 5(6): 394-399
Siegle, M.L.; Bühner, S.; Ehrlein, H.J. 1990: 5-Hydroxytryptophan modulates postprandial motor patterns of canine proximal small intestine. Canadian Journal of Physiology and Pharmacology 68(12): 1495-1502
Denoyer, M.; Kitahama, K.; Sallanon, M.; Touret, M.; Jouvet, M. 1989: 5-Hydroxytryptophan uptake and decarboxylating neurons in the cat hypothalamus. Neuroscience 31(1): 203-211
Titus, F.; Dávalos, A.; Alom, J.; Codina, A. 1986: 5-Hydroxytryptophan versus methysergide in the prophylaxis of migraine. Randomized clinical trial. European Neurology 25(5): 327-329
Chadwick, D.; Hallet, M.; Jenner, P.; Marsden, C.D. 1977: 5-Hydroxytryptophan-induced behaviour in guinea-pigs: its relevance to human myoclonus. British Journal of Clinical Pharmacology 4(3): 402p-403p
Koyama, T.; Lowy, M.T.; Meltzer, H.Y. 1987: 5-Hydroxytryptophan-induced cortisol response and CSF 5-HIAA in depressed patients. American Journal of Psychiatry 144(3): 334-337
Byerley, W.F.; Judd, L.L.; Reimherr, F.W.; Grosser, B.I. 1987: 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. Journal of Clinical Psychopharmacology 7(3): 127-137
Beck, O.; Lundman, A.; Jonsson, G. 1987: 5-Hydroxytryptophol and 5-hydroxyindoleacetic acid levels in rat brain: effects of various drugs affecting serotonergic transmitter mechanisms. Journal of Neural Transmission 69(3-4): 287-298
Takahashi, S.; Godse, D.D.; Naqvi, A.; Warsh, J.J.; Stancer, H.C. 1978: 5-Hydroxytryptophol in human cerebrospinal fluid: quantitative determination by gas chromatography-mass spectrometry using a deuterated internal standard. Clinica Chimica Acta; International Journal of Clinical Chemistry 84(1-2): 55-62
Tamir, H.; Wilchek, M. 1979: 5-Hydroxytryptophyl peptides: potent inhibitors of a storage compartment of serotonin. Journal of Neurochemistry 32(2): 593-598
Myers, C.E.; Muindi, J.R.; Zweier, J.; Sinha, B.K. 1987: 5-Iminodaunomycin. An anthracycline with unique properties. Journal of Biological Chemistry 262(24): 11571-11577
Tong, G.L.; Henry, D.W.; Acton, E.M. 1979: 5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline. Journal of Medicinal Chemistry 22(1): 36-39
Spryshkova, R.A.; Grigor'eva, E.I.; Brattsev, V.A.; Sevast'ianov, A.I.; Naĭdenov, M.G. 1992: 5-Iodo-2'-deoxyuridine in the assessment of the individual reaction of experimental tumors to irradiation. Voprosy Onkologii 38(3): 327-334
Ku, K.Y.; Goz, B. 1978: 5-Iodo-2'-deoxyuridine inhibition of Dictyostelium discoideum differentiation and cyclic AMP phosphodiesterase activity. Biochemical Pharmacology 27(11): 1597-1601
Nichols, D.E.; Johnson, M.P.; Oberlender, R. 1991: 5-Iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine. Pharmacology Biochemistry and Behavior 38(1): 135-139
Deutsch, M.; Rewers, A.B.; Redgate, E.S.; Fisher, E.R.; Boggs, S.S. 1989: 5-Iodo-2-deoxyuridine administered into the lateral cerebral ventricle as a radiosensitizer in the treatment of disseminated glioma. Journal of the National Cancer Institute 81(17): 1322-1325
Stobetskiĭ, V.I.; Khapchaev, I.K.; Mironova, L.L. 1987: 5-Iododeoxyuridine as well as 5-bromodeoxyuridine induce the formation of specific dicentric chromosomes in cells with micronuclei. Biulleten' Eksperimental'noi Biologii i Meditsiny 104(7): 83-85
Santos, O.; Pant, K.D.; Blank, E.W.; Ceriani, R.L. 1992: 5-Iododeoxyuridine increases the efficacy of the radioimmunotherapy of human tumors growing in nude mice. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 33(8): 1530-1534
Choi, H.S.; Stoeckler, J.D.; Parks, R.E. 1986: 5-Iodoribose 1-phosphate, an analog of ribose 1-phosphate. Enzymatic synthesis and kinetic studies with enzymes of purine, pyrimidine, and sugar phosphate metabolism. Journal of Biological Chemistry 261(2): 599-607
Morikawa, A.; Sone, T.; Asano, T. 1989: 5-Isoquinolinesulfonamide derivatives. 1. Synthesis and vasodilatory activity of N-(2-guanidinoethyl)-5-isoquinolinesulfonamide derivatives. Journal of Medicinal Chemistry 32(1): 42-46
Morikawa, A.; Sone, T.; Asano, T. 1989: 5-Isoquinolinesulfonamide derivatives. 2. Synthesis and vasodilatory activity of N-(2-aminoethyl)-5-isoquinolinesulfonamide derivatives. Journal of Medicinal Chemistry 32(1): 46-50
Morikawa, A.; Sone, T.; Asano, T. 1992: 5-Isoquinolinesulfonamide derivatives. III. Synthesis and vasodilatory activity of 1-(5-isoquinoline-sulfonyl)piperazine derivatives. Chemical and Pharmaceutical Bulletin 40(3): 770-773
Avigad, G.; Englard, S. 1975: 5-Keto-D-fructose and its phosphate esters-1. Methods in Enzymology 41: 84-90
Englard, S.; Avigad, G. 1975: 5-Keto-D-fructose reductase from Gluconobacter cerinus-1. Methods in Enzymology 41: 127-131
Englard, S.; Avigad, G. 1975: 5-Keto-D-fructose reductase from yeast-1. Methods in Enzymology 41: 132-138
Persaud, C.; Jackson, A.A. 1991: 5-L-oxoprolinuria and glycine sufficiency. Clinical Chemistry 37(9): 1660-1661
Mugridge, K.G.; Perretti, M.; Parente, L. 1991: 5-Lipoxygenase activation may facilitate an interleukin-1 transduction signal. Advances in Prostaglandin Thromboxane and Leukotriene Research 21b: 517-520
Reynolds, C.H. 1988: 5-Lipoxygenase and leukotriene synthesis: effects of calcium ions and of inhibitors. Prostaglandins 36(1): 59-68
Rouzer, C.A.; Samuelsson, B. 1987: 5-Lipoxygenase from human leukocytes associates with membrane in the presence of calcium. Advances in Prostaglandin Thromboxane and Leukotriene Research 17a: 60-63
Hostein, I.; Dorion-Bonnet, F.; Bloch, B.; Vaillier, D.; Juzan, M.; Gualde, N. 1992: 5-Lipoxygenase gene expression in the thymus. Thymus 20(2): 101-108
Jaschonek, K.; Steinhilber, D.; Einsele, H.; Ehninger, G.; Roth, H.J. 1989: 5-Lipoxygenase inhibition by antifungal azole derivatives: new tools for immunosuppression?. Eicosanoids 2(3): 189-190
Garceau, D.; Ford-Hutchinson, A.W.; Charleson, S. 1987: 5-Lipoxygenase inhibitors and allergic conjunctivitis reactions in the guinea-pig. European Journal of Pharmacology 143(1): 1-7
Rask-Madsen, J.; Bukhave, K.; Laursen, L.S.; Lauritsen, K. 1992: 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Agents and Actions Spec No: C37-C46
Nishizawa, M.; Izuhara, R.; Kaneko, K.; Koshihara, Y.; Fujimoto, Y. 1988: 5-Lipoxygenase inhibitors isolated from gardeniae fructus. Chemical and Pharmaceutical Bulletin 36(1): 87-95
Hlasta, D.J.; Casey, F.B.; Ferguson, E.W.; Gangell, S.J.; Heimann, M.R.; Jaeger, E.P.; Kullnig, R.K.; Gordon, R.J. 1991: 5-Lipoxygenase inhibitors: the synthesis and structure-activity relationships of a series of 1-phenyl-3-pyrazolidinones. Journal of Medicinal Chemistry 34(5): 1560-1570
Jessup, W.; Darley-Usmar, V.; O'Leary, V.; Bedwell, S. 1991: 5-Lipoxygenase is not essential in macrophage-mediated oxidation of low-density lipoprotein. Biochemical Journal 278: 163-169
Nathan, M.H.; Pek, S.B. 1991: 5-Lipoxygenase mRNA is expressed in rat pancreatic islets. Advances in Prostaglandin Thromboxane and Leukotriene Research 21a: 17-20
Pasechnikov, V.D.; Radsev, Y.A.; Guminskij, S.P. 1991: 5-Lipoxygenase products: their biosynthesis in human gastric mucosa and possible involvement in inflammatory response and oxygen saturation index reduction in gastric ulcer patients. Biochimica et Biophysica Acta 1097(1): 45-48
Evans, J.F.; Lévillé, C.; Mancini, J.A.; Prasit, P.; Thérien, M.; Zamboni, R.; Gauthier, J.Y.; Fortin, R.; Charleson, P.; MacIntyre, D.E. 1991: 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors. Molecular Pharmacology 40(1): 22-27
Wallace, J.L. 1990: 5-Lipoxygenase: a rational target for therapy of inflammatory bowel disease?. Trends in Pharmacological Sciences 11(2): 51-53
Parker, C.W. 1985: 5-Lipoxygenases. Advances in Prostaglandin Thromboxane and Leukotriene Research 15: 167-168
Young, A.R.; Potten, C.S.; Chadwick, C.A.; Murphy, G.M.; Cohen, A.J. 1990: 5-MOP induced protection against epidermal DNA damage by ultraviolet radiation in human skin. Basic Life Sciences 53: 105-116
Lane-Brown, M. 1987: 5-Methoxy psoralen, etretinate, and UVA for psoriasis. International Journal of Dermatology 26(10): 655-659
Archer, T.; Danysz, W.; Jonsson, G.; Minor, B.G.; Post, C. 1986: 5-Methoxy-N,N-dimethyltryptamine-induced analgesia is blocked by alpha-adrenoceptor antagonists in rats. British Journal of Pharmacology 89(2): 293-298
Gillin, J.C.; Tinklenberg, J.; Stoff, D.M.; Stillman, R.; Shortlidge, J.S.; Wyatt, R.J. 1976: 5-Methoxy-N,N-dimethyltryptamine: behavioral and toxicological effects in animals. Biological Psychiatry 11(3): 355-358
Raikhlin, N.T.; Kvetnoĭ, I.M. 1975: 5-Methoxy-N-acetyltryptamine (melatonin) in enterochromaffin cells. Tsitologiia 17(9): 1047-1050
Anonymous 1986: 5-Methoxypsoralen. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans 40: 327-347
Tanew, A.; Ortel, B.; Rappersberger, K.; Hönigsmann, H. 1988: 5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation. Journal of the American Academy of Dermatology 18(2 Part 1): 333-338
Hönigsmann, H.; Jaschke, E.; Gschnait, F.; Brenner, W.; Fritsch, P.; Wolff, K. 1979: 5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis. British Journal of Dermatology 101(4): 369-378
Souetre, E.; Salvati, E.; Belugou, J.L.; Krebs, B.; Darcourt, G. 1990: 5-Methoxypsoralen as a specific stimulating agent of melatonin secretion in humans. Journal of Clinical Endocrinology and Metabolism 71(3): 670-674
Mauviard, F.; Pévet, P.; Forlot, P. 1991: 5-Methoxypsoralen enhances plasma melatonin concentrations in the male rat: non-noradrenergic-mediated stimulation and lack of effect in pinealectomized animals. Journal of Pineal Research 11(1): 35-41
Souêtre, E.; Salvati, E.; Belugou, J.L.; Krebs, B.; Darcourt, G. 1989: 5-Methoxypsoralen increases evening sleepiness in humans: possible involvement of the melatonin secretion. European Journal of Clinical Pharmacology 36(1): 91-92
Souetre, E.; Salvati, E.; Belugou, J.L.; de Galeani, B.; Krebs, B.; Ortonne, J.P.; Darcourt, G. 1987: 5-Methoxypsoralen increases the plasma melatonin levels in humans. Journal of Investigative Dermatology 89(2): 152-155
Souêtre, E.; De Galeani, B.; Gastaud, P.; Salvati, E.; Darcourt, G. 1989: 5-Methoxypsoralen increases the sensitivity of the retina to light in humans. European Journal of Clinical Pharmacology 36(1): 59-61
Craig, D.A.; Eglen, R.M.; Walsh, L.K.; Perkins, L.A.; Whiting, R.L.; Clarke, D.E. 1990: 5-Methoxytryptamine and 2-methyl-5-hydroxytryptamine-induced desensitization as a discriminative tool for the 5-HT3 and putative 5-HT4 receptors in guinea pig ileum. Naunyn-Schmiedeberg's Archives of Pharmacology 342(1): 9-16
Raynaud, F.; Pévet, P. 1991: 5-Methoxytryptamine is metabolized by monoamine oxidase a in the pineal gland and plasma of golden hamsters. Neuroscience Letters 123(2): 172-174
Przegaliński, E.; Zebrowska-Lupina, I.; Wójcik, A.; Kleinrok, Z. 1977: 5-Methoxytryptamine-induced head twitches in rats. Polish Journal of Pharmacology and Pharmacy 29(3): 253-261
Segonzac, A.; Schoemaker, H.; Tateishi, T.; Langer, S.Z. 1985: 5-Methoxytryptoline, a competitive endocoid acting at [3H]imipramine recognition sites in human platelets. Journal of Neurochemistry 45(1): 249-256
Wilson, B.W.; Lynch, H.J.; Ozaki, Y. 1978: 5-Methoxytryptophol in rat serum and pineal: detection, quantitation, and evidence for daily rhythmicity. Life Sciences 23(10): 1019-1023
Skene, D.J.; Vivien-Roels, B.; Pevet, P. 1990: 5-Methoxytryptophol injections in the Syrian hamster: plasma and pineal concentrations. Neuroscience Letters 108(1-2): 138-142
Albani, M.; Schmidt, W.; Kersten, H.; Geibel, K.; Lüderwald, I. 1976: 5-Methoxyuridine, a new modified constituent in tRNAs of Bacillaceae. Febs Letters 70(1): 37-42
Ringdahl, B. 1988: 5-Methyl-2-pyrrolidone analogues of oxotremorine as selective muscarinic agonists. Journal of Medicinal Chemistry 31(3): 683-688
Poe, M.; Hensens, O.D.; Hoogsteen, K. 1979: 5-Methyl-5,6,7,8-tetrahydrofolic acid. Conformation of the tetrahydropyrazine ring. Journal of Biological Chemistry 254(21): 10881-10884
Gross, G.; Hanft, G.; Rugevics, C. 1988: 5-Methyl-urapidil discriminates between subtypes of the alpha 1-adrenoceptor. European Journal of Pharmacology 151(2): 333-335
Bordin, F.; Carlassare, F.; Baccichetti, F.; Guiotto, A.; Rodighiero, P. 1979: 5-Methylangelicin: a new highly photosensitizing angular furocoumarin. Experientia 35(12): 1567-1568
Schmidhammer, H.; Leander, J.D.; Mayer-Valkanover, K.; Nussbaumer, C.; Schmidt, C.; Schoepp, D.D.; Schratz, A.; Walla-Kugler, M. 1990: 5-Methylated naloxone, naltrexone, oxymorphone, and their 14-O-methyl ethers. Progress in Clinical and Biological Research 328: 41-44
Sakamoto, K.; Okada, N. 1985: 5-Methylcytidylic modification of in vitro transcript from the rat identifier sequence; evidence that the transcript forms a tRNA-like structure. Nucleic Acids Research 13(20): 7195-7206
Schnedl, W.; Miller, O.J.; Erlanger, B.F. 1975: 5-Methylcytosine as a specific building block of heterochromatin in man. Verhandlungen der Anatomischen Gesellschaft 69: 189-191
Rideout, W.M.; Coetzee, G.A.; Olumi, A.F.; Jones, P.A. 1990: 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 249(4974): 1288-1290
Rideout, W.M.; Coetzee, G.A.; Olumi, A.F.; Spruck, C.H.; Jones, P.A. 1991: 5-Methylcytosine as an endogenous mutagen in the p53 tumor suppressor gene. Princess Takamatsu Symposia 22: 207-219
Corvetta, A.; Della Bitta, R.; Luchetti, M.M.; Pomponio, G. 1991: 5-Methylcytosine content of DNA in blood, synovial mononuclear cells and synovial tissue from patients affected by autoimmune rheumatic diseases. Journal of Chromatography 566(2): 481-491
Lapeyre, J.N.; Becker, F.F. 1979: 5-Methylcytosine content of nuclear DNA during chemical hepatocarcinogenesis and in carcinomas which result. Biochemical and Biophysical Research Communications 87(3): 698-705
Singer, J.; Stellwagen, R.H.; Roberts-Ems, J.; Riggs, A.D. 1977: 5-Methylcytosine content of rat hepatoma DNA substituted with bromodeoxyuridine. Journal of Biological Chemistry 252(15): 5509-5513
Schnedl, W.; Dev, V.G.; Tantravahi, R.; Miller, D.A.; Erlanger, B.F.; Miller, O.J. 1975: 5-Methylcytosine in heterochromatic regions of chromosomes: chimpanzee and gorilla compared to the human. Chromosoma 52(1): 59-66
Caiafa, P.; Attină, M.; Cacace, F.; Tomassetti, A.; Strom, R. 1986: 5-Methylcytosine levels in nucleosome subpopulations differently involved in gene expression. Biochimica et Biophysica Acta 867(4): 195-200
Kempson, S.A. 1986: 5-Methylnicotinamide inhibits renal brush-border phosphate transport with no change in NAD. American Journal of Physiology 251(3 Part 2): F520-F527
Harnadek, G.J.; Ries, E.A.; Farhat, A.; Njus, D. 1990: 5-Methylphenazinium methylsulfate mediates cyclic electron flow and proton gradient dissipation in chromaffin-vesicle membranes. Journal of Biological Chemistry 265(30): 18135-18141
Taylor, R.T.; Hanna, M.L. 1975: 5-Methyltetrahydrofolate aromatic alkylamine N-methyltransferase: an artefact of 5,10-methylenetetrahydrofolate reductase activity. Life Sciences 17(1): 111-119
Kass, L.; Boroush, M.A. 1976: 5-Methyltetrahydrofolate-dependent methyltransferase activity in chronic erythremic myelosis and other types of anemias. Biochimica et Biophysica Acta 437(2): 639-642
La Ciura, P.; La Grotta, G.; Nigra, E.; Comandone, A.; Grecchi, G.; Leria, G.; Calciati, A. 1988: 5-Methyltetrahydrofolic acid (MFH4): an effective folate for the treatment of advanced colorectal cancer with 5-FU. Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres Dans les Recherches sur le Cancer 110: 219-225
Balk, S.D.; LeStourgeon, D.; Mitchell, R.S. 1978: 5-Methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid (folinic acid), and folic acid requirements of normal and Rous sarcoma virus-infected chicken fibroblasts. Cancer Research 38(11 Part 1): 3966-3968
O'Dwyer, P.J.; Wagner, B.H.; Hoth, D.F.; Leyland-Jones, B. 1987: 5-Methyltetrahydrohomofolate. Investigational new Drugs 5(3): 215-218
Ferro, A.J.; Barrett, A.; Shapiro, S.K. 1978: 5-Methylthioribose kinase. a new enzyme involved in the formation of methionine from 5-methylthioribose. Journal of Biological Chemistry 253(17): 6021-6025
Litosch, I.; Calista, C.; Wallis, C.; Fain, J.N. 1986: 5-Methyltryptamine decreases net accumulation of 32P into the polyphosphoinositides from [gamma-32P]ATP in a cell-free system from blowfly salivary glands. Activation of breakdown of the newly synthesized [32P]polyphosphoinositides. Journal of Biological Chemistry 261(2): 638-643
Schallenberg, J.; Berlin, J. 1979: 5-Methyltryptophan resistant cells of Catharanthus roseus. Zeitschrift für Naturforschung. Section C Biosciences 34(7-8): 541-545
Wilson, W.R.; Siim, B.G.; Denny, W.A.; van Zijl, P.L.; Taylor, M.L.; Chambers, D.M.; Roberts, P.B. 1992: 5-Nitro-4-(N,N-dimethylaminopropylamino)quinoline (5-nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: comparison with nitracrine. Radiation Research 131(3): 257-265
Anonymous 1990: 5-Nitro-ortho-toluidine. IARC monographs on the evaluation of carcinogenic risks to humans 48: 169-177
Kleinrok, Z.; Sermak, W.; Chodkowska, A.; Kozicka, M. 1990: 5-Nitrobenzylidene derivatives or 3-benzoyl-2-thiohydantoin and their pharmacological properties. Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina 45: 173-180
Wurm, G. 1975: 5-Nitrochromono (3',2'-3,4)cinnoline. Archiv der Pharmazie 308(1): 67-68
Egert, E.; Lindner, H.J.; Hillen, W.; Gassen, H.G. 1977: 5-Nitrouridine-monohydrate: crystal structure and conformation. Nucleic Acids Research 4(4): 929-937
Ljubojević, S.; Perinović, M.; Kesić, V. 1975: 5-Nok in the treatment of candidiasis. Medicinski Arhiv 29(6): 643-644
Hankiewicz, J.; Brudnik, B. 1976: 5-Nucleotidase. Polski Tygodnik Lekarski 31(52): 2235-2237
Heinen, E.; Kinet-Denoël, C.; Simar, L.J. 1985: 5-Nucleotidase activity in isolated follicular dendritic cells. Immunology Letters 9(2-3): 75-80
Torrence, P.F.; Spencer, J.W.; Bobst, A.M. 1978: 5-O-Alkylated derivatives of 5-hydroxy-2'-deoxyuridine as potential antiviral agents. Anti-herpes activity of 5-propynyloxy-2'-deoxyuridine. Journal of Medicinal Chemistry 21(2): 228-231
Van Der Werf, P.; Griffith, O.W.; Meister, A. 1975: 5-Oxo-L-prolinase (L-pyroglutamate hydrolase). Purification and catalytic properties. Journal of Biological Chemistry 250(17): 6686-6692
Seddon, A.P.; Li, L.; Meister, A. 1985: 5-Oxo-L-prolinase from Pseudomonas putida. Methods in Enzymology 113: 451-458
Meister, A.; Griffith, O.W.; Williamson, J.M. 1985: 5-Oxo-L-prolinase from rat kidney. Methods in Enzymology 113: 445-451
Wendel, A.; Flügge, U.I. 1975: 5-Oxoprolinase from rat kidney, I. Assay, purification, and determination of kinetic parameters. Hoppe-Seyler's Zeitschrift für Physiologische Chemie 356(6): 873-880
Wendel, A.; Flügge, U.I.; Jenke, H.S. 1975: 5-Oxoprolinase from rat kidney, II. Molecular weight determinations. Hoppe-Seyler's Zeitschrift für Physiologische Chemie 356(6): 881-885
Divry, P.; Roulaud-Parrot, F.; Dorche, C.; Zabot, M.T.; Contraire, B.; Hagenfeldt, L.; Larsson, A. 1991: 5-Oxoprolinuria (glutathione synthetase deficiency): a case with neonatal presentation and rapid fatal outcome. Journal of Inherited Metabolic Disease 14(3): 341-344
Robertson, P.L.; Buchanan, D.N.; Muenzer, J. 1991: 5-Oxoprolinuria in an adolescent with chronic metabolic acidosis, mental retardation, and psychosis. Journal of Pediatrics 118(1): 92-95
Grol, C.J.; Nordvall, G.; Johansson, A.M.; Hacksell, U. 1991: 5-Oxygenated N-alkyl- and N,N-Dialkyl-2-amino-1-methyltetralins. Effects of structure and stereochemistry on dopamine-D2-receptor affinity. Journal of Pharmacy and Pharmacology 43(7): 481-485
Cascio, G.; Manghisi, E.; Fregnan, G. 1989: 5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity. Journal of Medicinal Chemistry 32(10): 2241-2247
De Clercq, E.; Descamps, J.; Shugar, D. 1978: 5-Propyl-2'-deoxyuridine: a specific anti-herpes agent. Antimicrobial Agents and ChemoTherapy 13(3): 545-547
Al-Razzak, L.A.; Schwepler, D.; Decedue, C.J.; Balzarini, J.; De Clercq, E.; Mertes, M.P. 1987: 5-Quinone derivatives of 2'-deoxyuridine 5'-phosphate: inhibition and inactivation of thymidylate synthase, antitumor cell, and antiviral studies. Journal of Medicinal Chemistry 30(2): 409-419
Agrup, G.; Hansson, C.; Rorsman, H.; Rosengren A-M; Rosengren, E.; Tegner, E. 1978: 5-S-cysteinyldopa excretion after treatment with 8-methoxypsoralen and UVA light. Journal of Investigative Dermatology 70(1): 25-26
Aubert, C.; Rosengren, E.; Rorsman, H.; Rouge, F.; Foa, C.; Lipcey, C. 1977: 5-S-cysteinyldopa in diagnosis and treatment of human malignant melanomas and ultrastructural observations. European Journal of Cancer 13(11): 1299-1308
Carstam, R.; Brinck, C.; Fornstedt, B.; Rorsman, H.; Rosengren, E. 1990: 5-S-cysteinyldopac in human urine. Acta Dermato-Venereologica 70(5): 373-377
Hillen, W.; Gassen, G. 1978: 5-Substituents in the uridine moiety and their effect on the conformation of ApU-type dinucleoside phosphates. Biochimica et Biophysica Acta 518(1): 7-16
De Clercq, E. 1979: 5-Substituted 2'-deoxyuridines which selectively inhibit herpes simplex virus replication. Advances in Ophthalmology 38: 204-213
Vanzura, J.; Vinsová, J.; Hrabálek, A.; Nedvídková, J.; Stolba, P. 1989: 5-Substituted 3-mercapto-4H-1,2,4-triazoles as a potential thyrostaticagent. Ceskoslovenska Farmacie 38(8): 355-358
Torrence, P.F.; Huang, G.F.; Edwards, M.W.; Bhooshan, B.; Descamps, J.; De Clercq, E. 1979: 5-Substituted uracil arabinonucleosides as potential antiviral agents. Journal of Medicinal Chemistry 22(3): 316-319
Veres, Z.; Szabolcs, A.; Szinai, I.; Dénes, G.; Kajtár-Peredy, M.; Otvös, L. 1985: 5-Substituted-2,2'-anhydrouridines, potent inhibitors of uridine phosphorylase. Biochemical Pharmacology 34(10): 1737-1740
Franzen, S.J.; Deremee, R.A. 1977: 5-TU PPD tuberculin skin test. A comparison of readings at 24 and 48 hours. Minnesota Medicine 60(11): 793-794
Fenner, H.; Grauert, R.; Hemmerich, P.; Michel, H.; Massey, V. 1979: 5-Thia-5-deazaflavin, a 1e--transferring flavin analog. European Journal of Biochemistry 95(1): 183-191
Kim, J.H.; Kim, S.H.; Hahn, E.W.; Song, C.W. 1978: 5-Thio-D-glucose selectively potentiates hyperthermic killing of hypoxic tumor cells. Science 200(4338): 206-207
Prikhod'ko, G.G.; Babkin, I.V. 1991: 5-Variable genome sequence of the LIVP vaccinia virus. a possible role for short direct repeats in the formation of deletions. Genetika 27(1): 13-26
Cholody, W.M.; Martelli, S.; Paradziej-Lukowicz, J.; Konopa, J. 1990: 5-[(Aminoalkyl)amino]imidazo[4,5,1-de]acridin-6-ones as a novel class of antineoplastic agents. Synthesis and biological activity. Journal of Medicinal Chemistry 33(1): 49-52
Baranowska-Kortylewicz, J.; Makrigiorgos, G.M.; Van den Abbeele, A.D.; Berman, R.M.; Adelstein, S.J.; Kassis, A.I. 1991: 5-[123I]iodo-2'-deoxyuridine in the radiotherapy of an early ascites tumor model. International Journal of Radiation Oncology Biology Physics 21(6): 1541-1551
Komp, D.M.; Land, V.J.; Nitschke, R.; Cangir, A.; Dyment, P. 1975: 5-[3,3-Bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) in the treatment of childhood malignancy. Cancer ChemoTherapy Reports 59(2 Part 1): 371-376
Shealy, Y.F.; O'Dell, C.A.; Krauth, C.A. 1975: 5-[3-(2-Chloroethyl)-1-triazenyl] imidazole-4-carboxamide and a possible mechanism of action of 5-[3, 3-bis(2-chloroethyl)-1-triazenyl] imidazole-4-carboxamide. Journal of Pharmaceutical Sciences 64(1): 177-180
Peters, J.R.; Geaney, D.P.; Grahame-Smith, D.G. 1992: 5-[3H]hydroxytryptamine and [3H]lysergic acid diethylamide binding to human platelets. Methods in Enzymology 215: 201-213
Mariani, E.; Bargagna, A.; Longobardi, M.; Schenone, P.; Vitagliano, S.; Cenicola, M.L.; Losasso, C.; Russo, S.; Marmo, E. 1991: 5-[4-(omega-dialkylaminoalkoxy)phenylmethylene] -1,3,3-trimethyl-2-oxabicyclo[2.2.2]octan-6-ones with platelet antiaggregating and other activities. Farmaco 46(5): 657-668
Martin, R.P.; Sibler, A.P.; Gehrke, C.W.; Kuo, K.; Edmonds, C.G.; McCloskey, J.A.; Dirheimer, G. 1990: 5-[[(carboxymethyl)amino]methyl]uridine is found in the anticodon of yeast mitochondrial tRNAs recognizing two-codon families ending in a purine. Biochemistry 29(4): 956-959
Valenty, V.B.; Wos, J.D.; Lobo, A.P.; Lawson, W.B. 1979: 5-acyloxyoxazoles as serine protease inhibitors. Rapid inactivation of thrombin in contrast to plasmin. Biochemical and Biophysical Research Communications 88(4): 1375-1381
Aguilar, E.; Tena-Sempere, M.; Pinilla, L. 1992: 5-alpha androstane diol stimulates the pituitary growth hormone responsiveness to growth hormone releasing hormone more effectively than testosterone or dihydrotestosterone in rats. Acta Endocrinologica 126(2): 162-166
Heinzl, S. 1990: 5-alpha reductase inhibitor in prostatic adenoma?. Medizinische Monatsschrift für Pharmazeuten 13(12): 382-384
Greene, S.A.; Symes, E.; Brook, C.G. 1978: 5-alpha-Reductase deficiency causing male pseudohermaphroditism. Archives of Disease in Childhood 53(9): 751-753
Ross, R.K.; Bernstein, L.; Lobo, R.A.; Shimizu, H.; Stanczyk, F.Z.; Pike, M.C.; Henderson, B.E. 1992: 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339(8798): 887-889
Rembiesa, R.; Warchoł, A.; Warszyńska, A. 1988: 5-alpha-reductase activity in the hypothalamus and pituitary gland of rats in various stages of pregnancy. Endokrynologia Polska 39(1): 27-32
Yamadate, S.; Sekiguchi, M.; Kawano, K. 1986: 5-amino-2-nitrobenzoic acid as a reference material for the determination of gamma-GT activity. Clinica Chimica Acta; International Journal of Clinical Chemistry 160(1): 63-67
Rasmussen, S.N.; Bondesen, S.; Nielsen, O.H.; Binder, V.; Hansen, S.H.; Hvidberg, E. 1985: 5-amino-salicylic acid. a review of a new treatment of chronic inflammatory bowel disease. Ugeskrift for Laeger 147(36): 2811-2815
Anonymous 1978: 5-aminoacenaphthene. IARC monographs on the evaluation of the carcinogenic risk of chemicals to man 16: 243-247
Chiba, M.; Kikuchi, M. 1979: 5-aminolevulinate dehydratase activity in blood of rabbits given tin or lead. British Journal of Industrial Medicine 36(4): 323-325
Menendez-Pelaez, A.; Rodriguez, C.; Dominguez, P. 1991: 5-aminolevulinate synthase mRNA levels in the Harderian gland of Syrian hamsters: correlation with porphyrin concentrations and regulation by androgens and melatonin. Molecular and Cellular Endocrinology 80(1-3): 177-182
Pereira, B.; Curi, R.; Kokubun, E.; Bechara, E.J. 1992: 5-aminolevulinic acid-induced alterations of oxidative metabolism in sedentary and exercise-trained rats. Journal of Applied Physiology 72(1): 226-230
Järnerot, G. 1987: 5-aminosalicylic acid based drugs for the treatment of ulcerative colitis. Acta Gastro-Enterologica Belgica 50(3): 306-315
Ngô, Y.; Rambaud, J.C. 1992: 5-aminosalicylic acid enema (Pentasa) versus hydrocortisone acetate foam (Proctocort) for the treatment of outbreaks of proctitis and cryptogenetic proctosigmoiditis. a comparative randomized multicenter trial. Gastroenterologie Clinique et Biologique 16(6-7): 558-563
Campieri, M.; Lanfranchi, G.A.; Brignola, C.; Bazzochi, G.; Gionchetti, P.; Minguzzi, M.R.; Adami, F. 1985: 5-aminosalicylic acid for the treatment of inflammatory bowel diseases. Gastroenterology 89(3): 701-703
Breuer, N. 1989: 5-aminosalicylic acid in the long-term treatment of ulcerative colitis. Zeitschrift für Gastroenterologie 27(4): 234-235
Bresci, G.; Petrucci, A.; Banti, S. 1991: 5-aminosalicylic acid in the prevention of relapses of Crohn's disease in remission: a long-term study. International Journal of Clinical Pharmacology Research 11(4): 200-202
Cappello, M.; Puleo, A.; Calabrese, A.; Cipolla, C.; Orlando, A.; Gatto, G.; Oliva, L.; Cottone, M. 1987: 5-aminosalicylic acid treatment of ulcerative colitis during the acute phase in patients resistant or intolerant to salazopyrine. Recenti Progressi in Medicina 78(2): 76-78
Tromm, A.; May, B. 1991: 5-aminosalicylic acid-associated pancreatitis. Deutsche Medizinische Wochenschrift 116(28-29): 1125
Aeberli, P.; Eden, P.; Gogerty, J.H.; Houlihan, W.J.; Penberthy, C. 1975: 5-aryl-2,3-dihydro-5H-imidazo[2,1-a]isoindol-5-ols. a novel class of anorectic agents. Journal of Medicinal Chemistry 18(2): 177-182
Vermorken, J.B.; Tumolo, S.; Roozendaal, K.J.; Guastalla, J.P.; Splinter, T.A.; Renard, J. 1991: 5-aza-2'-deoxycytidine in advanced or recurrent cancer of the uterine cervix. European Journal of Cancer 27(2): 216-217
Jablonka, E.; Goitein, R.; Sperling, K.; Cedar, H.; Marcus, M. 1987: 5-aza-C-induced changes in the time of replication of the X chromosomes of Microtus agrestis are followed by non-random reversion to a late pattern of replication. Chromosoma 95(1): 81-88
Bouchard, J.; Walker, M.C.; Leclerc, J.M.; Lapointe, N.; Beaulieu, R.; Thibodeau, L. 1990: 5-azacytidine and 5-azadeoxycytidine inhibit human immunodeficiency virus type 1 replication in vitro. Antimicrobial Agents and ChemoTherapy 34(2): 206-209
Stopper, H.; Pechan, R.; Schiffmann, D. 1992: 5-azacytidine induces micronuclei in and morphological transformation of Syrian hamster embryo fibroblasts in the absence of unscheduled DNA synthesis. Mutation Research 283(1): 21-28
Denda, A.; Rao, P.M.; Rajalakshmi, S.; Sarma, D.S. 1985: 5-azacytidine potentiates initiation induced by carcinogens in rat liver. Carcinogenesis 6(1): 145-146
Parrow, V.C.; Aleström, P.; Gautvik, K.M. 1989: 5-azacytidine-induced alterations in the GH12C1 cells: effects on cellular morphology, chromosome structure, DNA and protein synthesis. Journal of Cell Science 93: 533-543
Mukherjee, A.B.; Luckett, D.C.; Herrera, R.J. 1986: 5-azacytidine-induced decrease in the frequency of Barr body in human fibroblasts. Genetical Research 47(3): 199-203
Fehrer, S.C.; Silsby, J.L.; el Halawani, M.E.; Guise, K.S. 1988: 5-azacytidine-induced increase in plasma prolactin levels of immature turkeys. Poultry Science 67(12): 1794-1796
Durante, M.; Cecchini, E.; Natali, L.; Citti, L.; Geri, C.; Parenti, R.; Nuti Ronchi, V. 1989: 5-azacytidine-induced tumorous transformation and DNA hypomethylation in Nicotiana tissue cultures. Developmental Genetics 10(4): 298-303
Higino, J.S.; Lins-Galdino, S.; Da Rocha-Pitta, I.; De Lima, J.G.; Luu-Duc, C. 1990: 5-benzylidene pyrrolones. IV--Synthesis and antifungal activity of some 5-benzylidene derivatives of 1,2-dimethyl-3-carbethoxy-pyrrol-4-one. Farmaco 45(12): 1283-1287
Peroutka, S.J.; McCarthy, B.G.; Guan, X.M. 1991: 5-benzyloxytryptamine: a relatively selective 5-hydroxytryptamine 1D/1B agent. Life Sciences 49(6): 409-418
Tapscott, S.J.; Lassar, A.B.; Davis, R.L.; Weintraub, H. 1989: 5-bromo-2'-deoxyuridine blocks myogenesis by extinguishing expression of MyoD1. Science 245(4917): 532-536
Coetzee, G.A.; Gevers, W. 1977: 5-bromo-2'-deoxyuridine-stimulated calcium ion- or magnesium ion-dependent ecto-(adenosine triphosphatase) activity of cultured hamster cardiac cells. Biochemical Journal 164(3): 645-652
Maddox, A.M.; Johnson, D.A.; Keating, M.J. 1989: 5-bromodeoxyuridine (BUdR) quenching of acridine orange fluorescence distinguishes cycling and non-cycling normal and malignant bone marrow cells in vitro. Leukemia Research 13(9): 781-790
Varshaver, N.B.; Gorbunova, L.V.; Lukash, L.L.; Shapiro, N.I. 1978: 5-bromodeoxyuridine and the mutagenic effect of oncogenic virus SV40. Doklady Akademii Nauk SSSR 242(3): 707
Evans, I.M.; Gross, P.R. 1978: 5-bromodeoxyuridine does not affect development of the sea urchin, Arbacia punctulata. Experimental Cell Research 114(1): 85-93
Githens, S.; Pictet, R.; Phelps, P.; Rutter, W.J. 1976: 5-bromodeoxyuridine may alter the differentiative program of the embryonic pancreas. Journal of Cell Biology 71(2): 341-356
Roufa, D.J. 1976: 5-bromodeoxyuridine-DNA strand symmetry and the repair of photolytic breaks in Chinese hamster cell chromosomes. Proceedings of the National Academy of Sciences of the United States of America 73(11): 3905-3909
Touraine, J.L.; Touraine, F.; Hadden, J.W.; Hadden, E.M.; Good, R.A. 1976: 5-bromodeoxyuridine-light inactivation of human lymphocytes stimulated mitogens and allogeneic cells: evidence for distinct T-lymphocyte subsets. International Archives of Allergy and Applied Immunology 52(1-4): 105-117
Wright, C.E.; Angus, J.A. 1989: 5-carboxamidotryptamine elicits 5-HT2 and 5-HT3 receptor-mediated cardiovascular responses in the conscious rabbit: evidence for 5-HT release from platelets. Journal of Cardiovascular Pharmacology 13(4): 557-564
Schwan, T.J.; Ellis, K.O. 1975: 5-chloro-2-pyrimidinyl analog of dantrolene. Journal of Pharmaceutical Sciences 64(2): 337-338
Greer, S.; Santos, O.; Gottlieb, C.; Schwade, J.; Marion, H.S. 1992: 5-chlorodeoxycytidine, a radiosensitizer effective against RIF-1 and Lewis lung carcinoma, is also effective against a DMBA-induced mammary adenocarcinoma and the EMT-6 tumor in BALB/c mice. International Journal of Radiation Oncology Biology Physics 22(3): 505-510
Hum, G.J.; Bateman, J.R. 1975: 5-day iv infusion with 5-fluorouracil (5-FU; NSC-19893) for gastroenteric carcinoma after failure on weekly 5-FU therapy. Cancer ChemoTherapy Reports 59(6): 1171-1179
Adams, G.A.; Swenson, S.D.; Rock, G. 1987: 5-day storage of human platelet concentrates in 30 ml of plasma or artificial medium. Vox Sanguinis 52(4): 305-312
Rock, G.; Senack, E.; Tittley, P. 1989: 5-day storage of platelets collected on a blood cell separator. Transfusion 29(7): 626-628
Rock, G.; Tittley, P.; McCombie, N. 1989: 5-day storage of single-donor platelets obtained using a blood cell separator. Transfusion 29(4): 288-291
Guy, J.T.; Fleming, T.; Pollock, T.W.; Rivkin, S.E.; Pugh, R.P.; Saiers, H.; Hynes, H.E.; Boyd, J.F. 1990: 5-day vinblastine infusion for pancreatic adenocarcinoma. a phase Ii Southwest Oncology Group study. Investigational new Drugs 8(2): 205-206
Schober, T. 1979: 5-day-week of humaneness? Planned legislation cuts the ground from under the diaconate's mission. Schwestern Revue 17(2): 4-6
Houser, R.M.; Olson, R.E. 1977: 5-demethylubiquinone-9-methyltransferase from rat liver mitochondria. Characterization, localization, and solubilization. Journal of Biological Chemistry 252(12): 4017-4021
Carey, R.W.; Sohier, W.D.; Kaufman, S.; Weitzman, S.A.; Kelley, R.M.; Lew, R.A.; Halpern, E. 1979: 5-drug adjuvant chemotherapy for breast cancer. Cancer 44(1): 35-41
Eastman, A.R.; Neville, A.M. 1977: 5-ene-3beta-hydroxysteroid dehydrogenase of human and bovine adrenocortical endoplasmic reticulum: solubilization and fractionation. Journal of Endocrinology 72(2): 225-233
Schönebeck, J. 1976: 5-fluorocytosine--a new antimycotic drug. Lakartidningen 73(25): 2342-2344
Alestig, K.; Eilard, T.; Norrby, R. 1975: 5-fluorocytosine--a new drug for treatment of severe mycotic infections. Lakartidningen 72(41): 3929-3930
Ashe, W.D.; Van Reken, D.E. 1977: 5-fluorocytosine: a brief review. Clinical Pediatrics 16(4): 364-366
Koeffler, H.P.; Golde, D.W. 1979: 5-fluorocytosine: inhibition of hematopoiesis in vitro and reversal of inhibition by uracil. Journal of Infectious Diseases 139(4): 438-443
Spasokukotskaja, T.; Taljanidisz, J.; Benczur, M.; Staub, M. 1988: 5-fluorodeoxyuridine decreases the effect of arabinofuranosyl-cytosine in undifferentiated human B lymphocytes. Acta Biochimica et Biophysica Hungarica 23(2): 159-173
Synzynys, B.I.; Brozmanova, E.; Gotlib, V.I.; Saenko, A.S. 1985: 5-fluorodeoxyuridine induces radioresistant synthesis of DNA and sensitizes Hela cells to gamma radiation. Radiobiologiia 25(5): 593-597
Taub, M.; Englesberg, E. 1978: 5-fluorotryptophan resistant mutants affecting the a and L transport systems in the mouse L cell line A9. Journal of Cellular Physiology 97(3 Pt 2 Suppl 1: 477-486
Ludwig, C.U.; Denz, H.; Gisin, H.; Obrecht, J.P. 1990: 5-fluorouracil (5-FU) plus high dose folinic acid (FA): a modified scheme with reduced toxicity. Annals of Oncology: Official Journal of the European Society for Medical Oncology 1(4): 303
Guaraldi, M.; Martoni, A.; Tononi, A.; Occhiuzzi, L.; Caliceti, U.; Dall'Olio, D.; Laudadio, P.; Pannuti, F. 1991: 5-fluorouracil + folinic acid with cisplatinum and bleomycin in the treatment of advanced head and neck squamous cell carcinoma. Annals of Oncology: Official Journal of the European Society for Medical Oncology 2(5): 379-381
Khaw, P.T.; Grierson, I.; Hitchings, R.A.; Rice, N.S. 1991: 5-fluorouracil and beyond. British Journal of Ophthalmology 75(10): 577-578
Marcuello, E.; Fernández, M.; Martínez, C.; Germa, J.R. 1975: 5-fluorouracil and cobalt therapy in bladder cancer as a preoperative study of immediate toxicity. Acta Oncologica 10(3): 141-146
Morrison, R.A.; Oseekey, K.B.; Fung, H.L. 1978: 5-fluorouracil and methotrexate sodium: an admixture incompatability?. American Journal of Hospital Pharmacy 35(1): 15; 18
Labianca, R.; Luporini, G. 1991: 5-fluorouracil cardiotoxicity: the risk of rechallenge. Annals of Oncology: Official Journal of the European Society for Medical Oncology 2(5): 383
Nozue, M.; Todoroki, T.; Ueda, H.; Fukuda, S.; Miyamoto, H.; Kawai, Y.; Iwasaki, Y. 1991: 5-fluorouracil concentration in gastroenterological tumor tissues, in adjacent normal tissues, and in serum after preoperative oral administration of 5'-deoxy-5-fluorouridine (5'-DFUR). Gan to Kagaku Ryoho. Cancer and ChemoTherapy 18(3): 377-382
Zelechowska, J.A.; Madej, G. 1976: 5-fluorouracil effectiveness and toxicity in the treatment of digestive trac.t neoplasms as a function of the mode of administration. Nowotwory 26(1): 29-36
Odom, L.D.; Plouffe, L.; Butler, W.J. 1990: 5-fluorouracil exposure during the period of conception: report on two cases. American Journal of Obstetrics and Gynecology 163(1 Pt 1): 76-77
Labandter, H.P.; Ryan, R.F. 1978: 5-fluorouracil in Gorlin's syndrome. Journal of the Louisiana State Medical Society: Official Organ of the Louisiana State Medical Society 130(4): 79-82
Fleischer, I.; Wainstein, R.; Milano, M.C. 1985: 5-fluorouracil in high doses. Principles and toxicity. Acta Gastroenterologica Latinoamericana 15(3): 165-170
Labandter, H.P.; Ryan, R.F. 1978: 5-fluorouracil in management of Gorlin's syndrome. New England Journal of Medicine 298(16): 913
Costanzi, J.J.; Gagliano, R.; Coltman, C.A.; Bickers, J.N. 1979: 5-fluorouracil in the treatment of acute leukemia: a Southwest Oncology Group Study. Cancer Treatment Reports 63(11-12): 2126-2128
Bansal, R.K.; Gupta, A. 1992: 5-fluorouracil in trabeculectomy for patients under the age of 40 years. Ophthalmic Surgery 23(4): 278-280
Lubec, G.; Szalay, S. 1979: 5-fluorouracil inhibits bacterial collagenase and the collagenolytic system of a human rhabdomyosarcoma. Onkologie 2(1): 38-40
Chodynicka, B.; Szarmach, H. 1976: 5-fluorouracil ointment in the treatment of basal cell epithelioma. Przeglad Dermatologiczny 63(5): 691-697
Krupp, P.J.; Bohm, J.W. 1978: 5-fluorouracil topical treatment of in situ vulvar cancer. A preliminary report. Obstetrics and Gynecology 51(6): 702-706
Georgescu, T.; Naftali, Z.; Varga, A.; Simon, G.; Pană, C.; Crăciun, C.; Nistor, V.; Ilniczky, P.; Boţianu, A.; Kovács, M. 1990: 5-fluorouracil treatment of acute pancreatitis and of pancreatic and duodenal fistulae. Revista de Chirurgie Oncologie Radiologie O.R.L. Oftalmologie Stomatologie. Chirurgie 39(1): 45-50
Muss, H.B.; Lokich, J.J.; Frei, E. 1975: 5-fluorouracil with cytosine arabinoside in metastatic gastrointestinal cancer. Clinical Pharmacology and Therapeutics 18(2): 234-237
Goldberg, R.M.; Smith, F.P.; Ueno, W.; Ahlgren, J.D.; Schein, P.S. 1986: 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 4(3): 395-399
Lam, W.K.; So, S.Y.; Kung, T.M.; Sham, M.K.; Ip, M. 1987: 5-fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy in advanced adenocarcinoma of the lung: comparison of two dosage schedules. Cancer ChemoTherapy and Pharmacology 19(3): 269-271
MacDonald, J.S.; Woolley, P.V.; Smythe, T.; Ueno, W.; Hoth, D.; Schein, P.S. 1979: 5-fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer 44(1): 42-47
Abad, A.; Rosell, R.; Barnadas, A.; Carles, J.; Ribelles, N.; Solano, V. 1991: 5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors. Annals of Oncology: Official Journal of the European Society for Medical Oncology 2(2): 153
Bunn, P.A.; Nugent, J.L.; Ihde, D.C.; Cohen, M.H.; Eddy, J.L.; Minna, J.D. 1978: 5-fluorouracil, methyl-CCNU, adriamycin, and mitomycin C in the treatment of advanced gastric cancer. Cancer Treatment Reports 62(9): 1287-1293
Beex, L.; Ross, A.; Smals, A.; Kloppenborg, P. 1977: 5-fluorouracil-induced increase of total serum thyroxine and triiodothyronine. Cancer Treatment Reports 61(7): 1291-1295
Ebbe, S.; Yee, T.; Phalen, E. 1989: 5-fluorouracil-induced thrombocytosis in mice is independent of the spleen and can be partially reproduced by repeated doses of cytosine arabinoside. Experimental Hematology 17(7): 822-826
Pokora, J.; Schabowski, J. 1978: 5-hour urinary excretion of adrenaline and noradrenaline in patients with dumping syndrome after loading with 50 g of glucose. Polskie Archiwum Medycyny Wewnetrznej 60(4): 355-359
Brus, R.; Herman, Z.S.; Szkilnik, R.; Dzikowski, A.; Opielka, L.; Bonczek, A. 1977: 5-hydroxydopamine, unspecific centrally acting false neurotransmitter. Acta Physiologica Polonica 28(1): 13-21
Massarotti, M. 1975: 5-hydroxyindoleacetic acid (5-HIAA) in lumbar CSF of patients with subarachnoid hemorrhage. Journal of Neurosurgical Sciences 19(1-2): 72-74
Massarotti, M.; Migliore, A.; Roccella, P.; Tegos, S.; Toffano, G. 1978: 5-hydroxyindoleacetic acid (5-HIAA) levels in the cerebrospinal fluid of hydrocephalic children before and after ventricular shunting procedure. Child's Brain 4(4): 195-204
Arendt, J.; Béguin, F. 1975: 5-hydroxyindoleacetic acid: a reflection of the fetal central nervous system?. Gynakologische Rundschau 15(Suppl 1): 43-46
Suzuki, O.; Yagi, S. 1975: 5-hydroxytraptamine and monoamine oxidase in developing chick spinal cord. Journal of Neurochemistry 25(2): 189-190
Millan, M.J.; Colpaert, F.C. 1991: 5-hydroxytryptamine (HT)1A receptors and the tail-flick response. II. High efficacy 5-HT1A agonists attenuate morphine-induced antinociception in mice in a competitive-like manner. Journal of Pharmacology and Experimental Therapeutics 256(3): 983-992
Jansen, I.; Blackburn, T.; Eriksen, K.; Edvinsson, L. 1991: 5-hydroxytryptamine antagonistic effects of ICI 169,369, ICI 170,809 and methysergide in human temporal and cerebral arteries. Pharmacology and Toxicology 68(1): 8-13
Paxinos, G.; Burt, J.; Atrens, D.M.; Jackson, D.M. 1977: 5-hydroxytryptamine depletion with para-chlorophenylalanine: effects on eating, drinking, irritability, muricide, and copulation. Pharmacology Biochemistry and Behavior 6(4): 439-447
Christenson, J.; Cullheim, S.; Grillner, S.; Hökfelt, T. 1990: 5-hydroxytryptamine immunoreactive varicosities in the lamprey spinal cord have no synaptic specializations--an ultrastructural study. Brain Research 512(2): 201-209
Pentreath, V.W. 1977: 5-hydroxytryptamine in identified neurons. Biochemical Society Transactions 5(4): 854-858
Gradwell, P.B.; Everitt, B.J.; Herbert, J. 1975: 5-hydroxytryptamine in the central nervous system and sexual receptivity of female rhesus monkeys. Brain Research 88(2): 281-293
Székely, M. 1978: 5-hydroxytryptamine induced changes in body temperature of newborn kittens and guinea-pigs and the effect of indomethacin thereon. Experientia 34(1): 58-59
Nishimura, T.; Tokimasa, T.; Akasu, T. 1988: 5-hydroxytryptamine inhibits cholinergic transmission through 5-HT1A receptor subtypes in rabbit vesical parasympathetic ganglia. Brain Research 442(2): 399-402
Sugita, S.; Shen, K.Z.; North, R.A. 1992: 5-hydroxytryptamine is a fast excitatory transmitter at 5-HT3 receptors in rat amygdala. Neuron 8(1): 199-203
Zhang, M.; Han, J.S. 1985: 5-hydroxytryptamine is an important mediator for both high and low frequency electroacupuncture analgesia. Zhen Ci Yan Jiu 10(3): 212-215
Herman, Z.S. 1975: 5-hydroxytryptamine metabolism in the brain under the influence of psychotropic drugs. Polish Journal of Pharmacology and Pharmacy 27(Suppl): 25-43
Burks, T.F.; Dafny, N. 1977: 5-hydroxytryptamine participation in morphine effects on sensory evoked responses. Proceedings of the Western Pharmacology Society 20: 393-398
Osman, F.H.; Ammar, E.M. 1975: 5-hydroxytryptamine receptors in uterine smooth muscle. Japanese Journal of Pharmacology 25(6): 631-637
Al-Humayyd, M.; White, T.D. 1985: 5-hydroxytryptamine releases adenosine 5'-triphosphate from nerve varicosities isolated from the myenteric plexus of guinea-pig ileum. British Journal of Pharmacology 84(1): 27-34
Hekmatpanah, C.R.; Peroutka, S.J. 1990: 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents. European Journal of Pharmacology 177(1-2): 95-98
Lecomte, J.; Dresse, A. 1988: 5-hydroxytryptamine, an endogenous amine. Revue Medicale de Liege 43(Suppl 1): 1-7
Soukop, M. 1991: 5-hydroxytryptamine-3 antagonists: a new class of potent antiemetics in cancer therapy. Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres Dans les Recherches sur le Cancer 121: 86-90
Fillion, G.; Rousselle, J.C.; Goiny, M.; Pradelles, P.; Dray, F.; Jacob, J. 1977: 5-hydroxytryptamine-sensitive adenylate cyclase activity in brain synaptosomal membrane preparations. Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences. Serie D: Sciences Naturelles 285(3): 265-268
Clark, A.H.; Garland, C.J. 1991: 5-hydroxytryptamine-stimulated accumulation of 1,2-diacylglycerol in the rabbit basilar artery: a role for protein kinase C in smooth muscle contraction. British Journal of Pharmacology 102(2): 415-421
Bielenberg, G.W.; Burkhardt, M. 1990: 5-hydroxytryptamine1A agonists. a new therapeutic principle for stroke treatment. Stroke 21(12 Suppl): Iv161-Iv163
Johnson, S.W.; Mercuri, N.B.; North, R.A. 1992: 5-hydroxytryptamine1B receptors block the GABAB synaptic potential in rat dopamine neurons. Journal of Neuroscience: the Official Journal of the Society for Neuroscience 12(5): 2000-2006
Waeber, C.; Hoyer, D.; Palacios, J.M. 1989: 5-hydroxytryptamine3 receptors in the human brain: autoradiographic visualization using [3H]ICS 205-930. Neuroscience 31(2): 393-400
Tonini, M.; Candura, S.M.; Onori, L.; Coccini, T.; Manzo, L.; Rizzi, C.A. 1992: 5-hydroxytryptamine4 receptor agonists facilitate cholinergic transmission in the circular muscle of guinea pig ileum: antagonism by tropisetron and DAU 6285. Life Sciences 50(21): PL173-PL178
Rusch, N.J.; Chyatte, D.; Sundt, T.M.; Vanhoutte, P.M. 1985: 5-hydroxytryptamine: source of activator calcium in human basilar arteries. Stroke 16(4): 718-720
Bertolini, S.; Elicio, N.; Costa, S.; Reggiani, E.; Balestreri, R. 1975: 5-hydroxytryptophan and response of the hypothalamo-hypophyseal-adrenocortical system to insulin-induced hypoglycemia in humans. Bollettino della Societa Italiana di Biologia Sperimentale 51(4): 164-170
Meiniel, A. 1977: 5-hydroxytryptophan decarboxylase (5-HTPD) and monoamine oxidase (MAO) activities in the embryonic pineal organ of Lacerta vivipara J. a qualitative and quantitative microscopic study of the uptake of 3H-5-HTP under experimental conditions and the histochemistry of MAO. Journal of Neural Transmission 41(2-3): 175-208
Baranowska-Kortylewicz, J.; Adelstein, S.J.; Kassis, A.I. 1990: 5-iodo-2'-deoxyuridine-protein conjugates: synthesis and enzymatic degradation. Selective Cancer Therapeutics 6(1): 1-13
Green, J.A.; Baron, S. 1975: 5-iododeoxyuridine potentiation of the replication in vitro of several unrelated RNA and DNA viruses. Science 190(4219): 1099-1101
Skoog, M.T.; Nichols, J.S.; Wiseman, J.S. 1986: 5-lipoxygenase from rat PMN lysate. Prostaglandins 31(3): 561-576
Suematsu, M.; Miura, S.; Suzuki, M.; Nagata, H.; Morishita, T.; Oshio, C.; Tsuchiya, M. 1988: 5-lipoxygenase inhibitor (AA-861) attenuates neutrophil-mediated oxidative stress on the venular endothelium in endotoxemia. Journal of Clinical and Laboratory Immunology 25(1): 41-45
Batt, D.G. 1992: 5-lipoxygenase inhibitors and their anti-inflammatory activities. Progress in Medicinal Chemistry 29: 1-63
Carter, G.W.; Young, P.R.; Albert, D.H.; Bouska, J.; Dyer, R.; Bell, R.L.; Summers, J.B.; Brooks, D.W. 1991: 5-lipoxygenase inhibitory activity of zileuton. Journal of Pharmacology and Experimental Therapeutics 256(3): 929-937
Musser, J.H.; Kreft, A.F. 1992: 5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors. Journal of Medicinal Chemistry 35(14): 2501-2524
Raĭkhlin, N.T.; Kvetnoĭ, I.M. 1976: 5-methoxy-N-acetyltryptamine (melatonin) and its role in physiological and pathological processes in the organism. Patologicheskaia Fiziologiia i Eksperimental'naia Terapiia 1: 76-79
Langer, S.Z.; Lee, C.R.; Schoemaker, H.; Segonzac, A.; Esnaud, H. 1985: 5-methoxytryptoline and close analogs as candidates for the endogenous ligand of the 3H-imipramine recognition site. Progress in Clinical and Biological Research 192: 441-455
Silman, R.E.; Hooper, R.J.; Leone, R.M.; Edwards, R.; Grudzinskas, J.G.; Gordon, Y.B.; Chard, T.; Savage, M.; Smith, I.; Mullen, P.E. 1979: 5-methoxytryptophol and pituitary function in man. Progress in Brain Research 52: 507-511
Carter, S.J.; Laud, C.A.; Smith, I.; Leone, R.M.; Silman, R.E.; Hooper, R.J.; Larson-Carter, D.L.; Finnie, M.D.; Mullen, P.E. 1979: 5-methoxytryptophol in rat pineal glands and other tissues. Progress in Brain Research 52: 267-269
Murao, K.; Hasegawa, T.; Ishikura, H. 1976: 5-methoxyuridine: a new minor constituent located in the first position of the anticodon of tRNAAla, tRNAThr, and tRNAVal from Bacillus subtilis. Nucleic Acids Research 3(10): 2851-2860
Coward, J.K.; Chello, P.L.; Cashmore, A.R.; Parameswaran, K.N.; DeAngelis, L.M.; Bertino, J.R. 1975: 5-methyl-5,6,7,8-tetrahydropteroyl oligo-gamma-L-glutamates: synthesis and kinetic studies with methionine synthetase from bovine brain. Biochemistry 14(7): 1548-1552
Fabricant, J.D.; Wagner, E.F.; Auer, B.; Schweiger, M. 1979: 5-methylcytosine content of DNA during differentiation in mouse teratocarcinoma cells. Experimental Cell Research 124(1): 25-29
Schnedl, W.; Erlanger, B.F.; Miller, O.J. 1976: 5-methylcytosine in heterochromatic regions of chromosomes in Bovidae. Human Genetics 31(1): 21-26
Jacobsen, S.J.; North, J.A.; Rao, N.A.; Mangum, J.H. 1977: 5-methyltetrahydrofolate: synthesis and utilization in normal and SV40-transformed BHK-21 cells. Biochemical and Biophysical Research Communications 76(1): 46-53
Meller, E.; Rosengarten, H.; Friedhoff, A.J.; Stebbins, R.D.; Silber, R. 1975: 5-methyltetrahydrofolic acid is not a methyl donor for biogenic amines: enzymatic formation of formaldehyde. Science 187(4172): 171-173
Rossier, A.B.; Fam, B.A. 1986: 5-microtransducer catheter in evaluation of neurogenic bladder function. Urology 27(4): 371-378
Reusch, R.N.; Sadoff, H.L. 1979: 5-n-Alkylresorcinols from encysting Azotobacter vinelandii: isolation and characterization. Journal of Bacteriology 139(2): 448-453
Anonymous 1978: 5-nitroacenaphthene. IARC monographs on the evaluation of the carcinogenic risk of chemicals to man 16: 319-324
Turnay, J.; Olmo, N.; Risse, G.; von der Mark, K.; Lizarbe, M.A. 1989: 5-nucleotidase activity in cultured cell lines. Effect of different assay conditions and correlation with cell proliferation. In Vitro Cellular and Developmental Biology; Journal of the Tissue Culture Association 25(11): 1055-1061
Spielberg, S.P.; Kramer, L.I.; Goodman, S.I.; Butler, J.; Tietze, F.; Quinn, P.; Schulman, J.D. 1977: 5-oxoprolinuria: biochemical observations and case report. Journal of Pediatrics 91(2): 237-241
Chapkin, R.S.; Hubbard, N.E.; Erickson, K.L. 1990: 5-series peptido-leukotriene synthesis in mouse peritoneal macrophages: modulation by dietary n-3 fatty acids. Biochemical and Biophysical Research Communications 171(2): 764-769
Huang, J.T.; Schinazi, R.F.; Gadler, H.; Price, R.W.; Su, T.L.; Watanabe, K.A. 1987: 5-substituted 2'-fluoro-arabinonucleosides as potential antiviral agents. Nucleic Acids Symposium Series 18: 261-264
Fossa, P.; Menozzi, G.; Schenone, P.; Filippelli, W.; Russo, S.; Lucarelli, C.; Marmo, E. 1991: 5-substituted 4-isoxazolecarboxamides with platelet antiaggregating and other activities. Farmaco 46(6): 789-802
Gut, M.; Hilfiker, B.; Schreiber, A. 1990: 5-t-7-year results of cementless Endler acetabular prosthesis. Zeitschrift für Orthopadie und ihre Grenzgebiete 128(6): 598-605
Monvall, E. 1975: 5-term education threatens to disappear. Tidskrift for Sveriges Sjukskoterskor 42(14): 57-58
Prabhakaran, K. 1976: 5-thio-D-glucose: o-diphenoloxidase inhibition as its mechanism of action. Experientia 32(2): 152-153
Anisuzzaman, A.K.; Whistler, R.L. 1977: 5-thio-L-rhamnose. Carbohydrate Research 55: 205-214
Sterkers, Y.; Goutallier, D. 1988: 5-to-10-year results of Chiari's osteotomy in developing coxarthrosis. Revue de Chirurgie Orthopedique et Reparatrice de l'Appareil Moteur 74(Suppl 2): 210-212
Mansurov, K.K.; Kan, C. 1979: 5-year ambulatory management of patients with precancerous diseases of the stomach. Terapevticheskii Arkhiv 51(1): 65-68
Cartel, J.C.; Gallais, J.J.; Naudillon, Y.; Millan, J.; Grosset, J.H. 1986: 5-year assessment of daily multi-drug therapy of leprosy in Guadeloupe since 1980. Acta Leprologica 4(4): 415-425
Baranyai, E.; Kis, E.; Szebeni, R. 1979: 5-year clinical experience with the kidney calculi solvent Magurlit. Orvosi Hetilap 120(30): 1823-1824
Wilder, A.D.; May, K.N.; Leinfelder, K.F. 1985: 5-year clinical study of UV-cured composites in the posterior region. Phillip Journal für Restaurative Zahnmedizin 2(9 Spec No): 259-263
Kusić, S.; Radmanović, M.; Posinković, B.; Turcić, I. 1977: 5-year clinico-statistical analysis of fractures of the distal 3d of the femur. Acta Chirurgica Iugoslavica 24(Suppl 2): 195-196
Tschakert, H. 1986: 5-year cure results in the radiotherapy of cervix uteri cancers between 1928 and 1977. An historical survey of a half-century reporting period. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 162(11): 680-685
Kim, Y.S. 1986: 5-year evaluation of a spiral implant. Taehan Ch'ikkwa Uisa Hyophoe Chi 24(9): 813-824
Peigue-Lafeuille, H.; Vanlieferinghen, P.; Sirot, J.; Gaulme, J. 1986: 5-year evaluation of bacteriological samples (CSF, blood cultures, urine) in neonatology. Pediatrie 41(2): 115-119
Yukna, R.A.; Mayer, E.T.; Amos, S.M. 1989: 5-year evaluation of durapatite ceramic alloplastic implants in periodontal osseous defects. Journal of Periodontology 60(10): 544-551
Roth, R.H. 1976: 5-year evaluation of straight-wire-apparatus of Andrews. Informationen aus Orthodontie und Kieferorthopadie: Mit Beitragen aus der Internationalen Literatur 8(3): 283-313
Witwicki, T.; Dulowski, W.; Górecki, A. 1979: 5-year evaluation of the results of treatment of soft tissue sarcomas of the limbs. Chirurgia Narzadow Ruchu i Ortopedia Polska 44(2): 185-190
Guareschi, B.; Rusconi, U.; Columbaro, G. 1976: 5-year experience in urographic and cysto-ureterographic studies on children with urinary tract infections. Minerva Pediatrica 28(5): 262-269
Romics, I.; Bach, D.; Rüssel, C. 1992: 5-year experience with BCG immunoprophylaxis in superficial bladder cancer. Orvosi Hetilap 133(36): 2275-2276; 2279-2281
Houber, G. 1975: 5-year experience with Linkow plates. Mondo Odontostomatologico 17(5): 64-76
Melicharová, D.; Válek, A. 1977: 5-year experience with construction, care and survival in arteriovenous fistulas and Scribner's shunts. Vnitrni Lekarstvi 23(6): 549-554
Stanisic, T.H.; Donovan, J.M.; Lebouton, J.; Graham, A.R. 1987: 5-year experience with intravesical therapy of carcinoma in situ: an inquiry into the risks of "conservative" management. Journal of Urology 138(5): 1158-1161
Rabkin, I.K.; Germashev, V.G. 1990: 5-year experience with roentgenologically controlled endovascular nitinol prosthesis. Kardiologiia 30(4): 11-17
Heinisch, M. 1985: 5-year experience with sterile and pyrogen-free irrigation solutions in transurethral surgery. Krankenpflege Journal 23(10): 10-12
Byk, S.M. 1986: 5-year experience with the organization of physical therapy services for ophthalmological patients in the city of Tashkent. Oftalmologicheskii Zhurnal 4: 241-243
Varga, G.; Krizsa, F.; Vezendi, K.; Cserháti, I. 1978: 5-year experience with the treatment of Hodgkin's disease. Orvosi Hetilap 119(47): 2881-2888
Tavelev, I.V. 1975: 5-year experience with the use of a disinfectant, pervomur, for fast treatment of surgeon's hands. Akusherstvo i Ginekologiia 8: 71
Renvert, S.; Nilvéus, R.; Dahlén, G.; Slots, J.; Egelberg, J. 1990: 5-year follow up of periodontal intraosseous defects treated by root planing or flap surgery. Journal of Clinical Periodontology 17(6): 356-363
Armata, J.; Przywora-Gondek, E. 1977: 5-year follow-up of a child with chloramphenicol-induced aplastic anemia and finally cured. Pediatria Polska 52(10): 1145-1147
Sekuła, J. 1976: 5-year follow-up of patients after subtotal laryngectomy. Otolaryngologia Polska 30(3): 241-246
Marcantonio, A.; Laganà, A.; D'Ottavio, G.; Pozza, D.; Zappavigna, D. 1987: 5-year follow-up of total gastrectomy and subtotal resection in patients operated on for neoplasms of the gastric antrum. Minerva Chirurgica 42(4): 287-290
Fujimoto, O.; Nakamura, T.; Ohta, Y.; Koga, T.; Fujii, H.; Nan'no, H. 1991: 5-year follow-up study of brain function in the healthy aged--study of the relationship between environmental factors and results of psychiatric examinations. Japanese Journal of Public Health 38(3): 182-191
Otto, D.; Robinson, G.; Baumann, S.; Schroeder, S.; Mushak, P.; Kleinbaum, D.; Boone, L. 1985: 5-year follow-up study of children with low-to-moderate lead absorption: electrophysiological evaluation. Environmental Research 38(1): 168-186
Kleinstein, R.N.; Gordon, A.; Wayne, J.; Charles, E. 1985: 5-year followup of the effect on optometrists of continuing education about hypertension. Public Health Reports 100(4): 364-368
Bazika, V.; Puchmayer, V.; Reinis, Z.; Pokorný, J.; Horáková, D.; Hrabovský, F. 1978: 5-year incidence of arterial obliteration disease in the lower extremities among men in Northern Bohemia. Casopis Lekaru Ceskych 117(38-39): 1214-1218
Metz, O.; Stoll, W.; Unverricht, A.; Walter, W. 1978: 5-year meningiosis "prevention" using radiogold in childhood leukemia (proceedings). Radiologia Diagnostica 19(1): 113-114
Herlitz, J.; Hjalmarson, A.; Karlson, B.W.; Bengtson, A. 1988: 5-year mortality rate in patients with suspected acute myocardial infarction in relation to early diagnosis. Cardiology 75(4): 250-259
Soussaline, M. 1986: 5-year personal experience in breast reconstruction. Apropos of 160 cases. Annales de Chirurgie Plastique et Esthetique 31(3): 263-267
Pitko, S. 1978: 5-year plan aims at providing 600 new nurses. Sairaanhoitaja. Sjukskoterskan 54(10): 8-9
Ptakovsky, H.; Hold, M.; Raynoschek, H.; Hagmüller, G. 1992: 5-year result of 305 supragenual femoro-popliteal bypasses. Vasa. Supplementum 37: 45-47
Ilić, S.; Ristić, B. 1988: 5-year results and complications following high intensity afterloading technique (CTR). Sonderbande Zur Strahlentherapie und Onkologie 82: 123-126
Balasundaram, V. 1988: 5-year results and complications of treatment of carcinoma of the cervix using the Cathetron in rural India. Sonderbande Zur Strahlentherapie und Onkologie 82: 147-150
Wamsteker, H. 1978: 5-year results and surgical-urological complications of the first kidney transplantations in Leiden. Nederlands Tijdschrift Voor Geneeskunde 122(44): 1693-1698
Djordjević, J.; Bilenjki, D.; Strinic, S. 1988: 5-year results of HDR afterloading in comparison with radium therapy in Sarajevo. Sonderbande Zur Strahlentherapie und Onkologie 82: 156-159
Comella, G.; Mastro, A.A.; Comella, P.; Castello, G.; De Simone, G.; Cerra, R.; Zarrilli, D. 1986: 5-year results of a chemo-immunotherapeutic treatment in stage-I and -II malignant melanoma. Minerva Medica 77(13): 507-510
Clerehugh, V.; Lennon, M.A.; Worthington, H.V. 1990: 5-year results of a longitudinal study of early periodontitis in 14- to 19-year-old adolescents. Journal of Clinical Periodontology 17(10): 702-708
Johnston, K.W.; Rae, M.; Hogg-Johnston, S.A.; Colapinto, R.F.; Walker, P.M.; Baird, R.J.; Sniderman, K.W.; Kalman, P. 1987: 5-year results of a prospective study of percutaneous transluminal angioplasty. Annals of Surgery 206(4): 403-413
Jacobs, J.R.; Fu, K.K.; Lowry, L.D.; Scotte Doggett, R.L.; Pajak, T.F.; Al-Sarraf, M. 1991: 5-year results of cisplatin and fluorouracil infusion in head and neck cancer. Archives of Otolaryngology--Head and Neck Surgery 117(3): 288-291
Olasz, L.; Szabó, I.; Herczegh, P. 1991: 5-year results of combines (radiation and surgical) treatment of intraoral squamous cell carcinoma. Fogorvosi Szemle 84(6-7): 193-197
De Saint Florent, G.; Magny, J.P.; Brocard, H. 1977: 5-year results of exereses for epidermoid bronchial cancers discovered by systematic radiologic screening. Broncho-Pneumologie 27(1): 41-46
Inoue, T.; Morita, K. 1988: 5-year results of postoperative extended-field irradiation on 76 patients with nodal metastases from cervical carcinoma stages IB to IIIB. Cancer 61(10): 2009-2014
Molnár, F. 1975: 5-year results of pulp treatment with metal foil and Ca(OH)2. Fogorvosi Szemle 68(3): 76-80
Longefait, H.; Huet, R. 1977: 5-year results of various bronchial carcinomas operated on as a result of clinical symptoms apropos of 1,511 cases. Broncho-Pneumologie 27(3): 231-237
Vahrson, H.; Römer, G. 1988: 5-year results with HDR afterloading in cervix cancer: dependence on fractionation and dose. Sonderbande Zur Strahlentherapie und Onkologie 82: 139-146
Hirschfeld, J.; Fiedel, U.; Reichmann, W. 1975: 5-year results with N.C. Petersen's surgical management of malignant melanoma. Zeitschrift für Hautkrankheiten 50(7): 281-289
Bradácková, I.; Brada, P.; Hofstetr, A. 1990: 5-year study of radiation loading due to nuclear medicine examinations in children in the Jihlava District. Ceskoslovenska Pediatrie 45(8): 473-476
Lauria, F.; Baccarani, M.; Fiacchini, M.; Frezza, R.; Gobbi, M.; Tura, S. 1978: 5-year survey of methotrexate, cyclophosphamide (Endoxan), and vincristine (MEV) therapy for advanced non-Hodgkin's lymphomas. Cancer Treatment Reports 62(8): 1193-1197
Zuchowska-Vogelgesang, B.; Pawlicki, M. 1979: 5-year survival and causes of treatment failure in patients with lymphosarcoma. Nowotwory 29(2): 115-119
Salajka, F. 1985: 5-year survival of a patient with untreated cancer of the lung. Vnitrni Lekarstvi 31(6): 592-594
Marchetti, M.; Sandri, A.; Silvestri, P.; Polonio, S. 1991: 5-year survival of endometrial carcinoma in the experience of the Gynaecological Clinic of Padua University: quality of life. Clinical and Experimental Obstetrics and Gynecology 18(4): 241-246
Kolodziejska, H.; Urbańska, A. 1977: 5-year survival of patients in the population in the Nowy Sacz Region. Nowotwory 27(3): 189-195
Strzeszyński, J. 1976: 5-year survival of patients with bladder carcinoma following x-ray therapy. Polski Przeglad Chirurgiczny 48(2 A): 263-268
Lovecchio, J.L.; Averette, H.E.; Donato, D.; Bell, J. 1989: 5-year survival of patients with periaortic nodal metastases in clinical stage IB and IIA cervical carcinoma. Gynecologic Oncology 34(1): 43-45
Schwarz, F.; Weyland, B.; Tillmanns, H.; Schuler, G.; Manthey, J.; Dietz, R.; Kübler, W.; Olschewski, M. 1988: 5-year survival rate in acute transmural heart infarct following thrombolysis and immediate coronary angioplasty. Zeitschrift für Kardiologie 77(11): 713-720
Lindahl, B.; Fernö, M.; Gullberg, B.; Norgren, A.; Willén, R. 1992: 5-year survival rate in endometrial carcinoma stage I-Ii related to steroid receptor concentration, degree of differentiation, age and myometrial invasion. Anticancer Research 12(2): 409-412
Gadomska, H. 1976: 5-year survival rate in patients with uterine cervix cancer registered in the years 1963-1965 in Warsaw City. Ginekologia Polska 47(9): 1023-1030